{"results": [[0, "Progressive mobilization of the patient was obtained as well as a complete normalization of the laboratory findings.", [" \"PARAMETER\": [\"lab findings\"]\n\nNote: \"lab findings\" is a common term used to refer to various laboratory test results, but it's important to keep in mind that it could include many different types of tests and parameters. In this context, it likely refers to the normalization of the protein concentrations mentioned earlier in the text.", {}]], [1, "We describe here the unexpected onset of heavy toxicity including rhabdomyolysis after the fourth course of trabectedin in a patient with retroperitoneal liposarcoma who at the same time was taking an alternative herbal medicine suspected of triggering this adverse event.", [" \"PARAMETER\": [\"heavy toxicity\", \"rhabdomyolysis\"]", {"Pathology": ["rhabdomyolysis", "retroperitoneal liposarcoma", "adverse event"], "Drug": ["trabectedin"]}]], [2, "In May 2009 he underwent surgical removal of the abdominal mass achieving a complete margin negative (R0) resection.", [" No specific parameters were mentioned in this text.", {}]], [3, "In spite of chemotherapy, the lesion progressed rapidly reaching 16 \u00d7 10 cm and extending into the pre-aortic seat of the retro-peritoneum space.", [" \"PARAMETER\": []", {}]], [4, "Due to the absence of co-morbidity, the patient had not received any other drugs during treatment with trabectedin.", [" \"PARAMETER\": []", {"Drug": ["trabectedin"]}]], [5, "As known, cancer patients are likely to experience drug interactions due to the increased number and types of chemotherapeutic drugs, their combinations in oncology practice and their narrow therapeutic index, the achievement of a prolonged life expectancy, and the common use of a broad range of ancillary medications to prevent and/or treat cancer-related syndromes and treatment-induced toxicity [8].", [" \"PARAMETER\": [\"cancer patients\", \"narrow therapeutic index\"]", {"Pathology": ["cancer", "cancer-related syndromes", "treatment-induced toxicity"]}]], [6, "Moreover, as the patient took a commercial preparation of chokeberry juice which did not provide information on the amounts of its compounds, it cannot be excluded that other interactions might have occurred such as the inhibition of transport mechanisms, the activation of the death receptor and other unknown mechanisms.", [" \"PARAMETER\": []\n\nThis sentence does not provide any specific parameters related to entities mentioned in the text. It is discussing the potential for other interactions with the commercial preparation of chokeberry juice, but it does not specify what those interactions might be.", {"Extraction process": ["chokeberry juice"]}]], [7, "This case report highlights the complexity associated with medicinal cannabis and the health risks associated with its use.", [" \"PARAMETER\": [\"medicinal cannabis\", \"health risks\"]", {"Herb name": ["cannabis"]}]], [8, "It was discovered that the patient took cannabis for chronic back pain, and a pharmacogenomics (PGx) test indicated the presence of variants for the COMT and HTR2A genes.", [" \"PARAMETER\": [\"COMMT\", \"HTR2A\"]", {"Herb name": ["cannabis"], "Pathology": ["chronic back pain"]}]], [9, "Neuronal death in this region results in low dopamine concentrations; therefore, treatment strategies for PD often involve initiating medications (e.g., carbidopa-levodopa, ropinirole, entacapone) that result in increased concentrations of dopamine to improve movement control [8].", [" \"PARAMETER\": [\"dopamine concentrations\"]", {"Pathology": ["PD"], "Drug": ["carbidopa-levodopa", "ropinirole", "entacapone"]}]], [10, "The case described herein demonstrates the importance of considering the pharmacokinetic and pharmacodynamic effects of cannabis and an individual\u2019s pharmacogenomic (PGx) data when evaluating a patient\u2019s medication regimen for therapeutic response and/or adverse drug events.", [" \"PARAMETER\": [\"pharmacokinetic effects\", \"pharmacodynamic effects\", \"individual\u2019s pharmacogenomic (PGx) data\"]", {"Herb name": ["cannabis"], "Pathology": ["adverse drug events"]}]], [11, "In addition to PD, the patient\u2019s past medical history includes spinal stenosis, vitamin D deficiency, frequent falls, a history of nicotine and alcohol dependence, mild kidney disease, and chronic neck, back, and shoulder pain.", [" \"PARAMETER\": [\"spinal stenosis\", \"vitamin D deficiency\", \"frequent falls\", \"history of nicotine and alcohol dependence\", \"mild kidney disease\"]", {"Pathology": ["PD", "spinal stenosis", "vitamin D deficiency", "frequent falls", "mild kidney disease", "chronic neck, back, and shoulder pain"]}]], [12, "The clinical pharmacist recommended dose increases of carbidopa-levodopa to help control his tremors still present early in the morning (Figure 1).", [" \"PARAMETER\": [\"dose increases\"]\n\n\"PARAMETER\": [\"carbidopa-levodopa\"]\n\n\"PARAMETER\": [\"his tremors\"]\n\n\"PARAMETER\": [\"early in the morning\"]", {"Drug": ["carbidopa-levodopa"], "Pathology": ["tremors"]}]], [13, "However, his PCP determined that additional medication for pain control was warranted.", [" No specific parameters were mentioned in this sentence.", {}]], [14, "Numerous factors can explain discrepancies between study results such as pain models, healthy subjects vs. patients, routes of administration (inhalation vs. oral), and sources of the product [19,20,21].", [" \"\"PARAMETER\"\": [\"pain models\", \"healthy subjects vs. patients\", \"routes of administration (inhalation vs. oral)\", \"sources of the product\"]\"\"\"\n\n[1] \"pain models\": [],\n[2] \"healthy subjects vs. patients\": [],\n[3] \"routes of administration (inhalation vs. oral)\": [],\n[4] \"sources of the product\": []\n\n[19]: \"\",\n[20]: \"\",\n[21]: \"\"\n\nThese lists are empty because no specific entities were mentioned in the text related to these parameters.", {"Pathology": ["pain", "healthy"]}]], [15, "When CB1Rs on presynaptic neurons are activated, inhibitory neurotransmitter levels are reduced and dopamine levels increase [5,24,25].", [" \"PARAMETER\": [\"CB1Rs\", \"inhibitory neurotransmitter levels\", \"dopamine levels\"]", {"Target": ["CB1Rs"], "Parameter": ["dopamine levels"]}]], [16, "Interestingly, the patient\u2019s PGx results (Table 1) reported a genotype for COMT Met/Met, therefore higher levels of dopamine in his synapses would be expected.", [" \"PARAMETER\": [\"PGx results\", \"genotype for COMT\"]\n\n\"COMMT\": [\"COMMT Met/Met\"]\n\n\"PARAMETER (COMMT)\": [\"higher levels of dopamine in his synapses\"]", {}]], [17, "Additionally, a previous study evaluated patients with PD and their subsequent reactions to cannabis use, reporting that one out of five patients experienced hallucinations [12].", [" \"PARAMETER\": [\"patients with PD\", \"one out of five patients\"]\n\n12. \"patients with PD\", \"five patients\"\n\n(Note: It's not clear from the text if \"hallucinations\" is a property of the patients or a reaction to cannabis use. I assumed it's a reaction based on the context, but it's worth double-checking if more context is available.)", {"Pathology": ["PD", "hallucinations"], "Herb name": ["cannabis"]}]], [18, "Given this patient\u2019s genetic results, guidelines, and current pain status, the clinical pharmacist suggested morphine as an alternative, as it does not utilize CYP2D6 for metabolism [34].", [" \"PARAMETER\": [\"morphine\"]", {"Pathology": ["pain"], "Drug": ["morphine"]}]], [19, "The authors want to thank Katie Meyer for her assistance.", [" \"PARAMETER\": []", {}]], [20, "During the past two decades, the world has witnessed an increased rate of conventional medicines integrated with CAM for treatment.", [" \"PARAMETER\": []", {"Duration": ["the past two decades"]}]], [21, "In China, 93.4% of cancer patients reported having used CAM in 2009-2010 [4].", [" \"PARAMETER\": [\"93.4% of cancer patients\"]\n\nReferences:\n[4] (if available)", {"Pathology": ["cancer"]}]], [22, "In South Korean population reported a range from 29% to 83% [5].", [" \"PARAMETER\": [\"range\", \"29% to 83%\"]}", {"Ethnic group": ["South Korean"]}]], [23, "An important fact is that most of these affected drugs have very narrow therapeutic indices.", [" \"PARAMETER\": [\"narrow therapeutic indices\"]", {}]], [24, "To date an increasing number of studies in evaluating HDIs have been reported [11].", [" \"PARAMETER\": [\"the number of studies in evaluating HDIs\"]\n\n11. \"studies in evaluating HDIs\"\n\nNote: HDIs stands for Herb-Drug Interactions.", {}]], [25, "In the following, we reviewed pharmacogenomics studies, mainly from clinic study, on some important herb products that have been reported to have HDIs.", [" \"PARAMETER\": [\"herb products\", \"pharmacogenomics studies\"]", {"Study": ["pharmacogenomics studies", "clinic study"]}]], [26, "The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene was significantly associated with the hypoglycemic effect of the drug (P = 0.001, FDR P = 0.043).", [" \"PARAMETER\": [\"rs1142345 (A>G)\", \"the hypoglycemic effect of the drug\"]\n\nNote: FDR stands for False Discovery Rate.", {"Parameter": ["The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene"], "Pathology": ["hypoglycemic"]}]], [27, "Therefore, rs1142345 was associated with the clinical effect of traditional hypoglycemic herbs.", [" \"PARAMETER\": [\"rs1142345\"]", {"Parameter": ["rs1142345"], "Pathology": ["hypoglycemic"]}]], [28, "AUC: concentration-time curve; EMs: extensive metabolizer; PM: poor metabolizer.", [" \"PARAMETER\": [\"AUC: concentration-time curve\", \"EMs: extensive metabolizer\", \"PM: poor metabolizer\"]", {"Parameter": ["AUC: concentration-time curve"]}]], [29, "With the boom in conventional therapeutic drugs, the utilization of herbal remedies sometimes in combination with other medications has increased tremendously over the last decade [1,2].", [" \"PARAMETER\": []\n\n[1,2]: These citations are not specific to any parameters.", {}]], [30, "Local names for this shrub include Faangum in Cameroon, Sasanemasa/Sesemasa or Esisimansa in Ghana, Lifui in Togo, and Akoko in Nigeria.", [" \"PARAMETER\": [\"Faangum (Cameroon)\", \"Sasanemasa/Sesemasa or Esisimansa (Ghana)\", \"Lifui (Togo)\", \"Akoko (Nigeria)\"]}", {"Herb name": ["Faangum", "Sasanemasa/Sesemasa", "Esisimansa", "Lifui", "Akoko"]}]], [31, "The cytochrome P450 (CYP450) family of enzymes especially plays an important role in the biotransformation of about 70% of xenobiotics and other endogenous substances [14].", [" \"PARAMETER\": [\"the cytochrome P450 (CYP450) family of enzymes\"]", {"Target": ["cytochrome P450 (CYP450)"]}]], [32, "This study concentrated on investigating the effects of potential interaction between extracts from Newbouldia laevis and Cassia abbreviata on CYP1A2, CYP2C9, and CYP2C19 activities.", [" \"PARAMETER\": [\"CYP1A2\", \"CYP2C9\", \"CYP2C19\"]", {"Extraction process": ["extracts"], "Herb name": ["Newbouldia laevis", "Cassia abbreviata"], "Target": ["CYP1A2", "CYP2C9", "CYP2C19"]}]], [33, "Linear regression analysis of the time course was used to determine the K A non-targeted approach was used in order to provide information about all possible metabolites present in the analysed samples.", [" \"PARAMETER\": [\"time course\", \"K A\"]", {}]], [34, "Since the intestinal absorption and plasma concentration of each test compound are not known and with the knowledge that herbal extracts have different bioavailability [24], the bioavailable concentration was estimated using the % yield (weight extracted powdered material/weight of original starting material) to give the soluble extract available in the GIT tract.", [" \"PARAMETER\": [\"bioavailable concentration\", \"the % yield\"]", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [35, "With the tremendous surge in the acceptance of and public interest in herbal medicinal remedies, researchers are adopting the guidelines and opinions proposed for DDI studies to study HDI.", [" \"PARAMETER\": [\"herbal medicinal remedies\", \"DDI studies\", \"HDI\"]", {"Study": ["DDI studies"]}]], [36, "The TDI effects of these herbals is felt when patients chronically use them because sufficient intermediary metabolites may be generated and this can be deleterious to consumers concomitantly taking conventional medications, as stated earlier.", [" \"PARAMETER\": [\"intermediary metabolites\"]", {}]], [37, "Extraction was performed using water to mimic the indigenous mode of extraction.", [" \"PARAMETER\": [\"\"]\n\n(No specific parameters were mentioned in the text)", {}]], [38, "[44].", [" I cannot determine any parameters from the given text as it only contains a citation.", {}]], [39, "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe.", [" \"PARAMETER\": [\"serial dilutions of the extracts\", \"regeneration system\", \"NADP Phytofingerprinting\", \"Waters Acquity UPLC system\", \"Waters Corporation\", \"Milford, MA, USA\", \"Acquity BEH C18 column\", \"2.1 mm \u00d7 100 mm\", \"1.7 \u00b5m particle size\", \"binary pump\", \"vacuum degasser\", \"autosampler\", \"column oven\", \"Micromass Xevo tandem quadrupole mass spectrometric detector\", \"QTOF xevo G2\", \"Waters micromass\", \"Manchester, UK\", \"ESI probe\"]", {"Extraction process": ["extracts", "extracts"], "Target": ["NADP"]}]], [40, "Currently, there is no specific pharmacological tool to predict HDI since almost all in vitro-in vivo-extrapolation (IVIVE) Drug-Drug Interaction (DDI) models deal with one inhibitor-drug and one victim-drug.", [" \"PARAMETER\": []", {}]], [41, "Currently, there are 29 putative SLC22 family members, 18 of which are believed to be OATs.", [" \"PARAMETER\": [\"29 putative SLC22 family members\", \"18 of which are believed to be OATs\"]", {"Parameter": ["SLC22", "OATs"]}]], [42, "Further, unique substrates that interact with Oat1, but not with Oat3 (and vice-versa) have been identified [7].", [" \"PARAMETER\": [\"unique substrates\"]}\n\n[References:]\n[7]: {}", {"Parameter": ["Oat1", "Oat3"]}]], [43, "For the most part these latter two transporter families and the OATs have fairly distinct substrate interactions; however, the possibility that they also may contribute to the overall clinical pharmacokinetic profile of Danshen components in vivo needs to be considered until investigated directly.", [" \"PARAMETER\": [\"Danshen components\", \"overall clinical pharmacokinetic profile\"]", {"Parameter": ["transporter families", "the OATs"], "Herb name": ["Danshen components"]}]], [44, "Keywords: pharmacokinetics, pharmacodynamics, gliclazide, St John's wort, CYP2C9, genotype Go to: Introduction  The incidence of type 2 diabetes is increasing in the community.", [" \"\"PARAMETER\"\": [\"\"]\n\n\"\"Introduction\"\": [\"the incidence of type 2 diabetes is increasing in the community\"]\n\n\"\"\"\n\nThis is the introduction of the article and it does not contain any specific parameters. The text only provides some general context about the topic of the study.", {"Drug": ["gliclazide"], "Herb name": ["St John's wort"], "Target": ["CYP2C9"], "Pathology": ["type 2 diabetes"]}]], [45, "Furthermore, 31% of diabetic patients have been reported to take alternative medicines, most in conjunction with conventional medicines (Ryan et al., 2001).", [" \"PARAMETER\": [\"31% of diabetic patients\"]\n\n\"PARAMETER\": [\"alternative medicines\"]\n\n\"PARAMETER\": [\"most in conjunction with conventional medicines\"]\n\n\"PARAMETER\": [\"Reported to take (Ryan et al., 2001)\"]", {"Pathology": ["diabetic"]}]], [46, "Four of these metabolites (6\u03b1, 6\u03b2, 7\u03b1 and 7\u03b2 positions) have been identified in urine, which represented 1, 20, 6 and 14% of urinary recovered dose 96\u2009h after dose, respectively (Oida et al., 1985).", [" \"PARAMETER\": [\"1, 20, 6, 14%\"]\n\nThis percentage represents the percentage of the urinary recovered dose for each of the identified metabolites 96 hours after the dose.", {}]], [47, "Elliot et al.", [" \"PARAMETER\": [\"Elliot et al.\"]\n\n(Assuming \"Elliot et al.\" is a reference to a specific study or authors)", {}]], [48, "Detection of the CYP2C9*2 and CYP2C9*3 alleles were carried out using a polymerase chain reaction based restriction fragment length polymorphism (polymerase chain reaction-RFLP) analysis.", [" \"PARAMETER\": [\"CYP2C9\\*2 and CYP2C9\\*3 alleles\"]", {"Target": ["CYP2C9*2", "CYP2C9*3"]}]], [49, "Briefly, PCR was performed in a final reaction volume of 50\u2009\u03bcl, which included 20\u2009\u03bcl 2.5 \u00d7 HotMasterMix (Eppendorf, Westbury, NY, USA), approximately 250\u2009ng of human genomic DNA and the primer pairs (0.25\u2009\u03bcM).", [" \"PARAMETER\": [\"human genomic DNA\", \"250 ng\"]", {}]], [50, "All participants were asked not to drink caffeine-containing beverages and to refrain from grapefruit from the day before until 2 days after taking gliclazide.", [" \"PARAMETER\": [\"caffeine-containing beverages\", \"grapefruit\"]", {"Herb name": ["caffeine", "grapefruit"], "Drug": ["gliclazide"]}]], [51, "(2003).", [" I cannot determine any parameters from the given text as it only contains a citation.", {}]], [52, "By contrast, for carriers of the CYP2C9*3 allele, the CL/Fs of glipizide (Kidd et al., 1999) and tolbutamide (Kirchheiner et al., 2002a) were significantly different from wild-type subjects, with ratios of 0.18 and 0.58, respectively.", [" \"PARAMETER\": [\"CL/Fs of glipizide\", \"CL/Fs of tolbutamide\"]\n\nFor carriers of the CYP2C9\\*3 allele: [\"CL/Fs\", \"0.18 (glipizide)\", \"0.58 (tolbutamide)\"]\n\n(Note: \"wild-type subjects\" is assumed to have a CL/Fs ratio of 1)", {"Target": ["CYP2C9*3 allele"], "Parameter": ["CL/Fs"], "Drug": ["glipizide", "tolbutamide"]}]], [53, "Park et al.", [" \"PARAMETER\": [\"Park et al.\"]\n\n(Assuming \"Park et al.\" refers to the authors of a study)", {}]], [54, "Serological titers for acute cytomegalovirus (CMV) and Epstein Barr virus (EBV) were negative.", [" \"PARAMETER\": [\"serological titers for acute cytomegalovirus (CMV)\", \"serological titers for Epstein Barr virus (EBV)\"]\n\nNote: In this context, \"serological titers\" refers to the level of antibodies present in the blood, indicating past or current infection.", {"Pathology": ["acute cytomegalovirus (CMV", "Epstein Barr virus (EBV"]}]], [55, "Antinuclear antibody (ANA) was 1 : 40 and smooth muscle antibody was modestly elevated at 1 : 80.", [" \"PARAMETER\": [\"antinuclear antibody (ANA)\", \"1 : 40\", \"smooth muscle antibody\", \"1 : 80\"]", {"Parameter": ["Antinuclear antibody (ANA", "smooth muscle antibody"], "Amount": ["1 : 40", "1 : 80"]}]], [56, "At this time, the liver histology demonstrated chronic hepatitis with fibroinflammatory expansion of portal tracts by moderate plasma cell rich interface hepatitis, rare periportal hepatocyte apoptosis, and mild cholangiolar proliferation (Figures 1(a) and 1(b)).", [" \"PARAMETER\": [\"liver histology\", \"chronic hepatitis\", \"fibroinflammatory expansion of portal tracts\", \"moderate plasma cell rich interface hepatitis\", \"rare periportal hepatocyte apoptosis\", \"mild cholangiolar proliferation\"]", {"Pathology": ["chronic hepatitis", "interface hepatitis"], "Parameter": ["periportal hepatocyte"]}]], [57, "The clinicopathological features of Case 1 are illustrated in Tables 1, 2, and 3.", [" \"PARAMETER\": [\"Tables 1, 2, and 3\"]\n\nNote: In this context, \"Tables\" refer to specific data sets presented in the article, and the parameters would depend on the contents of those tables. Without access to the article itself, it is impossible to determine the specific parameters.", {}]], [58, "Although she was initially asymptomatic, she developed right upper quadrant abdominal pain, fatigue, and lower extremity edema by the time of her presentation.", [" \"PARAMETER\": [\"right upper quadrant abdominal pain\", \"fatigue\", \"lower extremity edema\"]", {"Pathology": ["right upper quadrant abdominal pain", "fatigue", "lower extremity edema"]}]], [59, "The American College of Obstetrics and Gynecology included black cohosh as a possible remedy for the vasomotor symptoms of menopause [15].", [" \"PARAMETER\": [\"vasomotor symptoms of menopause\"]", {"Ethnic group": ["American"], "Herb name": ["black cohosh"], "Pathology": ["menopause"]}]], [60, "This case culminated in liver failure despite discontinuation of the herbal supplement [4].", [" \"PARAMETER\": [\"liver failure\"]", {"Pathology": ["liver failure"]}]], [61, "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response.", [" \"PARAMETER\": [\"drug or a metabolite\", \"immunogen\", \"autoimmune response\"]", {}]], [62, "Naranjo [8] Causality Scale for Adverse Drug Reactions.", [" \"PARAMETER\": [\"Naranjo Causality Scale for Adverse Drug Reactions\"]", {"Pathology": ["Adverse Drug Reactions"]}]], [63, "Similarities and differences among current case studies and published cases of black cohosh hepatotoxicity.", [" \"PARAMETER\": [\"current case studies\", \"published cases\"]", {"Herb name": ["black cohosh"], "Pathology": ["hepatotoxicity"]}]], [64, "Levofloxacin (LVFX) is used to treat numerous bacterial infections belonging to the third-generation fluoroquinolone antibiotic family [8].", [" \"PARAMETER\": [\"Levofloxacin (LVFX)\"]\n\nThis parameter refers to the specific antibiotic drug named Levofloxacin.", {"Drug": ["Levofloxacin (LVFX)", "third-generation fluoroquinolone antibiotic"]}]], [65, "For patients with urinary system infection, Relinqing\u00ae granule from Polygonum capitatum is usually combined with LVFX.", [" \"PARAMETER\": [\"Relinqing\u00ae granule\", \"Polygonum capitatum\", \"urinary system infection\", \"LVFX\"]", {"Pathology": ["urinary system infection"], "Herb name": ["Relinqing\u00ae granule", "Polygonum capitatum"], "Drug": ["LVFX"]}]], [66, "In vivo distribution studies are crucial in drug research as they can be performed to demonstrate the pharmacokinetic features of a drug [21, 22].", [" \"PARAMETER\": [\"pharmacokinetic features\"]\n\nReferences:\n[21], [22]\n\n(Note: I couldn't determine the exact parameters from the given context, but \"pharmacokinetic features\" is a common term used to describe various aspects of a drug's behavior within the body, including absorption, distribution, metabolism, and excretion.)", {"Study": ["In vivo distribution studies"]}]], [67, "Thereafter, 50\u2009\u03bcL of the IS solution (puerarin, 20\u2009ng/mL in methanol) and 50\u2009\u03bcL of 2% formic acid were added to 100\u2009\u03bcL of the rat tissue homogenate.", [" \"PARAMETER\": [\"rat tissue homogenate\", \"2% formic acid\", \"puerarin\"]", {"Herb name": ["puerarin"]}]], [68, "Group one was administered 42\u2009mg\u00b7kg Data are presented as mean\u2009\u00b1\u2009standard deviation (SD).", [" \"PARAMETER\": [\"mean\", \"standard deviation (SD)\"]\n\nThe value \"42 mg\u00b7kg\" is a dose of a substance, but it is not clear what substance it is, so it is not included in the output.", {}]], [69, "Based on our findings, the developed method is acceptable and accurate for analyzing LVFX in complex matrices.", [" \"PARAMETER\": [\"LVFX\"]", {"Drug": ["LVFX"]}]], [70, "The diluted samples were analyzed using a calibration curve to derive their integrities, which were within the acceptable limit of \u00b115%.", [" \"PARAMETER\": [\"integrities\"]", {}]], [71, "Polygonum capitatum may inhibit the entrance of LVFX into blood, thereby directly affecting its distribution rate in the tissue.", [" \"PARAMETER\": [\"the entrance of LVFX\", \"its distribution rate in the tissue\"]", {"Herb name": ["Polygonum capitatum"], "Drug": ["LVFX"]}]], [72, "At present, our current studies at the pharmacokinetic level may not be able to explain this problem strongly.", [" \"\"PARAMETER\"\": [\"\"]", {}]], [73, "However, drug interactions can be divided into pharmacokinetic interactions and pharmacodynamic interactions.", [" \"PARAMETER\": [\"pharmacokinetic interactions\", \"pharmacodynamic interactions\"]", {}]], [74, "KY[2017]073).", [" \"PARAMETER\": [\"KY[2017]073\"] (This is likely a citation, but without additional context it's unclear what the parameter represents in this case)", {}]], [75, "People with diabetes receiving this combination should be closely monitored to evaluate possible signs of reduced efficacy.", [" \"PARAMETER\": [\"people with diabetes\"]\n\n\"SIGN\": [\"should be closely monitored\"]\n\n\"EVENT\": [\"possible signs of reduced efficacy\"]", {"Pathology": ["diabetes"]}]], [76, "Furthermore, the extract and constituents of KF have been shown to possess anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties (Nadia et al., 2012; Fathilah et al., 2013).", [" \"PARAMETER\": [\"anticancer properties\", \"antioxidant properties\", \"anti-osteoporosis properties\", \"anti-inflammatory properties\"]", {"Herb name": ["the extract and constituents of KF"], "Pathology": ["anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties"]}]], [77, "Dulbecco\u2019s Modified Eagle Medium (DMEM), Minimal Essential Medium (MEM), Hanks balanced salt solution (HBSS), HEPES, Trypsin EDTA, Penicillin-streptomycin, and Sodium Pyruvate were from GIBCO BRL (Invitrogen Corp., Grand Island, NY, USA).", [" \"PARAMETER\": [\"Dulbecco\u2019s Modified Eagle Medium (DMEM)\", \"Minimal Essential Medium (MEM)\", \"Hanks balanced salt solution (HBSS)\", \"HEPES\", \"Trypsin EDTA\", \"Penicillin-streptomycin\", \"Sodium Pyruvate\"]", {"Extraction process": ["Hanks balanced salt solution (HBSS)", "HEPES", "Trypsin EDTA", "Sodium Pyruvate"], "Drug": ["Penicillin-streptomycin"]}]], [78, "Radio labeled digoxin [ Parental and transfected MDCK-II cells were grown in DMEM supplemented with 10% FBS, 1% non-essential amino acids, 1%  The assay for reversible inhibition was conducted in a total volume of 200 \u03bcL in 96-well microplates.", [" \"\"PARAMETER\"\": [\"200 \u03bcL\", \"96-well microplates\"]\n\n\"MEDIA\" : [\"DMEM supplemented with 10% FBS, 1% non-essential amino acids\"]\n\n\"CELLS\" : [\"parental and transfected MDCK-II cells\"]\n\n\"REAGENT\" : [\"radio labeled digoxin\"]", {"Drug": ["digoxin"], "Amount": ["10%", "1%", "1%", "200 \u03bcL"], "Extraction process": ["FBS"], "Herb name": ["non-essential amino acids"]}]], [79, "The two major classes of compounds isolated from the roots of KF are alkyl phenols and triterpene glycosides (saponins) as reported earlier (Ali and Khan, 2011).", [" \"PARAMETER\": [\"alkyl phenols\", \"terpene glycosides (saponins)\"]", {"Herb part": ["the roots"], "Herb name": ["KF", "alkyl phenols and triterpene glycosides (saponins)"]}]], [80, "IC Next, we determined the inhibition of P-gp by the extract of L. pumila and the constituents by using the two widely used probes calcein-AM and digoxin (Rautio et al., 2006).", [" \"PARAMETER\": [\"P-gp\", \"the extract of L. pumila\", \"constituents\"]", {"Target": ["P-gp"], "Herb name": ["the extract of L. pumila and the constituents", "calcein-AM"], "Drug": ["digoxin"]}]], [81, "*P < 0.05, **P < 0.01, and ***P < 0.001, determined by One way ANOVA, followed by Dunnett\u2019s multiple comparison tests.", [" No specific parameters mentioned in this text.", {}]], [82, "Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin.", [" \"PARAMETER\": [\"CYP2C8\", \"CYP2C9\", \"CYP3A4\", \"thiazolidinediones (TZDs)\", \"sulfonylureas\", \"atorvastatin\"]", {"Target": ["Cytochrome P450 enzymes", "CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["hypoglycemic drugs", "thiazolidinediones (TZDs)", "sulfonylureas", "hypocholesterolemic drugs", "atorvastatin"]}]], [83, "The anti-diabetic [9,10], anti-obesity [11], and cardio-protective effects [12,13,14] of rooibos extracts are of specific relevance given the global increase in the prevalence of diabetes and obesity [15,16,17].", [" \"PARAMETER\": [\"diabetes\", \"prevalence\", \"obesity\"]", {"Herb name": ["rooibos"], "Extraction process": ["extracts"], "Pathology": ["diabetes", "obesity"]}]], [84, "Flavonoids, common in the diet, are responsible for the modulation of the clinically relevant CYP2C8, CYP2C9, and CYP3A4 enzymes [31].", [" \"PARAMETER\": [\"CYP2C8\", \"CYP2C9\", \"CYP3A4\"]}\n\n[31]: {\"CITATION\": [\"flavonoids\", \"are responsible for the modulation of the clinically relevant CYP2C8, CYP2C9, and CYP3A4 enzymes\"]}", {"Herb name": ["Flavonoids"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [85, "Qualitative screening of extracts and compounds was used to identify potential inhibitory effects on CYP2C8, CYP2C9 and CYP3A4.", [" \"PARAMETER\": [\"CYP2C8\", \"CYP2C9\", \"CYP3A4\"]}\n\nThis text mentions three specific cytochrome P450 enzymes (CYP2C8, CYP2C9, and CYP3A4) and indicates that qualitative screening was used to identify potential inhibitory effects on these enzyms.", {"Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [86, "The organic solvents such as methanol, acetonitrile and DMSO showed no inhibitory effects on the respective enzymes (Supplementary Materials, Figure S1a\u2013c).", [" \"PARAMETER\": []", {}]], [87, "GRT and FRE inhibited the reaction rate of CYP2C8, CYP2C9, and CYP3A4 as measured over 30 min (Figure 2a\u2013c).", [" \"PARAMETER\": [\"reaction rate\", \"CYP2C8\", \"CYP2C9\", \"CYP3A4\"]", {"Extraction process": ["GRT", "FRE"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [88, "GRT containing higher levels of polyphenols, in particular ASP (12.78% compared to 0.36%), demonstrated a more potent inhibition of CYP3A4 activity than FRE with IC CYP2C9 plays a role in the oxidation of xenobiotic and endogenous compounds and is responsible for the metabolism of 15%\u201320% of drugs undergoing phase I metabolism [52,53].", [" \"PARAMETER\": [\"CYP3A4 activity\", \"IC\", \"CYP2C9\"]", {"Extraction process": ["GRT", "FRE"], "Herb name": ["polyphenols", "ASP"], "Target": ["CYP3A4", "CYP2C9"]}]], [89, "Stock solutions (10 mg/mL) were prepared by diluting the extracts and compounds in distilled water.", [" \"PARAMETER\": [\"10 mg/mL\"]\n\n\"PARAMETER\": [\"distilled water\"]\n\n\"PARAMETER\": [\"extracts\", \"compounds\"]\n\nNote: The parameters listed above are based on the given context and may not represent all possible entities mentioned in the article.", {}]], [90, "quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor).", [" \"PARAMETER\": [\"quercetin\", \"sulfaphenazole\", \"ketoconazole\"] (all are positive inhibitors)\n\n\"INHIBITOR\": [\"quercetin\", \"sulfaphenazole\", \"ketoconazole\"] (all are inhibitors)\n\n\"ENZYME\": [\"CYP2C8\", \"CYP2C9\", \"CYP3A4\"]", {"Herb name": ["quercetin"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["sulfaphenazole", "ketoconazole"]}]], [91, "Statistical analyses were performed using GraphPad Prism This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs.", [" \"PARAMETER\": [\"pharmacodynamics\", \"safety\"]", {"Study": ["in vitro study"], "Herb name": ["rooibos"], "Extraction process": ["extracts"], "Target": ["CYP2C8", "CYP3A4"]}]], [92, "All authors reviewed the manuscript.", [" No parameters found in this sentence.", {}]], [93, "Echinacea was well tolerated, and all participants completed the study.", [" No parameters found.", {"Herb name": ["Echinacea"]}]], [94, "2).", [" I'm assuming you mean that the following information is related to the second occurrence of the term \"parameters\" in the text.\n\n\"The following format must be followed:\n{'PARAMETER': ['List of physiological or medical parameters found in text']}\n\nPlease do not add supplementary in information. If no information is found for a field, leave the field empty.\n\nThe following herbs could affect the following parameters:\n\n* Celery: hepatic triglyceride concentrations\n* Echinacea: warfarin pharmacodynamics (apparent clearance)\n* Glipizide and tolbutamide: CL/Fs (for carriers of the CYP2C9*3 allele)\n* rs1142345: clinical effect of traditional hypoglycemic herbs\"\n\nSo the output would be:\n\n{\"PARAMETER\": [\"hepatic triglyceride concentrations\", \"warfarin pharmacodynamics (apparent clearance)\", \"CL/Fs (for carriers of the CYP2C9*3 allele)\", \"clinical effect of traditional hypoglycemic herbs\"]}", {}]], [95, "This result was statistically not significant.", [" \"\"PARAMETER\" : []", {}]], [96, "The commercially available E. purpurea extract did not significantly alter the pharmacokinetics of docetaxel.", [" \"PARAMETER\": []", {"Herb name": ["E. purpurea"], "Drug": ["docetaxel"]}]], [97, "Of these components, caffeic acid derivatives and the more bioavailable alkylamides are found in ethanolic liquid extracts for medicinal use [8].", [" \"PARAMETER\": [\"caffeic acid derivatives\", \"the more bioavailable alkylamides\"]", {"Herb name": ["caffeic acid derivatives", "alkylamides"], "Extraction process": ["ethanolic liquid extracts"]}]], [98, "The secondary objective was to assess the effect of E. purpurea supplementation on safety parameters, such as grade 3 and 4 toxicities induced by docetaxel [according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)].", [" \"PARAMETER\": [\"grade 3 and 4 toxicities\", \"safety parameters\"]\n\nThe National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0) was used to assess the effect of E. purpurea supplementation on safety parameters.", {"Herb name": ["E. purpurea"], "Pathology": ["toxicities", "Cancer", "Adverse Events"], "Drug": ["docetaxel"]}]], [99, "Subsequently, plasma was separated and stored at \u221220\u00b0C until analysis.", [" No specific parameters mentioned in this sentence.", {}]], [100, "The following pharmacokinetic parameters of docetaxel were calculated: area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e), elimination half-life (t1/2) and maximum plasma concentration (Cmax).", [" \"PARAMETER\": [\"area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e)\", \"elimination half-life (t1/2)\", \"maximum plasma concentration (Cmax)\"]", {"Drug": ["docetaxel"], "Parameter": ["area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e)", "elimination half-life (t1/2)", "maximum plasma concentration (Cmax)"]}]], [101, "Statistical analysis  For each patient, the values of AUC0\u2013\u221e, t1/2 and Cmax of docetaxel in cycle 1 (before E. purpurea) were compared with values obtained in cycle 2 (after E. purpurea).", [" \"PARAMETER\": [\"AUC0\u2013\u221e\", \"t1/2\", \"Cmax\"]}\n\nThese parameters refer to the pharmacokinetics of docetaxel.", {"Parameter": ["AUC0\u2013\u221e", "t1/2", "Cmax"], "Drug": ["docetaxel"], "Herb name": ["E. purpurea", "E. purpurea"]}]], [102, "The individual differences in docetaxel AUC0\u2013\u221e are depicted in Figure 3.", [" \"PARAMETER\": [\"AUC0\u2013\u221e\"]\n\nNote: AUC0\u2013\u221e stands for the area under the curve from time 0 to infinity, which is a measure of the total amount of drug absorbed from a single dose.", {"Drug": ["docetaxel"], "Parameter": ["AUC0\u2013\u221e"]}]], [103, "Compared with the clinical studies in which significant induction of CYP3A4 by E. purpurea was found using midazolam as a CYP3A4 probe [11, 12], our study differed in formulation, dose and dosing regimen, which may explain the divergent outcome.", [" \"PARAMETER\": [\"midazolam\", \"CYP3A4\"]", {"Study": ["clinical studies"], "Target": ["CYP3A4", "CYP3A4"], "Herb name": ["E. purpurea"], "Drug": ["midazolam"]}]], [104, "Our commercial product was only labelled to contain 95% aerial parts and 5% roots of E. purpurea, and no information was provided about the total amount of extract used.", [" \"PARAMETER\": []", {"Herb part": ["aerial parts", "roots"], "Herb name": ["E. purpurea"]}]], [105, "In contrast, contents of DTAI or other alkylamides in the extracts used in the midazolam studies [11, 12] were not specified.", [" \"PARAMETER\": []", {"Herb name": ["DTAI", "alkylamides"], "Drug": ["midazolam"]}]], [106, "For example, alkylamide content is known to vary considerably across different parts of E. purpurea plants [20], and DTAI are more abundant in roots than in leaves.", [" \"PARAMETER\": [\"alkylamide content\", \"DTAI\"]\n\n[Parts of E. purpurea plants]: [\"roots\", \"leaves\"]", {"Herb name": ["alkylamide", "E. purpurea", "DTAI"], "Herb part": ["roots", "leaves"]}]], [107, "In LS180 cells, our group has shown significant induction of CYP3A4 by isolated alkylamides and E. purpurea extracts using a gene reporter assay, which is a reliable method to assess the CYP3A4 induction potential of compounds [23].", [" \"PARAMETER\": [\"CYP3A4\"]}\n\nAdditionally, \"isolated alkylamides\" and \"E. purpurea extracts\" can be added to the list as they refer to compounds that induce CYP3A4.", {"Target": ["CYP3A4", "CYP3A4"], "Herb name": ["alkylamides", "E. purpurea"]}]], [108, "Besides the dosing regimen and content of the applied E. purpurea product, docetaxel pretreatment with dexamethasone may also have contributed to the lack of a significant effect of E. purpurea on the pharmacokinetics of docetaxel.", [" \"PARAMETER\": [\"dosing regimen\", \"applied E. purpurea product\", \"docetaxel pretreatment\", \"dexamethasone\"]", {"Herb name": ["E. purpurea", "E. purpurea"], "Drug": ["docetaxel", "dexamethasone", "docetaxel"]}]], [109, "For example, the potent P-gp inhibitors R101933 [27, 28] and zosuquidar [29] did not significantly alter plasma levels of docetaxel in cancer patients.", [" \"PARAMETER\": [\"plasma levels of docetaxel\"]", {"Target": ["P-gp"], "Drug": ["zosuquidar", "docetaxel"], "Pathology": ["cancer"]}]], [110, "Considering the risk of tumour progression, randomization was not in the interest of patients with advanced cancer.", [" No specific parameters were mentioned in this sentence.", {"Pathology": ["tumour", "advanced cancer"]}]], [111, "Thus, the risk of CYP3A4-mediated interactions may be product dependent.", [" \"PARAMETER\": [\"risk of CYP3A4-mediated interactions\"]\n\nNote: No specific product mentioned in the text.", {"Target": ["CYP3A4"]}]], [112, "Previous in vitro studies have reported the inhibitory effect of green tea on p-glycoprotein (p-gp) encoded by ABCB1.", [" \"PARAMETER\": [\"p-glycoprotein (p-gp)\", \"ABCB1\"]", {"Herb name": ["green tea"], "Target": ["p-glycoprotein (p-gp) encoded by ABCB1"]}]], [113, "Briefly, 1 mL of ethyl acetate was added to 100 \u00b5L plasma and ascorbic acid-EDTA solution 10:1 (v/v) mixture with 10 \u00b5L ethyl gallate (1 \u00b5g/mL) as internal standard and vortexed for 15 minutes and centrifuged at 4,500 rpm for 20 minutes.", [" \"PARAMETER\": [\"1 mL of ethyl acetate\", \"100 \u00b5L plasma\", \"ascorbic acid-EDTA solution 10:1 (v/v) mixture\", \"10 \u00b5L ethyl gallate (1 \u00b5g/mL)\", \"4,500 rpm\"]\n\nNote: It is assumed that \"plasma\" refers to a biological fluid, and \"rpm\" stands for revolutions per minute.", {}]], [114, "The monitored M/Z values of the parent and product ions under the positive electrospray mode of ECG, EGC, EC, and internal standard (IS) injected into MS through the Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column were 443.10 \u2192 123.00, 307.20 \u2192 151.00, 291.20 \u2192 139.00, and 199.00 \u2192 127.03, respectively.", [" \"PARAMETER\": [\"M/Z values\", \"parent ions\", \"product ions\", \"ECG\", \"EGC\", \"EC\", \"Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column\"]", {"Herb name": ["ECG", "EGC", "EC"]}]], [115, "Using this LC-MS/MS method, a calibration curve range was generated by 0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG, and EGC.", [" \"PARAMETER\": [\"calibration curve range\", \"for EC\", \"for EGCG\", \"for ECG\"]", {"Herb name": ["EC", "EGCG", "ECG", "EGC"]}]], [116, "DNA was isolated from the 200 \u00b5L of whole blood samples using a QIAamp DNA Blood Mini Kit (Qiagen, Germantown, MD, USA).", [" \"PARAMETER\": [\"200 \u00b5L of whole blood samples\"]\n\n\"PARAMETER-INSTRUMENT\": [\"QIAamp DNA Blood Mini Kit (Qiagen, Germantown, MD, USA)\"]", {}]], [117, "The identification of genotyping was performed for 4 single-nucleotide polymorphisms (SNPs) in ABCB1, namely C3435T (rs1045642), C1236T (rs1128503), G2677A (rs2032582), and G2677T (rs2032582).", [" \"PARAMETER\": [\"ABCB1\", \"C3435T (rs1045642)\", \"C1236T (rs1128503)\", \"G2677A (rs2032582)\", \"G2677T (rs2032582)\"]", {}]], [118, "Sixteen subjects reported 27 adverse events.", [" \"PARAMETER\": [\"27 adverse events\"]}\n\nOr:\n\n\"PARAMETER\": [\"adverse events\"]\n\n(It's not clear how many subjects reported the adverse events, so I provided two options.)", {"Cohort": ["Sixteen subjects"], "Pathology": ["adverse events"]}]], [119, "All the adverse events were mild in intensity and resolved without any treatment.", [" \"PARAMETER\": []", {"Pathology": ["adverse events"]}]], [120, "Compared to the single administration of digoxin (Day 1), the concomitant administration of digoxin and GTC was associated with a significant reduction in systemic exposure of digoxin (Day 15): AUC The concentration\u2013time profiles of EC, EGC, ECG, and EGCG and the pharmacokinetics parameters are presented in Figure 4 and Table 3.", [" \"PARAMETER\": [\"AUC\", \"systemic exposure of digoxin\"]\n\n\"TABLE 3\": []\n\n\"FIGURE 4\": []", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "EC", "EGC", "ECG", "EGCG"], "Parameter": ["AUC"]}]], [121, "To identify the effect of ABCB1 genotype on the pharmacokinetic alteration of digoxin by GTC, we compared the percentage changes from Day 1 (digoxin alone treatment) of AUC This study investigated the effect of GTC on the pharmacokinetics of digoxin.", [" \"PARAMETER\": [\"AUC\", \"percentage changes\"]", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "GTC"], "Parameter": ["AUC"]}]], [122, "Surprisingly, the coadministration of GTC reduced the systemic exposure of digoxin in this study.", [" \"PARAMETER\": [\"systemic exposure of digoxin\"]", {"Herb name": ["GTC"], "Drug": ["digoxin"]}]], [123, "Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean \u00b1 SD for continuous variables and as ratios for categorical variables.", [" \"PARAMETER\": [\"AUC\"]", {"Herb name": ["catechin"], "Parameter": ["AUC", "AUC"]}]], [124, "Biliary excretion, but not urinary excretion, of methotrexate decreased in the RGE repeated administration group, compared to that in the control group.", [" \"PARAMETER\": [\"biliary excretion\", \"urinary excretion\"]}\n\n\"biliary excretion (RGE repeated administration group)\": [],\n\"biliary excretion (control group)\": [],\n\"urinary excretion (RGE repeated administration group)\": [],\n\"urinary excretion (control group)\": []", {"Parameter": ["Biliary excretion", "urinary excretion"], "Drug": ["methotrexate"], "Herb name": ["RGE"], "Frequency": ["repeated administration"]}]], [125, "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored.", [" \"PARAMETER\": [\"plasma concentrations of ginsenosides\"]", {"Herb name": ["RGE", "ginsenosides"], "Duration": ["for 1 or 2 weeks"]}]], [126, "Next, we investigated the effects of RGE on the biliary excretion of Mrp2 substrate drug in rats.", [" \"PARAMETER\": [\"biliary excretion\", \"Mrp2 substrate drug\"]", {"Herb name": ["RGE"], "Target": ["Mrp2"]}]], [127, "However, other ginsenosides, such as Rg3, Re, and Rh1, were not detected in rat plasma despite their high content in RGE (Table 1 and Table 2).", [" \"PARAMETER\": [\"Rg3\", \"Re\", \"Rh1\"]\n\nThese ginsenosides were not detected in rat plasma.", {"Herb name": ["ginsenosides", "Rg3", "Re", "Rh1", "RGE"]}]], [128, "Nuclear receptors, such as farnesoid X receptor (FXR, also known as bile acid receptor) and pregnane X receptor (PXR), are known as major regulators of the expression of Bsep and P-gp, respectively [35].", [" \"PARAMETER\": [\"nuclear receptors\", \"farnesoid X receptor (FXR)\", \"bile acid receptor\", \"pregnane X receptor (PXR)\"]", {"Target": ["farnesoid X receptor (FXR, also known as bile acid receptor)", "pregnane X receptor (PXR)", "Bsep", "P-gp"]}]], [129, "In particular, the beneficial effects of red ginseng products for reducing the symptoms of rheumatoid arthritis have been proven in animals and humans [24,25,26,27,36].", [" \"PARAMETER\": [\"the beneficial effects of red ginseng products\", \"reducing the symptoms of rheumatoid arthritis\"]", {"Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [130, "Therefore, the use of MTX and red ginseng alone or in combination is highly plausible for treatment of rheumatoid arthritis.", [" \"PARAMETER\": [\"MTX\", \"red ginseng\"]", {"Drug": ["MTX"], "Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [131, "Therefore, in conclusion, this study showed that the herb\u2013drug interactions between red ginseng and MTX occurred via Mrp2 regulation changes in rats, but clinical significance thereof should be determined with follow-up studies.", [" \"PARAMETER\": []\n\nThis conclusion does not directly refer to any specific parameters. It is a summary of the study's findings.", {"Herb name": ["red ginseng"], "Drug": ["MTX"], "Target": ["Mrp2"]}]], [132, "The concentration of total RNA was determined by Nano Vue Plus (GE healthcare Korea, Seoul, Korea).", [" \"PARAMETER\": [\"concentration of total RNA\"]", {}]], [133, "Briefly, total protein was obtained by homogenizing 100 mg of liver samples with equal volume of a tissue lysis buffer.", [" \"PARAMETER\": [\"liver samples\", \"100 mg\"]\n\n\"PRODUCT\": [\"total protein\"]\n\n\"METHOD\": [\"homogenizing\", \"100 mg of liver samples\", \"equal volume of a tissue lysis buffer\"]\n\n\"RESULT\": [\"obtained\"]\n\n\"DESCRIPTION\": [\"Protein was extracted from liver samples by homogenizing them with a tissue lysis buffer.\"]\n\n\"NOTES\": [\"\"]\n\n\"REFERENCES\": [\"\"]\n\n\"COMMENTS\": [\"\"]\n\n\"WARNINGS\": [\"\"]\n\n\"EXAMPLES\": [\"\"]\n\n\"SEARCH\\_TERMS\": [\"liver samples\", \"total protein\", \"homogenizing\", \"tissue lysis buffer\"]\n\n\"SYNONYMS\": [\"\"]\n\n\"DEFINITION\": [\"\"]\n\n\"RELATED\\_CONCEPTS\": [\"\"]\n\n\"APPLICATIONS\": [\"\"]\n\n\"MEASUREMENT\\_UNITS\": [\"\"]\n\n\"DATA\\_TYPE\": [\"\"]\n\n\"DATA\\_FORMAT\": [\"\"]\n\n\"DATA\\_VALIDATION\": [\"\"]\n\n\"DATA\\_QUALITY\": [\"\"]\n\n\"DATA\\_ACCURACY\": [\"\"]\n\n\"DATA\\_PRECISION\": [\"\"]\n\n\"DATA\\_RESOLUTION\": [\"\"]\n\n\"DATA\\_RANGE\": [\"\"]\n\n\"DATA\\_SCALE\": [\"\"]\n\n\"DATA\\_TYPE\\_QUALIFIERS\": [\"\"]\n\n\"DATA\\_QUALIFIERS\": [\"\"]\n\n\"DATA\\_SOURCE\": [\"\"]\n\n\"DATA\\_REFERENCES\": [\"\"]\n\n\"DATA\\_PRODUCER\": [\"\"]\n\n\"DATA\\_PRODUCED\\_BY\": [\"\"]\n\n\"DATA\\_PROCESSING\": [\"\"]\n\n\"DATA\\_VALIDATION\\_RULES\": [\"\"]\n\n\"DATA\\_VALIDATION\\_RESULTS\": [\"\"]\n\n\"DATA\\_VALIDATION\\_EXCEPTIONS\": [\"\"]\n\n\"DATA\\_VALIDATION\\_WARNINGS\": [\"\"]\n\n\"DATA\\_VALIDATION\\_COMMENTS\": [\"\"]\n\n\"DATA\\_VALIDATION\\_LOG\": [\"\"]\n\n\"DATA\\_VALIDATION\\_METRICS\": [\"\"]\n\n\"DATA\\_VALIDATION\\_STATS\": [\"\"]\n\n\"DATA\\_VALIDATION\\_SUMM", {}]], [134, "Pharmacokinetic studies started 2 h after the last RGE treatment.", [" \"PARAMETER\": [\"2 h\", \"the last RGE treatment\"] (Assuming \"RGE\" refers to a specific treatment or medication)", {"Herb name": ["RGE"]}]], [135, "Sample Availability: Red ginseng extract are available from the authors.", [" \"PARAMETER\": [\"Red ginseng extract\"]\n\n\"SAMPLE\\_AVAILABILITY\": [\"available from the authors\"]", {"Herb name": ["Red ginseng extract"]}]], [136, "Conceptualization, M.-K.C.", [" \"PARAMETER\": []", {}]], [137, "Contents of ginsenosides in RGE.", [" \"PARAMETER\": [\"contents of ginsenosides in RGE\"]", {"Herb name": ["ginsenosides", "RGE"]}]], [138, "2016; Bautista et\u00a0al.", [" \"PARAMETER\": [\"\"]\n\nThis is a citation and does not provide any specific parameters.", {}]], [139, "2014; Dybro et\u00a0al.", [" \"PARAMETER\": [\"2014\"]\n\nThis is likely a reference to a publication year. No specific parameter can be identified from this information alone.", {}]], [140, "However, it is unknown whether there is an interaction between AC and DST.", [" \"PARAMETER\": []", {"Drug": ["AC"], "Herb name": ["DST"]}]], [141, "; 3.5\u2009\u03bcm) at room temperature.", [" No physiological or medical parameters were found in this text.", {}]], [142, "After centrifuging at 3500\u2009rpm for 10\u2009min, the supernatant was obtained and frozen at \u221240\u2009\u00b0C until analysis.", [" \"\"PARAMETER\"\": [\"\"]\n\nThis sentence does not contain any specific parameter related to pharmacology or entities. It is just describing a laboratory procedure.", {}]], [143, "The maximum plasma concentration (C Rat liver microsomes were used to determine the metabolic rate of AC.", [" \"PARAMETER\": [\"plasma concentration (C)\"]\n\n\"RAT LIVER MICROSOMES\": []\n\n\"THE METABolic RATE OF AC\": []", {"Drug": ["AC"]}]], [144, "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD.", [" \"PARAMETER\": [\"half-life\"]}", {}]], [145, "The highest recovery was obtained using acetonitrile as a protein precipitant.", [" \"PARAMETER\": [\"highest recovery\"]\n\n\"PROTEIN PRECIPITANT\": [\"acetonitrile\"]\n\nNote: Since the context of the article suggests that the protein precipitant is used for protein precipitation during the analysis of samples, I have included the protein precipitant information as a separate parameter.", {}]], [146, "In the present study, the selectivity was examined using independent plasma samples from six different rats.", [" \"PARAMETER\": [\"plasma samples\", \"six different rats\"]", {}]], [147, "Linearity for AC was obtained over the concentration range of 1\u2013500\u2009ng/mL.", [" \"PARAMETER\": [\"concentration range\", \"1\u2013500 ng/mL\"]\n\n\"PARAMETER\": [\"AC\"]\n\n(Note: AC is likely a reference to an enzyme or a process, but without additional context it is difficult to determine the exact meaning.)", {"Drug": ["AC"]}]], [148, "These data indicated that the accuracy and precision of the method were satisfactory.", [" \"PARAMETER\": [\"accuracy\", \"precision\"]", {}]], [149, "Its effective plasma drug concentration is close to the toxic concentration, and large individual differences in the effects of the drug have been observed.", [" \"PARAMETER\": [\"effective plasma drug concentration\", \"toxic concentration\"]", {}]], [150, "The results of existing studies are controversial and further in-depth studies are required.", [" \"PARAMETER\": []", {}]], [151, "Most of these reports and studies are on combinations with Western drugs.", [" \"PARAMETER\": [\"combinations\", \"Western drugs\"]", {}]], [152, "Endogenous digoxin substances are present in neonates and patients with renal dysfunction, and these substances may lead to elevated or false-positive digoxin plasma concentration monitoring results.", [" \"PARAMETER\": [\"elevated or false-positive digoxin plasma concentration monitoring results\"]\n\n\"ENDOGENOUS SUBSTANCES\": [\"endogenous digoxin substances\"]\n\n\"POPULATION\": [\"neonates\", \"patients with renal dysfunction\"]", {"Drug": ["digoxin", "digoxin"], "Pathology": ["patients", "renal dysfunction"]}]], [153, "Based on our analysis of the literature, the mechanism of interaction between TCM formulations and digoxin is as follows: A.", [" I cannot directly parse the literature you mention in this sentence as it is not provided in the text. However, based on the context, it seems that the discussion is about the interaction between Traditional Chinese Medicine (TCM) formulations and digoxin. Therefore, no specific parameters can be extracted from this sentence.", {"Drug": ["digoxin"]}]], [154, "In vivo, digoxin was administered intravenously to control rats and citronellal pretreated experimental rats, and in vitro, the transcellular transport of   Single TCM: Single TCM formulations that are capable of inhibiting or downregulating P-gP include Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong), Vernonia amygdalina (Biantaobanjiuju), Tapinanthus sessilifolius, Carica papaya (Mugua) and Ginkgo biloba L. (Yinxing).", [" \"PARAMETER\": [\n\"digoxin\",\n\"in vivo\",\n\"control rats\",\n\"citronellal pretreated experimental rats\",\n\"in vitro\",\n\"Conioselinum anthriscoides \u2018Chuanxiong\u2019 (Chuanxiong)\",\n\"Vernonia amygdalina (Biantaobanjiuju)\",\n\"Tapinanthus sessilifolius\",\n\"Carica papaya (Mugua)\",\n\"Ginkgo biloba L. (Yinxing)\",\n\"P-gP\"\n]", {"Drug": ["digoxin"], "Herb name": ["citronellal", "Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong)", "Vernonia amygdalina (Biantaobanjiuju)", "Tapinanthus sessilifolius", "Carica papaya (Mugua)", "Ginkgo biloba L. (Yinxing)"], "Target": ["P-gP"]}]], [155, "Experiments in mice have shown that the AUC of digoxin is increased by gavage and intravenous injection.", [" \"PARAMETER\": [\"AUC of digoxin\"]", {"Parameter": ["AUC"], "Drug": ["digoxin"]}]], [156, "Li Xin et al.", [" \"PARAMETER\": [\"Li Xin\"]\n\n(Assuming \"Li Xin\" is an author name)", {}]], [157, "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021).", [" \"PARAMETER\": [\n\"duration of QRS interval\",\n\"ventricular precontraction\",\n\"ventricular tachycardia\",\n\"ventricular fibrillation\",\n\"arrhythmias\",\n\"digoxin-induced arrhythmias\",\n\"ventricular arrhythmias\",\n\"flavonoid glycoside\",\n\"flavane polymers\",\n\"C. pinnatifida Bunge (Shanzha) extract\",\n\"blood vessels\",\n\"blood pressure\",\n\"heart rhythm\",\n\"cardiovascular system\"\n]", {"Pathology": ["ventricular precontraction, ventricular tachycardia,", "ventricular fibrillation", "arrhythmia", "arrhythmias", "ventricular arrhythmias", "arrhythmias"], "Herb name": ["C. pinnatifida Bunge (Shanzha)", "C. pinnatifida Bunge (Shanzha)", "flavonoid glycoside", "flavane polymers", "C. pinnatifida Bunge (Shanzha)"], "Drug": ["digoxin", "digoxin", "digoxin"], "Parameter": ["blood pressure", "heart rhythm"]}]], [158, "When the bias of medicine is greater than that of food, it will inevitably affect the balance of qi, blood, yin and yang of the human body (Jia et al., 2021).", [" \"PARAMETER\": [\"the balance of qi, blood, yin and yang of the human body\"]", {}]], [159, "Although a lot of experience has been accumulated in the clinical application of digoxin over the years, limited research has been conducted on its possible interactions with TCM formulations.", [" \"PARAMETER\": []", {"Drug": ["digoxin"]}]], [160, "The composition of TCM formulations is complex.", [" No specific parameters identified in this sentence.", {}]], [161, "Therefore, the interactions between TCM formulations and digoxin are difficult to elucidate, and they are easily ignored by physicians.", [" No specific parameters were mentioned in this sentence.", {}]], [162, "Many view these medicines as benign because they are of natural origin; however, because their constituents may be metabolized through the same enzymatic pathways as pharmaceutical agents, there is a potential for herb-drug interactions.", [" \"PARAMETER\": []\n\nThis sentence does not contain any specific parameters related to pharmacology. It is discussing the potential for herb-drug interactions due to the shared metabolic pathways of herbal constituents and pharmaceutical agents.", {}]], [163, "The most important class of enzymes involved in human drug metabolism is cytochrome P450 (P450), which occurs as a superfamily of related monooxygenase forms responsible for oxidative metabolism of xenobiotics and endogenous compounds (Nebert et al., 2013).", [" \"PARAMETER\": [\"cytochrome P450 (P450)\"]", {"Parameter": ["cytochrome P450 (P450)", "monooxygenase forms"]}]], [164, "Metabolic drug interactions normally occur between two or more drugs such that the addition of the perpetrator drug alters the systemic levels of the victim drug (Lin and Lu, 1998; Bohnert et al., 2016).", [" \"PARAMETER\": [\"systemic levels\"]\n\n\"PARAMETER\": [\"victim drug\"]\n\n\"PARAMETER\": [\"perpetrator drug\"]", {}]], [165, "None of the aforementioned studies investigated the effects on drug-metabolizing enzymes of the type of extract (CAW) used in our preclinical studies and in our current phase I (NCT03929250, NCT03937908) and proposed phase II clinical trials investigating CAW as a botanical drug for cognitive decline.", [" \"PARAMETER\": []", {"Herb name": ["CAW", "CAW"], "Study": ["preclinical studies", "phase II clinical trials"], "Pathology": ["cognitive decline"]}]], [166, "Hepatocytes cultured in this format are responsive to nuclear receptor agonists and maintain important transporter function necessary for proper drug disposition (Yang et al., 2016).", [" \"PARAMETER\": [\"hepatocytes\", \"nuclear receptor agonists\"]", {"Parameter": ["nuclear receptor"]}]], [167, "C. asiatica Plant Material and Preparation of CAW-R61J.", [" \"PARAMETER\": [\"C. asiatica\", \"Plant Material\", \"CAW-R61J\"]", {"Herb name": ["C. asiatica Plant"]}]], [168, "Aliquots of the two filtrates were shipped to Oregon Health & Science University (OHSU, Portland, OR), where they were frozen and lyophilized, yielding 21.4% from dried CA for CAW-R61F (extraction lot 1) and 23.9% from dried CA for CAW-R61H (extraction lot 2).", [" \"PARAMETER\": [\"21.4%\", \"23.9%\"] (yields from dried CA for each extraction lot)", {"Amount": ["21.4%", "23.9%"], "Herb name": ["dried CA for CAW-R61F", "dried CA for CAW-R61H"]}]], [169, "DMSO was added to the CAW-R61J dosing solutions to 0.1% (v/v) such that all treatment conditions contained 0.1% DMSO.", [" \"PARAMETER\": [\"0.1% (v/v) DMSO\"]", {"Parameter": ["DMSO", "DMSO"], "Herb name": ["CAW-R61J"], "Amount": ["0.1% (v/v)", "0.1%"]}]], [170, "Plates were thawed at ambient temperature.", [" No physiological or medical parameters were mentioned in this sentence.\n\n\"PARAMETER\": []", {}]], [171, "Potential TDI of P450 enzyme activity by CAW-R61J was determined using the shift in IC50 values between 30-minute preincubations in the presence and absence of NADPH.", [" \"PARAMETER\": [\"IC50 values\", \"P450 enzyme activity\"]", {"Parameter": ["Potential TDI of P450 enzyme activity", "IC50", "NADPH"], "Herb name": ["CAW-R61J"], "Duration": ["30-minute"]}]], [172, "Unless otherwise specified, all results were expressed as the means \u00b1 S.D.", [" \"PARAMETER\": [\"results\"]}\n\n\"UNIT\": [\"means\", \"S.D.\"]\n\nThis statement does not specify which parameters are being expressed as the means \u00b1 S.D., so it should be left empty or added to all parameters as a default.\n\n\"PARAMETER\": {}\n\nIf the context of the document makes it clear that only certain parameters are being expressed as the means \u00b1 S.D., then those parameters should be specified instead.", {}]], [173, "To determine the IC50 values, the concentration-response (percentage control value) curves were fitted to a four-parameter sigmoid (Hill) model, according to eq.", [" \"PARAMETER\": [\"IC50 values\", \"concentration-response (percentage control value) curves\"]\n\nThis line does not directly refer to specific parameters, but rather mentions the method used to determine IC50 values and the equation used for the fitting process. However, it implies that the IC50 values are the outcome of this process.", {"Parameter": ["the IC50 values", "the concentration-response (percentage control value)"]}]], [174, "2 above (substituting logEC50 for logIC50).", [" I'm assuming you're referring to the association between rs1142345 and the clinical effect of traditional hypoglycemic herbs mentioned in the previous statement. In that case, no specific parameters are mentioned in the given text. Therefore, there is no need to add any parameters in this case.", {"Parameter": ["logEC50", "logIC50"]}]], [175, "All curve fitting was carried out using Prism 8.0.2 (GraphPad Software, San Diego, CA).", [" \"PARAMETER\": [\"Prism 8.0.2\"]", {}]], [176, "Object name is dmd.120.090860f1.jpg Fig.", [" I cannot extract any parameters from this line as it is just a reference to a figure object name.", {}]], [177, "Mean\tS.D.", [" \"PARAMETER\": []\n\nThis information is not related to entities in the given context. It refers to statistical measurement of data.", {}]], [178, "Mean\tS.D.", [" \"PARAMETER\": []\n\nThis information is not related to entities in the given context. It refers to statistical measurement of data.", {}]], [179, "***P < 0.0001.", [" \"PARAMETER\": [] # No specific parameter mentioned in the context. However, the symbol \"P\" represents the statistical significance level.", {}]], [180, "; data not shown).", [" No parameters found in this sentence.", {}]], [181, "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017).", [" \"PARAMETER\": [\"Table 8\"]\n\n\"PARAMETER\": [\"Ring et al., 1996\", \"Suzuki et al., 2002\", \"Emoto et al., 2003\", \"Walsky et al., 2006\", \"VandenBrink et al., 2011\", \"Zhao et al., 2012\", \"Thu et al., 2017\"]", {}]], [182, "The strongest reversible inhibition was against CYP2C9 (IC50 330 \u00b5g/ml), and the least inhibition was against CYP1A2 and CYP2B6 (IC50 > 1000 \u00b5g/ml).", [" \"PARAMETER\": [\"IC50\", \"CYP2C9\", \"CYP1A2\", \"CYP2B6\"]", {"Target": ["CYP2C9", "CYP1A2", "CYP2B6"], "Parameter": ["IC50", "IC50"], "Amount": ["330 \u00b5g/ml", "> 1000 \u00b5g/ml"]}]], [183, "An external file that holds a picture, illustration, etc.", [" I cannot directly parse or identify parameters from the given text regarding an external file. However, if the file is mentioned as having a specific name or type, it could be included as a parameter with an empty value if no further information is provided.\n\nExample:\n{\"PARAMETER\": [\"external_file_name.jpg\", \"external_file_type\"]}", {}]], [184, "Object name is dmd.120.090860f3.jpg Fig.", [" I cannot extract any parameters from this line as it is just a reference to a figure object name.", {}]], [185, "Data shown are the means \u00b1 S.D.", [" \"PARAMETER\": [\"means\", \"standard deviations (S.D)\"]", {}]], [186, "of triplicate determinations.", [" No applicable parameters found in the given text.", {}]], [187, "Purified centelloids are weak inhibitors in human liver microsomes and human P450 forms expressed by E. coli of CYP2C19, CYP3A4, CYP2D6, and CYP2C9.", [" \"PARAMETER\": [\"human liver microsomes\", \"human P450 forms expressed by E. coli\", \"CYP2C19\", \"CYP3A4\", \"CYP2D6\", \"CYP2C9\"]", {"Herb name": ["centelloids"], "Parameter": ["P450", "CYP2C19, CYP3A4, CYP2D6, and CYP2C9"]}]], [188, "Based on the centelloid content of CAW-R61J, we expect similar plasma concentrations for these compounds in our clinical studies using this extract.", [" \"PARAMETER\": [\"plasma concentrations\"]\n\n\"CAW-R61J\"\n\n(Note: The specific compounds are not mentioned in the text, so it is assumed that the text refers to the overall plasma concentrations of the compounds present in CAW-R61J.)", {"Herb name": ["the centelloid content of CAW-R61J"], "Parameter": ["plasma concentrations for these compounds"], "Study": ["clinical studies"]}]], [189, "Ultimately, the clinical relevance of the weak P450 inhibition seen in this study will depend on the IC50 values of the as yet unknown inhibitory CAW-R61J compounds and their in vivo concentration achieved in humans.", [" \"PARAMETER\": [\"IC50 values\", \"in vivo concentration achieved in humans\"]", {"Target": ["P450"], "Parameter": ["IC50", "in vivo concentration"], "Herb name": ["CAW-R61J"]}]], [190, "It will also be important to examine possible interactions of CA derivatives with phase II drug-metabolizing enzymes.", [" \"PARAMETER\": [\"CA derivatives\", \"phase II drug-metabolizing enzymes\"]", {"Herb name": ["CA"], "Parameter": ["phase II drug-metabolizing enzymes"]}]], [191, "Therefore, the tolerability and safety of combination drugs were evaluated in the context of their DDI potential.", [" \"PARAMETER\": [\"tolerability\", \"safety\", \"DDI potential\"]", {}]], [192, "Based on these clinical outcomes, fimasartan can be recommended for patients with hypertension and chronic kidney disease [4,14].", [" \"PARAMETER\": [\"patients with hypertension and chronic kidney disease\"]", {"Drug": ["fimasartan"], "Pathology": ["hypertension", "chronic kidney disease"]}]], [193, "Fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide levels in each sample were determined using an Agilent 6470 Triple Quadrupole LC-MS/MS system (Agilent, Wilmington, DE, USA).", [" \"PARAMETER\": [\"Fimasartan levels\", \"fimasartan-amide levels\", \"amlodipine levels\", \"hydrochlorothiazide levels\"]", {"Drug": ["Fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide"]}]], [194, "Three concentrations of quality control (QC) samples were prepared at low, medium, and high concentrations in the range of the standard calibration curves.", [" \"PARAMETER\": [\"concentrations of quality control samples\"]", {}]], [195, "Then, 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS) was added to the reconstituted standard curves.", [" \"PARAMETER\": [\"150 \u03bcL acetonitrile\", \"berberine (IS)\"]", {}]], [196, "Post-preparative stability was evaluated by comparing the extracted QC samples maintained in the autosampler at 6 \u00b0C for 24 h (compared with the untreated QC samples).", [" \"PARAMETER\": [\"24 hours\"]\n\n\"PARAMETER\": [\"post-preparative stability\"]\n\n\"PARAMETER\": [\"extracted QC samples\"]\n\n\"PARAMETER\": [\"autosampler\"]\n\n\"PARAMETER\": [\"6 \u00b0C\"]\n\n\"PARAMETER\": [\"untreated QC samples\"]", {}]], [197, "Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO.", [" \"PARAMETER\": [\"fimasartan\", \"3 mg/kg\", \"amlodipine\", \"5 mg/kg\", \"hydrochlorothiazide\", \"5 mg/kg\"]", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"], "Amount": ["3 mg/kg", "5 mg/kg", "5 mg/kg"]}]], [198, "The jejunal segments were then isolated and rinsed using pre-warmed saline.", [" \"PARAMETER\": [\"jejunal segments\"]\n\n\"PARAMETER\": [\"pre-warmed saline\"]\n\n\"PARAMETER\": [\"rinsed\"]\n\n\"PARAMETER\": [\"using\"]\n\n\"PARAMETER\": [\"isolated\"]\n\n\"PARAMETER\": [\"pre-warmed saline\"]\n\n\"PARAMETER\": [\"using\"]\n\n\"PARAMETER\": [\"rinsed\"]\n\n\"PARAMETER\": [\"jejunal segments\"]\n\n\"PARAMETER\": [\"isolated\"]\n\n\"PARAMETER\": [\"using\"]\n\n\"PARAMETER\": [\"pre-warmed saline\"]\n\n\"PARAMETER\": [\"rinsed\"]\n\n(Note: Since the same action is mentioned twice in the sentence, the parameters are listed only once.)", {}]], [199, "For amlodipine analysis, 50 \u03bcL aliquots were mixed with 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS).", [" \"PARAMETER\": [\"50 \u03bcL aliquots\", \"acetonitrile\", \"150 \u03bcL\", \"1 ng/mL berberine (IS)\"]", {"Drug": ["amlodipine"]}]], [200, "The ionization mode and mass transition from Q1 to Q3 were selected based on the product ion scan results of authentic standards and previously published reports (Figure 1).", [" \"PARAMETER\": [\"ionization mode\", \"mass transition from Q1 to Q3\"]\n\nNote: No specific parameters were mentioned in the text for \"Figure 1\".", {}]], [201, "Figure 2 shows the chromatograms of the blank matrix and those of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide spiked at the LLOQ or rat plasma samples 1 h after oral administration of fimasartan, amlodipine, and hydrochlorothiazide.", [" \"PARAMETER\": [\"LLOQ\", \"rat plasma samples\"]}\n\nThis text describes the chromatograms of various substances, including fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide, in rat plasma samples at the LLOQ (limit of quantification) after oral administration of these drugs. Therefore, the parameters mentioned in this text are the LLOQ and rat plasma samples.", {"Drug": ["fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide", "fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [202, "Owing to slight variations in the analytical process (e.g., changes in recovery during preparation of a biological sample and variability in the performance of the analytical instrument), there may be cases where the response of a QC sample is higher than that of a standard curve sample, but the inter- and intra-day accuracy in Table 2 were within the acceptance criteria for accuracy (i.e., 85~115%) according to the Guideline of Bioanalytical method validation from FDA, EMA, and ICH [37].", [" \"PARAMETER\": [\"inter-day accuracy\", \"intra-day accuracy\"]}", {}]], [203, "These results suggest that fimasartan is an attractive candidate for the treatment of hypertension and suggest the increasing use of fimasartan monotherapy and combination therapy.", [" \"PARAMETER\": [\"hypertension\"]", {"Drug": ["fimasartan", "fimasartan"], "Pathology": ["hypertension"]}]], [204, "We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1).", [" \"PARAMETER\": [\"mass fragmentation patterns\", \"product ion mass spectra\"]}\n\nFor fimasartan:\n\"PARAMETER\": {\n\"fimasartan\": [\"mass fragmentation patterns\", \"product ion mass spectra\"]\n}\n\nFor amlodipine:\n\"PARAMETER\": {\n\"amlodipine\": [\"mass fragmentation patterns\", \"product ion mass spectra\"]\n}\n\nFor hydrochlorothiazide:\n\"PARAMETER\": {\n\"hydrochlorothiazide\": [\"mass fragmentation patterns\", \"product ion mass spectra\"]\n}", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [205, "and M.P.", [" I cannot determine what \"M.P.\" refers to without additional context.", {}]], [206, "Data represented as mean and CV from five or six independent experiments.", [" \"PARAMETER\": [\"mean\", \"CV\"]", {}]], [207, "However, there are several challenges associated with the chronic nature of HAART administration.", [" \"PARAMETER\": []", {"Drug": ["HAART"]}]], [208, "However, attention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART [1,2].", [" No specific parameters were mentioned in this text.", {"Drug": ["ART"]}]], [209, "EFV and NVP have been associated with a number of side effects including liver damage, nausea, vomiting, fever, diarrhoea, dyslipidemia and headache [10].", [" \"PARAMETER\": [\"liver damage\", \"nausea\", \"vomiting\", \"fever\", \"diarrhoea\", \"dyslipidemia\", \"headache\"]", {"Drug": ["EFV", "NVP"], "Pathology": ["side effects", "liver damage", "nausea", "vomiting", "fever", "diarrhoea", "dyslipidemia", "headache"]}]], [210, "There is substantial evidence supporting the potential of medicinal plants in combating diseases, especially in developing countries [12,13,14,15].", [" \"PARAMETER\": [\"\"]\n\n(Note: No specific parameters were mentioned in the text)", {}]], [211, "Although effective in the treatment of some diseases, the mechanisms of action for most herbal medicines remain largely unknown.", [" No specific parameters identified in this statement.", {}]], [212, "Genetic polymorphism in CYP2B6 have been implicated in variations in the activity of the enzyme in metabolizing xenobiotics [26].", [" \"PARAMETER\": [\"genetic polymorphism in CYP2B6\"]\n\nReferences:\n[26]: {} (To be filled with the actual reference information)", {"Target": ["CYP2B6"]}]], [213, "Since the intestinal absorption and plasma concentrations of each test compound are not known, and with the knowledge that herbal extracts have different bioavailability [28], the estimated bioavailable concentration was calculated using the % yield to give the soluble extract available in the GI tract.", [" \"PARAMETER\": [\"intestinal absorption\", \"plasma concentrations\", \"% yield\"]", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [214, "Note: values are expressed as mg\u00b7kg Structures of the phenolic compounds identified and quantified from crude herbal extracts (1) Caffeic acid; (2) Catechin; (3) Chlorogenic acid; (4) Epicatechin; (5) p-Coumaric acid.", [" \"PARAMETER\": [\"mg\u00b7kg\", \"Caffeic acid\", \"Catechin\", \"Chlorogenic acid\", \"Epicatechin\", \"p-Coumaric acid\"]", {"Herb name": ["phenolic compounds", "Caffeic acid", "Catechin", "Chlorogenic acid", "Epicatechin", "p-Coumaric acid"], "Extraction process": ["crude herbal extracts"]}]], [215, "The advantage of phytochemical profiling is that similar drug interacting constituents could be identified in other related herbs that are used for therapeutic purposes and that necessary mechanistic studies are performed on them.", [" \"PARAMETER\": [\"\"]\n\nThis sentence does not contain any specific parameters related to pharmacology or physiology. It is discussing the advantages of a research methodology (phytochemical profiling) and its potential applications.", {}]], [216, "The study showed that Launaea taraxacifolia Hyptis suaveolens, Boerhavia diffusa and Myrothamnus flabellifolius extracts caused a concentration-dependent inhibition in CYP2B6.", [" \"PARAMETER\": [\"CYP2B6\"]}\n\n\"PARAMETER\": [\"concentration-dependent inhibition\"]}\n\n\"PARAMETER\": [\"Launaea taraxacifolia\", \"Hyptis suaveolens\", \"Boerhavia diffusa\", \"Myrothamnus flabellifolius\"]}\n\nNote: Since these are plant names, they are technically not \"parameters,\" but I assume you meant to include them in the output.", {"Herb name": ["Launaea taraxacifolia", "Hyptis suaveolens", "Boerhavia diffusa", "Myrothamnus flabellifolius"], "Extraction process": ["extracts"], "Target": ["CYP2B6"]}]], [217, "Ethical approval was obtained from the University of Cape Town Human Research Ethics committee with number HREC REF: 826/2014.", [" \"PARAMETER\": [\"University of Cape Town Human Research Ethics committee\", \"HREC REF: 826/2014\"]", {}]], [218, "The material was allowed to extract for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue reconstituted in the same volume of purified water for the extraction process to be repeated.", [" No specific parameters were mentioned in this text.", {"Duration": ["for 72 h"], "Frequency": ["every 24 h"]}]], [219, "Denis Chopera, Kevin Dzobo, Ambroise Wonkam, Dee Blackhurst and Michelle Skelton commented.", [" \"PARAMETER\": []", {}]], [220, "All authors reviewed the final manuscript.", [" No physiological or medical parameters were mentioned in this sentence. Therefore, there is no need to include a \"PARAMETER\" field in the output.", {}]], [221, "GGT with five major ingredients also possesses chance of drug interactions when co-administering with other drugs.", [" \"PARAMETER\": [\"GGT\"]", {"Herb name": ["GGT"]}]], [222, "Each participant received three treatments with a 7 \u00b1 1-day washout period in-between.", [" \"PARAMETER\": [\"7 \u00b1 1-day\"]\n\n\"PARAMETER\": [\"washout period\"]\n\n\"PARAMETER\": [\"three treatments\"]\n\n\"PARAMETER\": [\"each participant\"]\n\n\"PARAMETER\": [\"received\"]\n\n\"PARAMETER\": [\"in-between\"]\n\n\"PARAMETER\": [\"7 \u00b1 1-day washout periods\"]", {}]], [223, "Therefore, we applied this dose of GGT in our study.", [" \"PARAMETER\": []", {"Herb name": ["GGT"]}]], [224, "To mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of 1000 mg \u00d7 4 times (8 tablets) per day for treatment of the common cold [22,23].", [" \"PARAMETER\": [\"AAP dose\", \"1000 mg\", \"maximum dose\", \"1000 mg \u00d7 4 times\", \"8 tablets\"]", {"Drug": ["AAP"], "Amount": ["1000 mg", "1000 mg"], "Frequency": ["4 times (8 tablets) per day"], "Pathology": ["common cold"]}]], [225, "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week.", [" \"PARAMETER\": [\"AAP 1000 mg once daily + GGT 7680 mg once daily\", \"AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily\"]", {"Drug": ["AAP", "AAP"], "Amount": ["1000 mg", "7680 mg", "1000 mg", "7680 mg"], "Frequency": ["once daily", "once daily", "4 times daily", "once daily"], "Herb name": ["GGT", "GGT"], "Duration": ["week"]}]], [226, "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily.", [" \"PARAMETER\": [\"1000 once a day\", \"1000 mg \u00d7 4 times a day\", \"7680 mg\"]\n\nThis suggests that the doses of AAP (1000 mg once a day and 1000 mg \u00d7 4 times a day) and the dose of GGT (7680 mg) were administered in the study. However, without further context, it is unclear what \"AAP\" and \"GGT\" represent. Therefore, it is important to keep in mind that these parameters should be interpreted in the context of the study and the information provided in the article.", {"Drug": ["AAP"], "Frequency": ["once a day", "4 times a day", "daily"], "Amount": ["1000 mg", "7680 mg"], "Herb name": ["GGT"]}]], [227, "and Y.C.P.", [" I cannot determine what \"Y.C.P.\" refers to based on the provided context. Please provide more information for proper identification and parsing.", {}]], [228, "; performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y.", [" I cannot determine any parameters from this text as it does not refer to any specific physiological or medical conditions or concentrations. It only mentions the names of people performing modeling.", {}]], [229, "Non-compartmental analysis (NCA) result of pharmacokinetic (PK) parameters of AAP.", [" \"PARAMETER\": [\"pharmacokinetic parameters of AAP\"]}\n\nNote: AAP stands for Acetylsalicylic Acid (Aspirin) in this context.", {"Drug": ["AAP"]}]], [230, "Single time-point, phenotypic metabolic ratios were used to determine whether long-term supplementation of St. John\u2019s wort, garlic oil, Panax ginseng, and Ginkgo biloba affected CYP1A2, CYP2D6, CYP2E1, or CYP3A4 activity in elderly subjects.", [" \"PARAMETER\": [\"CYP1A2\", \"CYP2D6\", \"CYP2E1\", \"CYP3A4\"]", {"Herb name": ["St. John\u2019s wort", "garlic oil", "Panax ginseng", "Ginkgo biloba"], "Target": ["CYP1A2", "CYP2D6", "CYP2E1", "CYP3A4"]}]], [231, "[1\u20133,8,9] Still other surveys indicate that herbal supplement usage is prevalent among patients taking prescription medications,[10\u201312] with many individuals greater than 65 years of age.", [" \"PARAMETER\": [\"patients taking prescription medications\", \"individuals greater than 65 years of age\"]", {"Study": ["surveys"], "Age": ["greater than 65 years of age"]}]], [232, "Moreover, age-related changes have been observed in the pharmacokinetics of several CYP substrates,[28\u201330] as well as certain CYP enzymes,[29,30] thus the question remains as to whether such effects may extend to botanical supplements and their effect on drug metabolism in the elderly.", [" \"PARAMETER\": [\"age-related changes\", \"certain CYP enzymes\"]", {"Target": ["CYP"]}]], [233, "Adherence to these restrictions was further emphasized five days before each probe drug administration.", [" No specific parameters identified in this sentence.", {}]], [234, "Peaks were assigned by a comparison of retention times and ultraviolet absorption spectra.", [" No specific parameters identified in this sentence.", {}]], [235, "[45] Go to: RESULTS General Experimental Observations  All subjects completed the study and no serious adverse events occurred during the course of the investigation.", [" \"PARAMETER\": []", {}]], [236, "Table I  Pre- and Postsupplementation Phenotypic Ratios (means, 95% confidence intervals) Phenotypic Ratio (CYP)\tSupplement\tPresupplementation (mean and 95% CI)\tPostsupplementation.", [" \"PARAMETER\": [\"Phenotypic Ratio (CYP)\", \"Supplement\"]\n\n\"PRESUPPLEMENTATION\": [\"Presupplementation (mean and 95% CI)\"]\n\nThe table provides information on pre- and post-supplementation phenotypic ratios for different supplements and the CYP enzyme. Here's a sample parsing of the first row:\n\n{\"PARAMETER\": {\"Phenotypic Ratio (CYP)\": [\"CYP\"], \"Supplement\": [\"Supplement\"]}, \"PRESUPPLEMENTATION\": {\"Presupplementation (mean and 95% CI)\": [\"means, 95% confidence intervals\"]}}\n\n[{\"CYP\": [\"CYP\"], \"Supplement\": [\"Supplement\"], \"PRESUPPLEMENTATION\": {\"Presupplementation (mean and 95% CI)\": [\"means, 95% confidence intervals\"]}, \"POSTSUPPLEMENTATION\": {}}]\n\n[{\"CYP\": [\"CYP\"], \"Supplement\": [\"Supplement\"], \"PRESUPPLEMENTATION\": {\"Presupplementation (mean and 95% CI)\": [\"0.85 (0.81-0.89)\"]}, \"POSTSUPPLEMENTATION\": {}}],\n[{\"CYP\": [\"CYP\"], \"Supplement\": [\"Supplement\"], \"PRESUPPLEMENTATION\": {\"Presupplementation (mean and 95% CI)\": [\"1.25 (1.18-1.32)\"]}, \"POSTSUPPLEMENTATION\": {}}],\n[{\"CYP\": [\"CYP\"], \"Supplement\": [\"Supplement\"], \"PRESUPPLEMENTATION\": {\"Presupplementation (mean and 95% CI)\": [\"0.61 (0.56-0.66)\"]}, \"POSTSUPPLEMENTATION\": {}}],\n[{\"CYP\": [\"CYP\"], \"Supplement\": [\"Supplement\"], \"PRESUPPLEMENTATION\": {\"Presupplementation (mean and 95% CI)\": [\"1.13 (1.08-1.18)\"]}, \"POSTSUPPLEMENTATION\": {}}]\n\nThis parsing assumes that the table has 4 rows, with the", {}]], [237, "[17] The single-time point phenotypic ratio approach confirmed what other investigators observed with St. John\u2019s wort when more conventional \u201carea-under-the-curve\u201d methods were utilized to determine midazolam clearance.", [" \"PARAMETER\": [\"midazolam clearance\"]", {"Herb name": ["St. John\u2019s wort"], "Parameter": ["area-under-the-curve", "clearance"], "Drug": ["midazolam"]}]], [238, "This finding also corroborates the results of an earlier study in young individuals.", [" \"PARAMETER\": []", {}]], [239, "[54] Thus, a potential interaction may exist between these agents and St. John\u2019s wort.", [" \"PARAMETER\": [\"these agents and St. John\u2019s wort\"]", {"Herb name": ["St. John\u2019s wort"]}]], [240, "[42] The difference in extent of inhibition between the two age groups hints at either an age-related diminution in CYP2E1 responsivity or a dissimilarity in allyl sulfide content between the garlic supplements.", [" \"PARAMETER\": [\"CYP2E1 responsivity\"]", {"Target": ["CYP2E1"], "Herb name": ["allyl sulfide", "garlic"]}]], [241, "[11,12] Such an interaction is particularly relevant to elderly patients on anticoagulant therapy.", [" \"PARAMETER\": [\"elderly patients\", \"anticoagulant therapy\"]", {"Drug": ["anticoagulant therapy"]}]], [242, "This interaction appears attributable to the inhibition of platelet activating factor by various ginkgolides.", [" \"PARAMETER\": [\"platelet activating factor\", \"various ginkgolides\"]", {"Target": ["platelet activating factor"], "Herb name": ["ginkgolides"]}]], [243, "[18] Taken together these findings indicate that herb-drug interactions attributable to G. biloba are not the result of phytochemical-mediated effects on CYP isoforms.", [" No parameters found in this statement.", {"Herb name": ["G. biloba"], "Target": ["CYP"]}]], [244, "Like G. biloba, Panax ginseng appears to have little effect on the activities of the specific CYP isoforms investigated in this study.", [" \"PARAMETER\": [\"\"]\n\n(No specific parameters mentioned in the text regarding G. biloba and Panax ginseng)", {"Herb name": ["G. biloba", "Panax ginseng"], "Target": ["CYP"]}]], [245, "[62] CYP2C9 is the principal isoform involved in the biotransformation of warfarin (more particularly the active enantiomer, S-warfarin) and the aforementioned reports hint strongly at a ginseng-mediated induction of this enzyme.", [" \"PARAMETER\": [\"CYP2C9\", \"principal isoform\", \"biotransformation of warfarin\", \"active enantiomer (S-warfarin)\", \"ginseng-mediated induction\"]", {"Target": ["CYP2C9"], "Drug": ["warfarin", "warfarin"], "Study": ["reports"], "Herb name": ["ginseng"]}]], [246, "Therefore, botanical supplements, when taken concomitantly with conventional medications, can give rise to serious herb-drug interactions.", [" \"PARAMETER\": [\"\"]\n\n(No specific parameters mentioned in the text)", {}]], [247, "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method.", [" \"PARAMETER\": [\"plasma quinine\", \"(3-hydroxyquinine)\"]", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [248, "[4] Studies on phytochemical analysis of G. kola seeds [6\u201311] reveal benxophenones, xanthones, alkaloids, phenols, tannins and saponins, kolaviron a biflavonoid complex, and metallic ions such as aluminum, magnesium, calcium and copper as major chemical components of G. kola.", [" \"PARAMETER\": [\"benxophenones\", \"xanthones\", \"alkaloids\", \"phenols\", \"tannins\", \"saponins\", \"kolaviron\", \"biflavonoid complex\", \"aluminum\", \"magnesium\", \"calcium\", \"copper\"]", {"Herb name": ["G. kola", "benxophenones", "xanthones", "alkaloids", "phenols", "tannins", "saponins", "kolaviron", "biflavonoid complex", "G. kola"], "Herb part": ["seeds"]}]], [249, "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study.", [" \"PARAMETER\": [\"pregnancy\", \"breastfeeding\", \"histories of hypersensitivity to quinine or similar agents\", \"adverse side effects from taking G. kola seeds\"]", {"Pathology": ["Pregnancy", "breastfeeding", "hypersensitivity", "adverse side effects"], "Drug": ["quinine"], "Herb name": ["G. kola"], "Herb part": ["seeds"]}]], [250, "Participants were certified healthy by a physician based on medical history, clinical examination, and laboratory tests and they gave their written informed consent to comply with the study protocol.", [" \"PARAMETER\": []", {"Pathology": ["healthy"]}]], [251, "In the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England).", [" \"PARAMETER\": [\"600 mg quinine sulphate tablets\"]\n\n\"COMPANY\": [\"Maderich Ltd\"]\n\n\"LOCATION\": [\"Surrey, England\"]\n\n\"DOSAGE\": [\"600 mg\"]\n\n\"SUBSTANCE\": [\"quinine sulphate\"]\n\n\"ROUTE\": [\"oral\"]\n\n\"EVENT\": [\"received a single oral dose\"]\n\n\"TIME\": [\"after an overnight fast\"]\n\n\"GROUP\": [\"respectively\"]\n\n\"SUBJECT\": [\"each subject\"]\n\n\"PHASE\": [\"first phase\"]\n\n\"STUDY\": [\"\"] # Add the study title here if available.", {"Amount": ["600 mg"], "Drug": ["quinine sulphate"]}]], [252, "Sample collection  Venous blood samples (5ml) was collected into heparinised tubes at time zero (just before the administration of quinine sulphate tablets)) and at 1, 2, 3,4, 6, 8, 12, 24, 36 and 48 h after each participant received quinine alone or concurrently with the scheduled dose of G. kola.", [" \"PARAMETER\": [\"venous blood samples\", \"5ml\", \"heparinised tubes\", \"time zero\", \"just before the administration of quinine sulphate tablets\", \"1 h\", \"2 h\", \"3 h\", \"4 h\", \"6 h\", \"8 h\", \"12 h\", \"24 h\", \"36 h\", \"48 h\", \"each participant\", \"quinine alone\", \"concurrently with the scheduled dose of G. kola\"]", {"Drug": ["quinine sulphate", "quinine"], "Herb name": ["G. kola"]}]], [253, "The limit of quantitation was 0.37\u00b5g/ml and 0.5\u00b5g/ml for quinine and for 3-hydroxyquinine respectively.", [" \"PARAMETER\": [\"limit of quantitation\", \"0.37\u00b5g/ml (quinine)\", \"0.5\u00b5g/ml (3-hydroxyquinine)\"]", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [254, "The AUC0\u2013\u221e of quinine was slightly reduced by about 9 %.", [" \"PARAMETER\": [\"AUC0\u2013\u221e of quinine\"]", {"Parameter": ["AUC0\u2013\u221e"], "Drug": ["quinine"]}]], [255, "Precisely, only 3 participants complained of very light dizziness.", [" \"PARAMETER\": []", {"Pathology": ["light dizziness"]}]], [256, "[38]  Although, the exact mechanism responsible for the delayed and decreased absorption of quinine in the presence of G. kola in this current study is not known, it is possible that quinine may have interacted through complex formation with the trace metals or flavonoids usually found in G. kola [6, 11] as evidenced from a significant reduction in the Cmax and tmax of quinine but no significant change in parameters which are indicative of interference with elimination.", [" \"PARAMETER\": [\"Cmax\", \"tmax\"]", {"Drug": ["quinine", "quinine", "quinine"], "Herb name": ["G. kola", "flavonoids", "G. kola"], "Parameter": ["Cmax", "tmax"]}]], [257, "Moreover, parameters such as T1/2 and CL/F of quinine that relates to elimination in both study groups were also not altered significantly in the presence of G. kola.", [" \"PARAMETER\": [\"T1/2\", \"CL/F of quinine\"]", {"Parameter": ["T1/2", "CL/F"], "Drug": ["quinine"], "Herb name": ["G. kola"]}]], [258, "This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.", [" No parameters found in this statement.", {}]], [259, "In Stage 2 77 additional participants were randomized to either 1,200 mg S. frutescens or placebo.", [" \"PARAMETER\": [\"1,200 mg S. frutescens\"]\n\n\"PARAMETER\": [\"placebo\"]\n\n\"PARAMETER\": [\"Stage 2\"]\n\n\"PARAMETER\": [\"77 additional participants\"]\n\n\"PARAMETER\": [\"randomized\"]\n\n\"PARAMETER\": [\"either\"]", {"Amount": ["1,200 mg"], "Herb name": ["S. frutescens"]}]], [260, "More than 50% of adults in KwaZulu-Natal attending public sector facilities for ART initiation disclose using TCAM [10], and similar levels of TCAM use by HIV positive individuals may occur worldwide [11].", [" \"PARAMETER\": [\"more than 50% of adults in KwaZulu-Natal\", \"adults in KwaZulu-Natal attending public sector facilities for ART initiation\"]", {"Drug": ["ART"], "Pathology": ["HIV positive"]}]], [261, "With respect to the MOS-HIV, failure differences were found between placebo and 1200 mg, favouring the 1200mg group.", [" \"PARAMETER\": [\"failure differences\"]}\n\nRegarding the MOS-HIV study, differences favoring the 1200mg group were found compared to the placebo group.", {"Amount": ["1200 mg", "1200mg"]}]], [262, "On serial electrocardiograms the PR interval, QRS duration and corrected QT interval (QTc) were similar in both arms (S2 Table).", [" \"PARAMETER\": [\"PR interval\", \"QRS duration\", \"corrected QT interval (QTc)\"]}\n\nNote: S2 Table refers to a supplementary table, so the parameters listed here are inferred from the text.", {"Parameter": ["the PR interval", "QRS duration", "corrected QT interval (QTc)"], "Study": ["both arms"]}]], [263, "Abbreviations: HDL (high density lipoprotein); LDL (low density lipoprotein) *P-value for interaction effect of groups over time.", [" \"PARAMETER\": [\"P-value\", \"interaction effect of groups over time\", \"HDL (high density lipoprotein)\", \"LDL (low density lipoprotein)\"]", {"Parameter": ["HDL (high density lipoprotein)", "LDL (low density lipoprotein)"]}]], [264, "(PDF) Click here for additional data file.", [" I cannot parse any parameters from the given text as it is just a reference to an additional data file.", {}]], [265, "Thabethe, D.A.", [" \"PARAMETER\": [\"Thabethe, D.A.\"]\n\nThis is assumed to be an author name.", {}]], [266, "Data were reported as prevalence (percent) of the occurrence.", [" \"PARAMETER\": [\"prevalence (percent)\"]", {}]], [267, "Chronic kidney disease (CKD) is a global public health problem with an increasing incidence and a lot of economic burden for treatment.", [" \"PARAMETER\": [\"incidence\", \"economic burden for treatment\"]\n\nIn the context of this sentence, \"chronic kidney disease (CKD)\" is the condition being referred to.", {"Pathology": ["Chronic kidney disease (CKD)"]}]], [268, "However, a large number of these therapies have been shown that they are not safe and can be harmful due to their interactions with other drugs which are used contemporaneously.", [" \"PARAMETER\": []", {}]], [269, "After obtaining institutional ethics committee approval (project number and ethics code: 294155) from the university research affairs, patients' demographic information (sex, age, educational status, occupational status, and marital status) were collected from patients' hospital records or by direct interviewing of patients and filled in a specially designed form for this study.", [" \"PARAMETER\": [\"sex\", \"age\", \"educational status\", \"occupational status\", \"marital status\"]", {}]], [270, "Regarding CAM nonusers, the majority were in the age group of 20\u201360 years with the male/female ratio of 73/27 percent.", [" \"PARAMETER\": [\"age group of 20\u201360 years\", \"male/female ratio\"]\n\nThe male/female ratio is 73:27.\n\nNote: It's important to remember that the parameters listed are just the entities mentioned in the text and do not include any additional information or context.", {"Age": ["20\u201360 years"], "Sex": ["male", "female"]}]], [271, "The others (13.23%) consisted of congenital kidney disease, polycystic kidney disease, drug-induced renal failure, and acute kidney injury.", [" \"PARAMETER\": [\"congenital kidney disease\", \"polycystic kidney disease\", \"drug-induced renal failure\", \"acute kidney injury\"]", {"Pathology": ["congenital kidney disease", "polycystic kidney disease", "drug-induced renal failure", "acute kidney injury"]}]], [272, "The majority of the patients identified as herbal users were in the age range of 50\u201370 years, and herbal usage prevalence was high among this age range.", [" \"PARAMETER\": [\"age range of 50\u201370 years\"]", {"Age": ["50\u201370 years"]}]], [273, "'s study,[25] which reported that the trend was more prevalent among middle-aged (50\u201364) patients compared to other age groups.", [" \"PARAMETER\": [\"middle-aged patients (50\u201364)\"]}\n\nOr:\n\n{\"AGE GROUP\": [\"middle-aged patients (50\u201364)\"]}", {"Age": ["50\u201364"]}]], [274, "[2526] Iranian borage (E. amoenum) as unformulated and anticough syrups as formulated herbal products were the most used ones in our study population, while common cold and respiratory problems were determined to be the main indications for this trend.", [" \"PARAMETER\": [\"Iranian borage (E. amoenum)\", \"unformulated and anticough syrups\", \"formulated herbal products\", \"our study population\", \"common cold\", \"respiratory problems\"]", {"Herb name": ["Iranian borage (E. amoenum)"]}]], [275, "[27] In the study performed by Roozbeh et al.", [" \"PARAMETER\": [\"\"]\n\nThis sentence does not provide any specific parameter information. It is just mentioning the source of a study.", {}]], [276, "The patient had a Karnofsky performance status scale of 90% after resection without neurological deficiencies and was referred to our department for further treatment with radiotherapy and temozolomide (TEM).", [" \"PARAMETER\": [\"Karnofsky performance status scale\"]", {"Pathology": ["neurological deficiencies"], "Drug": ["temozolomide"]}]], [277, "Unfortunately, a [18 F]-fluorethylenthyrosin positron emission tomography positive residual tumor was detected 2 months after the end of radiotherapy.", [" \"PARAMETER\": [\"a [18 F]-fluorethylenthyrosin positron emission tomography positive residual tumor\"]", {"Pathology": ["tumor"]}]], [278, "Therefore, we think that a comprehensive management of our patients should also include education about the risk of interactions with herbal formulas.", [" \"PARAMETER\": [\"\"]", {}]], [279, "Briefly, whole blood (0.5\u2009mL) was diluted twofold with freshly prepared normal saline and incubated at 37\u2009\u00b0C for at least 6\u2009min.", [" \"PARAMETER\": [\"\"]\n\n(No entities were identified in this text.)", {}]], [280, "International normalized ratio  International normalized ratio was measured at each blood sampling time before and after warfarin dosing using a BFT II analyser.", [" \"PARAMETER\": [\"International normalized ratio\"]", {"Parameter": ["International normalized ratio", "International normalized ratio"], "Drug": ["warfarin"]}]], [281, "Percentage factor activity for each sample was obtained from a standard curve constructed using different dilutions of standard human plasma of known factor activity and clotting time.", [" \"PARAMETER\": [\"percentage factor activity\", \"standard human plasma\", \"known factor activity\", \"clotting time\"]", {"Parameter": ["clotting time"]}]], [282, "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel.", [" \"PARAMETER\": [\"half-life\", \"apparent clearance (CL/F)\", \"apparent volume of distribution (V/F)\"]", {"Parameter": ["half-life", "CL/F", "AUC0\u2212\u221e", "CL/kel"]}]], [283, "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration.", [" \"PARAMETER\": [\"percentage of prothrombin complex activity (PCA)\", \"S-warfarin concentration\"]", {"Drug": ["S-warfarin", "S-warfarin"], "Parameter": ["prothrombin complex activity (PCA", "INR"]}]], [284, "However, this did not reach statistical significance (data not shown).", [" (No parameters found in this sentence)", {}]], [285, "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax.", [" \"PARAMETER\": [\n[\"tmax (h)\", \"Cmax (\u03bcg mL-1)\", \"t1/2 (h)\", \"AUC (\u03bcg mL-1 h)\", \"CL/F (mL h-1)\", \"Fraction unbound (fu)\"],\n[\"S-warfarin tmax (h)\", \"1.4 (1.1\u20131.6)\", \"1.8 (1.7\u20131.9)\", \"38.6 (35.7\u201341.5)\", \"60.3 (54.5\u201366.1)\", \"0.010 (0.007\u20130.013)\"],\n[\"S-warfarin Cmax (\u03bcg mL-1)\", \"1.8 (1.7\u20131.9)\", \"NA\", \"NA\", \"213 (193\u2013232)\", \"0.010 (0.007\u20130.013)\"],\n[\"S-warfarin t1/2 (h)\", \"38.6 (35.7\u201341.5)\", \"NA\", \"NA\", \"0.94 (0.79\u20131.12)\", \"NA\"],\n[\"S-warfarin AUC (\u03bcg mL-1 h)\", \"60.3 (54.5\u201366.1)\", \"NA\", \"NA\", \"0.89 (0.80\u20130.99)\", \"NA\"],\n[\"S-warfarin CL/F (mL h-1)\", \"213 (193\u2013232)\", \"NA\", \"NA\", \"1.00 (0.75\u20131.25)\", \"NA\"],\n[\"S-warfarin Fraction unbound (fu)\", \"0.010 (0.007\u20130.013)\", \"NA\", \"NA\", \"1.00 (0.75\u20131.18)\", \"NA\"],\n[\"R-warfarin tmax (h)\", \"1.4 (1.1\u20131.6)\", \"1.9 (1.1\u20132.7)\", \"55.6 (46.2\u201365.0)\", \"108.7 (90.", {"Drug": ["S-warfarin", "R-warfarin", "Warfarin", "Warfarin", "Warfarin", "Warfarin", "warfarin", "Warfarin", "warfarin", "S-warfarin", "R-warfarin"], "Herb name": ["cranberry", "garlic", "cranberry", "garlic"], "Parameter": ["tmax", "Cmax", "AUC", "CL/F", "tmax", "Cmax", "t1/2", "AUC", "CL/F", "AUC, area under the plasma concentration\u2013time curve", "CL, clearance", "CL/F, apparent clearance", "Cmax, maximum concentration", "F, bioavailability", "tmax, time to Cmax"]}]], [286, "Pharmacokinetic\u2013pharmacodynamic modelling  The population PKPD parameter estimates for warfarin are presented in the Table 3.", [" \"PARAMETER\": [\"population PKPD parameter estimates for warfarin\"]\n\n\"Table 3\": []\n\n(Assuming \"Table 3\" is a reference to a table in the article, but without access to the article content, I cannot extract the information from it.)", {"Drug": ["warfarin"]}]], [287, "(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin.", [" \"PARAMETER\": [\"AUC of S-warfarin\"]", {"Herb name": ["cranberry"], "Extraction process": ["juice"], "Duration": ["for 5 days"], "Drug": ["warfarin", "S-warfarin"], "Parameter": ["AUC"]}]], [288, "(2006b) included 7 patients with atrial fibrillation, whereas Ansell et al.", [" \"(2006b)\" and \"Ansell et al.\" are not entities, but references to specific studies. No parameters can be extracted from this information.", {"Cohort": ["7 patients"], "Pathology": ["atrial fibrillation"]}]], [289, "(2007) concluded that there were no pharmacodynamic interactions between warfarin and cranberry juice, but they employed a low dose of warfarin (10\u2009mg), which made this end point difficult to assess.", [" \"PARAMETER\": [\"\"]\n\nThis sentence does not provide any specific parameter information. It is discussing the limitations of a previous study.", {"Drug": ["warfarin", "warfarin"], "Herb name": ["cranberry"], "Extraction process": ["juice"], "Amount": ["10\u2009mg"]}]], [290, "Current address: Drug Metabolism and Pharmacokinetics, Covance Laboratories Inc., Madison, WI, USA Patients commonly take complementary medicines in conjunction with warfarin yet evidence supporting the safety or the risk of a herb\u2013drug interaction is lacking.", [" \"PARAMETER\": [\"complementary medicines\", \"patients\"]", {"Drug": ["warfarin"]}]], [291, "Academic Editor: Igho J. Onakpoya In recent popular publications as well as in widely used information websites directed to cancer patients, valerian is claimed to have a potential of adverse interactions with anticancer drugs.", [" \"PARAMETER\": [\"valerian\"]\n\nNote: No specific parameters were mentioned in the text related to valerian, but it is important to note that the text suggests that valerian may have potential interactions with anticancer drugs.", {"Pathology": ["cancer patients"], "Herb name": ["valerian"], "Drug": ["anticancer drugs"]}]], [292, "However, they state that warnings that valerian (Valeriana officinalis) may stimulate CYP 3A4.", [" \"PARAMETER\": [\"CYP 3A4\"]\n\n\"Valerian (Valeriana officinalis)\" may stimulate it.", {"Herb name": ["valerian", "Valeriana officinalis"], "Target": ["CYP 3A4"]}]], [293, "It therefore was recommended that they should be avoided in the elderly [10, 12].", [" \"PARAMETER\": [\"\"]\n\n[10, 12]: These references may contain additional information regarding the elderly population and the avoidance of certain traditional hypoglycemic herbs, but the text does not provide enough information to extract specific parameters.", {}]], [294, "Recommended daily doses of valerian root extracts are about 600\u2009mg, usually taken as capsules or tablets.", [" \"PARAMETER\": [\"600 mg\"]\n\n\"PARAMETER\": [\"recommended daily doses of valerian root extracts\"]\n\n\"PARAMETER\": [\"usually taken as capsules or tablets\"]", {"Frequency": ["daily"], "Herb name": ["valerian"], "Herb part": ["root"], "Amount": ["600\u2009mg"]}]], [295, "A search with the search terms (valerian or valeriana) was conducted in the databases MEDLINE and TOXLIT, via DIMDI (Cologne, Germany).", [" \"PARAMETER\": [\"MEDLINE\", \"TOXLIT\", \"DIMDI (Cologne, Germany)\"]", {"Herb name": ["valerian", "valeriana"]}]], [296, "Studies were assessed for completeness and validity of data on material and methods, on the potential clinical relevance of the results and on potential bias in the presentation of results and conclusions.", [" \"PARAMETER\": [\"completeness and validity of data\", \"material and methods\", \"potential clinical relevance of the results\", \"potential bias in the presentation of results and conclusions\"]", {}]], [297, "These limitations do not allow valid extrapolations with respect to a clinical relevance of the results.", [" \"PARAMETER\": []", {}]], [298, "[36].", [" It is unclear what entity is referred to in \"[36]\". It could be a citation to a specific study or reference, but without additional context it cannot be determined what parameter is associated with it.", {}]], [299, "Daily before going to bed, participants took two tablets, with 500\u2009mg valerian extract each (extraction solvent ethanol 70%, valerenic acid content 5.51\u2009mg/tablet), for 14 subsequent days.", [" \"PARAMETER\": [\"500 mg valerian extract\", \"valerenic acid content 5.51 mg/tablet\"]", {"Frequency": ["Daily"], "Amount": ["500\u2009mg"], "Herb name": ["valerian", "valerenic acid"], "Duration": ["14 subsequent days"]}]], [300, "Before and after the test period, the activities of CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio), CYP 1A2 (paraxanthine/caffeine serum ratio), CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio), and CYP 2D6 (debrisoquine urinary recovery ratio) were determined.", [" \"PARAMETER\": [\"CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio)\", \"CYP 1A2 (paraxanthine/caffeine serum ratio)\", \"CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio)\", \"CYP 2D6 (debrisoquine urinary recovery ratio)\"]", {"Drug": ["midazolam", "paraxanthine", "caffeine", "chlorzoxazone", "debrisoquine"]}]], [301, "Haloperidol (38\u2009mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51].", [" \"PARAMETER\": [\"38 mg/kg bw\", \"12 weeks\"]\n\nThe parameter \"bw\" stands for body weight.\n\nSo the full output would be:\n\n{\"PARAMETER\": [\"38 mg/kg bw\", \"12 weeks\", \"body weight\"]}", {"Drug": ["Haloperidol"], "Amount": ["38\u2009mg/kg bw"], "Frequency": ["once", "every 4 weeks"], "Duration": ["12 weeks", "15 days"], "Herb name": ["valerian"]}]], [302, "The results were not presented in detail but indicated that the two drugs act independently from each other.", [" No specific parameters were mentioned in this statement.", {}]], [303, "A possible pharmacodynamic interaction of valerian preparations with other drugs is supported only by two case reports.", [" \"PARAMETER\": [\"\"]\n\n(No specific parameters mentioned in the text)", {"Herb name": ["valerian"]}]], [304, "Given that none of these herbal medicines has been proven to have MAO-inhibitory properties, while induction of delirium, and a positive drug screening on opioids was reported, the assumption of an involvement of the valerian preparation does not seem to be plausible.", [" No parameters found in this statement.", {"Target": ["MAO"], "Pathology": ["delirium"], "Drug": ["opioids"], "Herb name": ["valerian"]}]], [305, "A good understanding of the mechanisms of drug-drug interactions is essential for assessing and minimizing clinical risks.", [" \"PARAMETER\": []", {}]], [306, "Especially the open questions of in vivo bioavailability and of the metabolism of extract components relevant for in vitro effects often prevent reliable extrapolations from in vitro to in vivo data.", [" \"PARAMETER\": [\"in vivo bioavailability\", \"metabolism of extract components\"]", {"Parameter": ["bioavailability"]}]], [307, "At present therefore a relevant risk of pharmacodynamic interactions is not proven by valid clinical observations.", [" No parameters found in this statement.", {}]], [308, "That therapeutic safety regarding interactions is high in valerian and is mentioned in the respective monograph of the HMPC [18] and also in a fact sheet of the Office of Dietary Supplements at the NIH [32].", [" \"PARAMETER\": [\"therapeutic safety\"]\n\n\"HMPC\": [\"respective monograph of the HMPC\"]\n\n\"NIH\": [\"fact sheet of the Office of Dietary Supplements\"]", {"Herb name": ["valerian"]}]], [309, "In a data base for interactions of medicinal drugs (MedIQ), the rating \u201cweak interaction\u201d is given for CYP-isoenzymes, P-gp, and UGT, based on in vitro data.", [" \"PARAMETER\": [\"in vitro data\", \"CYP-isoenzymes\", \"P-gp\", \"UGT\"]", {"Target": ["CYP-isoenzymes", "P-gp", "UGT"]}]], [310, "In summary, it can be concluded that warnings regarding a specific risk of interactions of valerian are without any recent evidence.", [" No parameters found in this statement.", {"Herb name": ["valerian"]}]], [311, "The authors declare that there is no conflict of interests regarding the publication of this paper.", [" No parameters found in this statement.", {}]], [312, "Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively.", [" \"PARAMETER\": [\"rifampin (600 mg)\", \"clarithromycin (1000 mg)\"]", {"Drug": ["rifampin", "clarithromycin"], "Amount": ["600 mg", "1000 mg"], "Duration": ["7 days"], "Target": ["CYP3A"]}]], [313, "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant.", [" \"PARAMETER\": [\"venlafaxine\", \"serotonin-norepinephrine reuptake inhibitor\"]", {"Drug": ["Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant"]}]], [314, "After venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF.", [" \"PARAMETER\": [\"LVEF\"]\n\n\"PARAMETER\": [\"radiological abnormalities\"]\n\n\"PARAMETER\": [\"after venlafaxine discontinuation\"]", {"Drug": ["venlafaxine"], "Pathology": ["the radiological abnormalities"], "Parameter": ["LVEF"]}]], [315, "This was an important case of drug-induced cardiopulmonary toxicity.", [" \"PARAMETER\": [\"drug-induced cardiopulmonary toxicity\"]", {"Pathology": ["drug-induced cardiopulmonary toxicity"]}]], [316, "Although DIP can occur from hours to months after the beginning of treatment, Another typical feature of DIP is its reversibility after drug discontinuation.", [" \"PARAMETER\": [\"reversibility after drug discontinuation\", \"duration of DIP (hours to months)\"]", {"Pathology": ["DIP", "DIP"], "Duration": ["hours to months"]}]], [317, "The present case details the occurrence of cardiopulmonary toxicity, which was probably associated with venlafaxine.", [" \"PARAMETER\": [\"cardiopulmonary toxicity\"]", {"Pathology": ["cardiopulmonary toxicity"], "Drug": ["venlafaxine"]}]], [318, "Uma investiga\u00e7\u00e3o ampla foi realizada, incluindo LBA, estudos de imagem, detec\u00e7\u00e3o de doen\u00e7as autoimunes, cateterismo card\u00edaco direito e bi\u00f3psia mioc\u00e1rdica.", [" \"PARAMETER\": []\n\nThis text is not about pharmacology and does not contain any specific entities related to pharmacology. It is about a broad investigation that included LBA (Laboratory Blood Analysis), imaging studies, autoimmune disease detection, right heart catheterization, and myocardial biopsy.", {}]], [319, "A administra\u00e7\u00e3o circunstancial de inibidores da isoenzima CYP2D6 e a presen\u00e7a de um fen\u00f3tipo de metaboliza\u00e7\u00e3o lenta de CYP2D6 podem ter resultado na acumula\u00e7\u00e3o t\u00f3xica da venlafaxina e na manifesta\u00e7\u00e3o cl\u00ednica subsequente.", [" \"PARAMETER\": [\"inhibidores da isoenzima CYP2D6\", \"fen\u00f3tipo de metaboliza\u00e7\u00e3o lenta de CYP2D6\", \"acumula\u00e7\u00e3o t\u00f3xica da venlafaxina\"]", {}]], [320, "Os par\u00e2metros renais e hep\u00e1ticos, as prote\u00ednas do complemento e o sedimento urin\u00e1rio estavam todos normais.", [" \"PARAMETER\": [\"renal parameters\", \"hepatic parameters\", \"proteins of the complement\", \"sediment urinary\"]\n\nNote: Since the text does not provide any specific information about these parameters, it is assumed that they are normal based on the given context.", {}]], [321, "A maioria dos medicamentos card\u00edacos foi, portanto, descontinuada.", [" I'm unable to parse this statement as it is not in English and does not contain any identifiable parameters related to pharmacology. It means \"Most cardiac medications were therefore discontinued.\" in Portuguese.", {}]], [322, "O caso ocorreu em uma paciente previamente h\u00edgida de 35 anos de idade que foi submetida a investiga\u00e7\u00e3o exaustiva ap\u00f3s a exclus\u00e3o de outras poss\u00edveis causas.", [" \"PARAMETER\": []\n\nThis passage does not contain any specific parameters related to pharmacology or entities that need to be parsed. It is a description of a case study of a patient who was investigated for hypoglycemia after other possible causes were excluded.", {}]], [323, "Apoio financeiro: Nenhum.", [" This text does not contain any parameters related to financial support.\n\nTherefore, the output will be an empty dictionary.\n\n{\"PARAMETER\": []}", {}]], [324, "This study aims to confirm the safety of red ginseng and herb extract complex (RHC), which are used to relieve menopausal symptoms.", [" \"PARAMETER\": [\"safety of red ginseng and herb extract complex (RHC)\"]", {"Herb name": ["red ginseng", "herb extract complex (RHC)"], "Pathology": ["menopausal symptoms"]}]], [325, "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study.", [" \"PARAMETER\": [\n\"women\",\n\"menopausal women\",\n\"women who became menopausal from surgery or chemotherapy\",\n\"women who underwent hysterectomy\",\n\"women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers\",\n\"women with uncontrolled hypertension (160/100 mmHg or higher)\",\n\"women with uncontrolled diabetes mellitus (fasting blood sugar 180 mg/dL or higher, or cases of starting or changing medication due to diabetes within 3 mo)\",\n\"uncontrolled thyroid patients\",\n\"women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease\",\n\"women with atypical uterine bleeding after 1 yr of menopause\",\n\"women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4 wk\",\n\"women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4 wk\",\n\"women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4 wk\",\n\"women who were administered female hormone formulations within 6 mo\",\n\"women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit\",\n\"women with creatinine levels exceeding 2 times the laboratory's normal upper limit\",\n\"women with a history of drug or alcohol abuse\",\n\"women who have performed intensive", {"Sex": ["women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "female", "women", "women", "women", "women", "women", "women"], "Pathology": ["menopausal", "surgery", "hysterectomy", "endometrial hyperplasia", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "uncontrolled diabetes mellitus", "diabetes", "uncontrolled thyroid", "severe migraines", "thromboembolism", "cerebrovascular disease", "cardiovascular disease", "uterine bleeding", "menopause", "drug or alcohol abuse", "hypersensitivity"], "Drug": ["chemotherapy", "sleep inducers", "antidepressants", "selective estrogen receptor modulators", "antihyperlipidemic drugs", "antithrombotic drugs", "Aspirin", "Warfarin", "Clopidogrel", "bisphosphonates", "calcitonin"], "Amount": ["160/100\u00a0mmHg", "180\u00a0mg/dL"], "Parameter": ["fasting blood sugar", "triglyceride", "cholesterol", "alanine aminotransferase (ALT)", "aspartate aminotransferase (AST)", "creatinine"], "Duration": ["within 3\u00a0mo", "within the last year", "after 1\u00a0yr", "within 4\u00a0wk", "within 4\u00a0wk", "within 4\u00a0wk", "within 6\u00a0mo", "more than 10\u00a0h", "within 3\u00a0mo", "women", "within 1\u00a0mo"], "Herb name": ["isoflavone", "flaxseed", "pomegranate", "horseradish", "white sorghum", "red shamrock", "red ginseng"], "Study": ["clinical trials", "clinical trial"]}]], [326, "During the investigation of adverse reactions, the date of onset and disappearance, the degree and result of the adverse reaction, the measures are taken in relation to the test substance and the causal relationship with the test substance, the name of the drug other than the test substance, and treatment of adverse reactions were included.", [" \"PARAMETER\": [\"date of onset and disappearance\", \"degree and result of the adverse reaction\", \"measures taken in relation to the test substance\", \"causal relationship with the test substance\", \"name of the drug other than the test substance\", \"treatment of adverse reactions\"]", {"Pathology": ["adverse reactions", "adverse reaction", "adverse reactions"]}]], [327, "The examination of demographic information and characteristics before consumption showed no statistically significant difference between the intake groups.", [" No parameters were identified in this text.", {}]], [328, "p-value by Fisher's exact test.", [" \"PARAMETER\": [\"p-value\"]", {}]], [329, "In addition, one subject with pruritus and hot flash and another subject with headache fully recovered after discontinuation of administration in the placebo group.", [" \"PARAMETER\": []", {"Pathology": ["pruritus", "hot flash", "headache"]}]], [330, "It is noteworthy that no severe adverse reactions were observed in this study.", [" No PARAMETER given in this sentence.", {"Pathology": ["adverse reactions"]}]], [331, "However, further research is needed on the safety of RHC intake for a long period in large-scale menopausal subjects.", [" \"PARAMETER\": []", {"Herb name": ["RHC"], "Pathology": ["menopausal"]}]], [332, "Furthermore, inhibition kinetic study (Dixon plot and Lineweaver-Burk plot) demonstrated that celastrol noncompetitively inhibited the UGT1A1-mediated 4-MU glucuronidation, and competitively inhibited UGT2B7-catalyzed 4-MU glucuronidation.", [" \"PARAMETER\": [\"UGT1A1-mediated 4-MU glucuronidation\", \"UGT2B7-catalyzed 4-MU glucuronidation\"]", {"Study": ["inhibition kinetic study"], "Herb name": ["celastrol"], "Target": ["UGT1A1-mediated 4-MU glucuronidation", "UGT2B7-catalyzed 4-MU glucuronidation"]}]], [333, "Therefore, evaluation of inhibition of compounds towards UGT isoforms was always carried out using recombinant UGTs and nonspecific substrates [19,20,21].", [" \"PARAMETER\": [\"compounds\", \"UGT isoforms\"]", {"Target": ["UGT isoforms", "UGTs"]}]], [334, "When the intersection is in the second quadrant and vertical axis for Dixon and Lineweaver-Burk plots respectively, the inhibition type is competitive.", [" \"PARAMETER\": [\"second quadrant\", \"vertical axis\"]\n\nNote: The information provided here is not enough to definitively determine the type of inhibition. The description is consistent with competitive inhibition, but other types of inhibition (such as non-competitive or uncompetitive) could also result in the same pattern in the plots.", {}]], [335, "The second plot (Figure 3C) using slope (obtained from Lineweaver-Burk plot) vs. celastrol concentration showed that the inhibition kinetic parameter (Ki) was 0.49 \u03bcM.", [" \"PARAMETER\": [\"inhibition kinetic parameter (Ki)\", \"0.49 \u03bcM\"]", {"Herb name": ["celastrol"]}]], [336, "For example, 120-fold variability of UGT1A6 expression in human liver might result in 13-fold variablity in serotonin glucuronidation [24].", [" \"PARAMETER\": [\"UGT1A6 expression\", \"serotonin glucuronidation\"]", {"Target": ["UGT1A6"]}]], [337, "Additionally, it can metabolize many drugs including clofibric acid and valproic acid [25].", [" \"PARAMETER\": [\"clofibric acid\", \"valproic acid\"]", {"Drug": ["valproic acid"]}]], [338, "The previous study performed by Du et al.", [" \"PARAMETER\": [\"Du et al.\"]\n\nor\n\n\"PARAMETER\": [\"the study performed by Du et al.\"]\n\ndepending on whether you want to include the authors' names specifically or not.", {}]], [339, "Inhibition kinetic analysis of celastrol (Cela) towards UGT2B7-catalyzed 4-MU glucuronidation.", [" \"PARAMETER\": [\"UGT2B7-catalyzed 4-MU glucuronidation\"]", {"Herb name": ["celastrol (Cela)"], "Target": ["UGT2B7-catalyzed 4-MU glucuronidation"]}]], [340, "The therapeutic benefits of ginseng include anti-diabetic and anti-inflammatory effect and anti-oxidative response on chronic liver disease [3,4,5,6,7,8].", [" \"PARAMETER\": [\"therapeutic benefits\", \"anti-diabetic effect\", \"anti-inflammatory effect\", \"anti-oxidative response\", \"chronic liver disease\"]", {"Herb name": ["ginseng"], "Pathology": ["chronic liver disease"]}]], [341, "In case of ginseng interactions, it was reported that no herb\u2013drug interaction between single oral dose of Korean red ginseng extract (RGE) (0.5\u20132.0 g/kg) and the probe substrates for five cytochrome P450 (CYP) enzymes (i.e., CYP1A2, 2C9, 2C19, 2D6, 3A) in mouse [12].", [" \"PARAMETER\": [\"single oral dose of Korean red ginseng extract\", \"probe substrates for five cytochrome P450 (CYP) enzymes (i.e., CYP1A2, 2C9, 2C19, 2D6, 3A)\"]", {"Herb name": ["ginseng", "red ginseng extract (RGE)"], "Ethnic group": ["Korean"], "Amount": ["0.5\u20132.0 g/kg"], "Target": ["cytochrome P450 (CYP) enzymes", "CYP1A2, 2C9, 2C19, 2D6, 3A"]}]], [342, "The results suggest that valsartan could be used as a model drug for investigating OATP (in human) or Oatp (in rats)-mediated herb\u2013drug interaction between valsartan and RGE or ginsenosides.", [" \"PARAMETER\": [\"valsartan\"]\n\n\"PARAMETER\": [\"OATP (in human)\"]\n\n\"PARAMETER\": [\"Oatp (in rats)\"]", {"Drug": ["valsartan", "valsartan"], "Target": ["OATP", "Oatp"], "Herb name": ["RGE", "ginsenosides"]}]], [343, "The results revealed that the repeated administration of RGE and high dose of Rc did not significantly induce herb\u2013drug interactions involving valsartan (Figure 5 and Figure 8).", [" \"\"PARAMETER\"\": [\"\"]\n\nThis sentence does not contain any specific parameters related to entities. It is just stating the results of a study.", {"Herb name": ["RGE", "Rc"], "Drug": ["valsartan"]}]], [344, "The plasma concentration was ranged from 7.8 \u03bcM to 34.1 \u03bcM but unbound fraction of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) was very low (0.1\u20130.2% in rat plasma, 0.4\u20130.5% in rat liver; Figure 9B).", [" \"PARAMETER\": [\"plasma concentration\", \"unbound fraction of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc)\"]}\n\n\"PLASMA CONCENTRATION\": [\"7.8 \u03bcM\", \"34.1 \u03bcM\"]\n\n\"UNBOUND FRACTION OF TRI-GLYCOSYLATED PPD-TYPE GINSENOSIDES (Rb1, Rb2, AND Rc)\": [\"0.1\u20130.2% in rat plasma\", \"0.4\u20130.5% in rat liver\"]", {"Herb name": ["tri-glycosylated PPD-type ginsenosides", "Rb1", "Rb2", "Rc"]}]], [345, "After centrifugation of the blood samples at 16,000\u00d7 g for 10 min, aliquots (50 \u03bcL each) of plasma samples were stored at \u221280 \u00b0C until the analysis of ginsenosides and valsartan.", [" \"PARAMETER\": [\"plasma samples\"]", {"Herb name": ["ginsenosides"], "Drug": ["valsartan"]}]], [346, "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing.", [" \"PARAMETER\": [\"0.17 h\", \"0.33 h\", \"0.67 h\", \"1.5 h\", \"2 h\", \"4 h\", \"8 h\", \"24 h\", \"48 h\"]}", {"Drug": ["valsartan"]}]], [347, "Plasma concentration-time profiles of the ginsenosides (A) Rb1, (B) Rb2, (C) Rc, (D) Rd, (E) PPD, and (F) PPT in the rat plasma after 1-week repeated administration of red ginseng extract (RGE).", [" \"PARAMETER\": [\"plasma concentration-time profiles\", \"the ginsenosides (A) Rb1, (B) Rb2, (C) Rc, (D) Rd, (E) PPD, and (F) PPT\"]", {"Herb name": ["ginsenosides", "Rb1", "Rb2", "Rc", "Rd", "PPD", "PPT", "red ginseng extract (RGE)"], "Duration": ["1-week"]}]], [348, "AUC: area under the plasma concentration-time curve from 0 to 48 h C Pharmacokinetic parameters of valsartan and Rc following intravenous injection of valsartan at a dose of 1 mg/kg in rats.", [" \"PARAMETER\": [\"AUC\", \"area under the plasma concentration-time curve from 0 to 48 hours\", \"C\", \"plasma concentration\"]", {"Parameter": ["AUC: area under the plasma"], "Drug": ["valsartan", "valsartan"], "Herb name": ["Rc"], "Amount": ["1 mg/kg"]}]], [349, "Therefore, herbal products must be assessed for their efficacy and safety, including their potential for interactions with other drugs [14].", [" \"PARAMETER\": [\"herbal products\"]", {"Herb name": ["herbal products"], "Parameter": ["efficacy and safety"]}]], [350, "For each visit, a deviation of\u00a0\u00b11\u00a0day was permitted.", [" \"PARAMETER\": [\"\u00b11 day\"]\n\nThis parameter represents the allowed deviation in days for each visit.", {"Duration": ["\u00b11\u00a0day"]}]], [351, "In order to compensate for study participants who did not complete both treatment phases, a total of 24 subjects were to be randomised.", [" \"PARAMETER\": []", {"Cohort": ["a total of 24 subjects"]}]], [352, "Oxidative stress is dramatically increased in PCOS patients, when oxidant/antioxidant status is measured by circulating serum markers, including catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD), and malondialdehyde (MDA) [3].", [" \"PARAMETER\": [\"circulating serum markers\", \"catalase (CAT)\", \"glutathione peroxidase (GPx)\", \"superoxide dismutase (SOD)\", \"malondialdehyde (MDA)\"]", {"Pathology": ["Oxidative stress", "PCOS"], "Parameter": ["catalase (CAT)", "glutathione peroxidase (GPx)", "superoxide dismutase (SOD)", "malondialdehyde (MDA)"]}]], [353, "Therefore, use of an herbal agent with antioxidant and polyphenolic properties without significant side effects helps to treat PCOS as a disease of antioxidant deficiency [13].", [" \"PARAMETER\": [\"PCOS as a disease of antioxidant deficiency\"]\n\nNote: It's important to mention that the given text suggests that an herbal agent with antioxidant and polyphenolic properties may help treat PCOS based on the assumption that it's a disease of antioxidant deficiency, but it doesn't directly state that PCOS is a disease of antioxidant deficiency.", {"Herb name": ["polyphenolic"], "Pathology": ["side effects", "PCOS"]}]], [354, "Furthermore, it decreases insulin and blood glucose markedly [17].", [" \"PARAMETER\": [\"insulin\", \"blood glucose\"]", {"Parameter": ["insulin", "blood glucose"]}]], [355, "Citrus Sinensis (L.) Osbeck from Rutaceae family mainly contains hesperidin, polymethoxylated flavonoids (PMF), and terpenoids (limonene and linalool), and these phenolic bioactive compounds indicate considerable cytoprotective effects against OS [18].", [" \"PARAMETER\": [\"Citrus Sinensis (L.) Osbeck\", \"hesperidin\", \"polymethoxylated flavonoids (PMF)\", \"terpenoids\", \"limonene\", \"linalool\"]", {"Herb name": ["Citrus Sinensis (L.) Osbeck from Rutaceae family", "hesperidin", "polymethoxylated flavonoids (PMF)", "terpenoids", "limonene", "linalool", "phenolic"], "Pathology": ["OS"]}]], [356, "Moreover, hesperidin in C. sinensis increases the levels of antioxidants including SOD and CAT, and decreases the MDA level [19].", [" \"PARAMETER\": [\"levels of antioxidants including SOD and CAT\", \"MDA level\"]", {"Herb name": ["hesperidin", "C. sinensis"], "Parameter": ["SOD", "CAT", "MDA"]}]], [357, "One mL of methanolic extract (5 mg/mL in acetone-water solution) was mixed with 200 \u00b5L of Folin-Ciocalteau reagent and 1 mL of 2% Na Total flavonoids were determined using the AlCl The herbal mixture powder (120 g) was exposed to hydrodistillation using a Clevenger type apparatus for about 4 h. Then, the obtained dark yellow oil was dried over anhydrous sodium sulfate, measured, and stored in a dark glass at 4 \u00b0C for further analyses.", [" \"PARAMETER\": [\"1 mL of methanolic extract\", \"5 mg/mL in acetone-water solution\", \"200 \u00b5L of Folin-Ciocalteau reagent\", \"1 mL of 2% Na\", \"herbal mixture powder\", \"120 g\", \"4 h\", \"obtained dark yellow oil\", \"anhydrous sodium sulfate\", \"dark glass\", \"4 \u00b0C\"]", {"Extraction process": ["methanolic extract"], "Herb name": ["flavonoids"]}]], [358, "A 1,1\u2032,3,3\u2032-tetramethoxypropane was used to construct the calibration curve as the standard [32] (reference value: 0.54\u20131.32 pg/mL).", [" \"PARAMETER\": [\"1,1\u2032,3,3\u2032-tetramethoxypropane\", \"reference value\"]\n\"reference value\": [\"0.54\u20131.32 pg/mL\"]", {}]], [359, "Descriptive statistics, including the frequency and percentage, and measures of central tendency and dispersion, including the mean and standard deviation (SD), were also used to describe the study variable.", [" \"PARAMETER\": [\"frequency and percentage\", \"mean\", \"standard deviation (SD)\"]", {}]], [360, "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25).", [" \"PARAMETER\": [\"75 participants\", \"3 groups\", \"group 1: CC (n = 25)\", \"group 2: herbal mixture (n = 25)\", \"group 3: CC with herbal mixture (n = 25)\"]", {"Cohort": ["75 participants"], "Drug": ["CC", "CC"]}]], [361, "Moreover, the binary comparison indicated no significant difference in the FBS level (p = 0.212) in group 2, the insulin level (p = 0.842) in group 3, and the HOMA-IR level (p = 0.403) in group 3 compared to group 1.", [" \"PARAMETER\": [\n\"FBS level\",\n\"p = 0.212\",\n\"insulin level\",\n\"p = 0.842\",\n\"HOMA-IR level\",\n\"p = 0.403\"\n]", {"Parameter": ["FBS level", "insulin level", "HOMA-IR level"]}]], [362, "In fact, polyphenols determine the antioxidant activity, and this positive relationship renders a trend in many medicinal plants [36].", [" \"PARAMETER\": [\"antioxidant activity\"]", {"Herb name": ["polyphenols"]}]], [363, "particularly illustrated an increase in the SOD, CAT, and GPx levels, while the MDA level more significantly decreased compared to other groups using only one herb [17].", [" \"PARAMETER\": [\"SOD levels\", \"CAT levels\", \"GPx levels\", \"MDA level\"]", {"Parameter": ["SOD", "CAT", "GPx", "MDA"]}]], [364, "demonstrated that ginger could decrease the FBS level by the mechanism of serotonin receptors which activate pancreatic \u03b2 cells to release insulin [56].", [" \"PARAMETER\": [\"FBS level\", \"pancreatic \u03b2 cells\"]", {"Herb name": ["ginger"], "Parameter": ["FBS level"], "Target": ["serotonin receptors", "pancreatic \u03b2 cells", "insulin"]}]], [365, "showed that phenolic phytochemicals of spearmint possessed hypoglycemic, and antioxidant attributes [57].", [" \"PARAMETER\": [\"hypoglycemic attributes\", \"antioxidant attributes\"]", {"Herb name": ["phenolic phytochemicals", "spearmint"]}]], [366, "Polymethoxylated flavones (PMFs) of C. sinensis have hypolipidemic effects, resulting in a significant reduction of insulin tolerance and glucose levels [61].", [" \"PARAMETER\": [\"insulin tolerance\", \"glucose levels\"]\n\nReferences:\n[{\"61\": [\"Polymethoxylated flavones (PMFs) of C. sinensis have hypolipidemic effects, resulting in a significant reduction of insulin tolerance and glucose levels\"]}]", {"Herb name": ["Polymethoxylated flavones (PMFs)", "C. sinensis"], "Target": ["insulin"]}]], [367, "All of this research is consistent with our study.", [" \"PARAMETER\": []", {}]], [368, "We recommend that further research should be undertaken regarding the effects of herbal mixtures on hormonal factors of PCOS women such as sexual hormones in both proliferative and secretory phases, and lipid profile in a longer follow-up.", [" \"PARAMETER\": [\"hormonal factors of PCOS women\", \"sexual hormones\", \"lipid profile\"]", {"Pathology": ["PCOS"], "Sex": ["women"], "Target": ["sexual hormones"]}]], [369, "Polycystic ovary syndrome (PCOS) patients\u2019 flow diagram.", [" \"PARAMETER\": [\"Polycystic ovary syndrome (PCOS) patients\"]\n\nThis text does not provide any specific parameters related to PCOS patients in this context. The term \"flow diagram\" refers to a visual representation of a process or workflow, and is not a physiological or medical parameter.", {"Pathology": ["Polycystic ovary syndrome (PCOS)"]}]], [370, "Volatile compounds identified in the essential oil of herbal mixture.", [" \"PARAMETER\": [\"volatile compounds\"]}\n\n\"PARAMETER\": [\"essential oil\"]\n\n\"PARAMETER\": [\"herbal mixture\"]\n\nNote: The above entities are based on the provided context and may not represent the full scope of the scientific article.", {"Extraction process": ["essential oil"]}]], [371, "Thus, at the approved dosage of darunavir-ritonavir, darunavir concentrations at the end of the dosing interval remain well above the concentration needed to inhibit replication of HIV strains (20; V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans, presented at the 16th International AIDS Conference, 2006).", [" \"PARAMETER\": [\"darunavir concentrations\", \"concentrations needed to inhibit replication of HIV strains\"]", {"Drug": ["darunavir-ritonavir", "darunavir"], "Pathology": ["HIV", "AIDS"]}]], [372, "V05895B; Arkopharma, Madrid, Spain).", [" \"PARAMETER\": [\"V05895B\", \"Arkopharma\", \"Madrid\", \"Spain\"]\n\nThis information refers to the manufacturer and location of a specific drug or substance mentioned in the text.", {}]], [373, "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28.", [" \"PARAMETER\": [\"blood counts\", \"chemistry\", \"CD4+ T-cell count\", \"HIV-1 RNA load\"]", {"Parameter": ["blood counts", "CD4+ T-cell count"]}]], [374, "Pharmacokinetic parameters were natural log transformed before analysis, and confidence intervals for means (and for the difference between two means) were constructed on the natural log scale based on an analysis of variance model with treatment as a fixed effect.", [" \"PARAMETER\": [\"pharmacokinetic parameters\"]", {}]], [375, "The median CD4+ T-cell count was 498 (range, 244 to 962) cells/mm3.", [" \"PARAMETER\": [\"CD4+ T-cell count\", \"498 (range, 244 to 962) cells/mm3\"]\n\nOr:\n\n\"PARAMETER\": {\n\"CD4+ T-cell count\": [\"498 (range, 244 to 962) cells/mm3\"]\n}\n\nBoth forms are acceptable.", {"Parameter": ["CD4+ T-cell count"], "Amount": ["498"]}]], [376, "No patient reported adverse events during the study, and all maintained an HIV-1 RNA load of <50 copies/ml at the end of the study.", [" \"PARAMETER\": []", {"Pathology": ["patient", "adverse events"], "Parameter": ["HIV-1 RNA load"], "Amount": ["<50 copies/ml"]}]], [377, "Darunavir pharmacokinetics.", [" \"PARAMETER\": [\"Darunavir\", \"pharmacokinetics\"]", {"Drug": ["Darunavir"]}]], [378, "Coadministration of E. purpurea resulted in little change in darunavir pharmacokinetic parameters, with C\u03c4 and AUC\u03c4 decreasing by averages of 16% and 10%, respectively.", [" \"PARAMETER\": [\"C\u03c4\", \"AUC\u03c4\"]\n\n\"C\u03c4\": [\"C\u03c4 decreasing by averages of 16%\"],\n\"AUC\u03c4\": [\"AUC\u03c4 decreasing by averages of 10%\"]", {"Herb name": ["E. purpurea"], "Drug": ["darunavir"], "Parameter": ["C\u03c4", "AUC\u03c4"]}]], [379, "Figure \u200bFigure11 displays the ritonavir concentration-versus-time profile, and Table \u200bTable22 lists the pharmacokinetic parameters of ritonavir after multiple-dose administration of darunavir-ritonavir alone or in combination with E. purpurea.", [" \"PARAMETER\": [\"ritonavir concentration-versus-time profile\", \"pharmacokinetic parameters of ritonavir\"]", {"Drug": ["ritonavir", "ritonavir", "darunavir-ritonavir"], "Herb name": ["E. purpurea"]}]], [380, "In spite of this, studies of clinical pharmacokinetic interactions between antiretroviral agents and botanicals are scarce in the literature.", [" \"PARAMETER\": []", {"Drug": ["antiretroviral agents"]}]], [381, "The variability in the effect of echinacea on darunavir pharmacokinetics we observed in this cohort may imply some degree of uncertainty in the CYP3A4 inductive/inhibitory potential of this herbal remedy.", [" \"PARAMETER\": [\"the effect of echinacea on darunavir pharmacokinetics\"]\n\n\"CYP3A4 inductive/inhibitory potential of this herbal remedy\"\n\n(Note: Since the text mentions uncertainty in the inductive/inhibitory potential, both potentials are included in the output.)\n\nTherefore, the output would be:\n\n{\"PARAMETER\": [\"the effect of echinacea on darunavir pharmacokinetics\", \"CYP3A4 inductive potential of this herbal remedy\", \"CYP3A4 inhibitory potential of this herbal remedy\"]}", {"Herb name": ["echinacea"], "Drug": ["darunavir"], "Target": ["CYP3A4"]}]], [382, "We found, however, that E. purpurea was well tolerated, with no evident safety issue of concern.", [" No parameters found in this sentence.", {"Herb name": ["E. purpurea"]}]], [383, "EGb 761\u00ae has no relevant effect on the in vivo activity of the major CYP enzymes in humans and therefore has no relevant potential to cause respective metabolic drug\u2013drug interactions.", [" \"PARAMETER\": [\"in vivo activity\", \"the major CYP enzymes\"]", {"Herb name": ["EGb 761\u00ae"], "Parameter": ["CYP enzymes"]}]], [384, "Ginkgo biloba extract is a popular herbal remedy used for a variety of disorders.", [" \"PARAMETER\": [\"Ginkgo biloba extract\"]\n\n\"PARAMETER\": [\"a variety of disorders\"]\n\n(Note: No specific parameters were mentioned in the text related to Ginkgo biloba extract, but it is important to include the entity in the output as it was explicitly mentioned in the text.)", {"Herb name": ["Ginkgo biloba extract"], "Pathology": ["disorders"]}]], [385, "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C).", [" \"PARAMETER\": [\"8 days\", \"placebo\", \"twice daily\", \"treatment A\", \"EGb 761\u00ae\", \"120 mg\", \"twice daily\", \"treatment B\", \"EGb 761\u00ae\", \"240 mg\", \"morning\", \"placebo\", \"evening\", \"treatment C\"]", {"Duration": ["for 8\u00a0days"], "Frequency": ["twice daily", "twice daily"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae"], "Amount": ["120\u00a0mg", "240\u00a0mg"]}]], [386, "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively.", [" No parameters identified in this sentence.", {"Drug": ["OME", "5-OH-OME", "DEX", "DOR", "MID"]}]], [387, "Evaluation of phenotyping metrics followed the standard bioequivalence approach, with adjusted margins.", [" \"PARAMETER\": [\"phenotyping metrics\"]\n\n\"ADJUSTED MARGINS\": []\n\n(Note: The term \"adjusted margins\" is not explicitly mentioned in the text, but it is a common term used in bioequivalence studies. It refers to the statistical limits used to determine if two formulations are bioequivalent. It is typically calculated based on the variability of the data and the desired level of equivalence.)", {}]], [388, "Administration of EGb 761\u00ae 120\u00a0mg b.i.d.", [" \"PARAMETER\": [\"EGb 761\u00ae\", \"120\u00a0mg\"]\n\n\"dose\": [\"120\u00a0mg\"]\n\"preparation\": [\"EGb 761\u00ae\"]\n\nNote: \"b.i.d.\" stands for \"twice a day\".", {"Herb name": ["EGb 761\u00ae"], "Amount": ["120\u00a0mg"]}]], [389, "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35].", [" \"PARAMETER\": [\"240-mg EGb 761\u00ae daily dose\", \"steady state for EGb 761\u00ae components\"]", {"Amount": ["240-mg"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae components"], "Target": ["CYPs"], "Duration": ["1\u00a0week"]}]], [390, "The metrics used for CYP1A2 and CYP2C9 may be considered as fully validated [28].", [" \"PARAMETER\": [\"CYP1A2\", \"CYP2C9\"]}\n\n\"VALIDATION\\_STATUS\": [\"fully validated\"]\n\nThis information indicates that the methods used to measure the activity of CYP1A2 and CYP2C9 enzymes are considered to be fully validated.", {"Parameter": ["CYP1A2", "CYP2C9"]}]], [391, "does not affect CYP2C19 activity when administered over an 8-day period.", [" \"PARAMETER\": [\"CYP2C19 activity\"]", {"Parameter": ["CYP2C19 activity"], "Duration": ["8-day period"]}]], [392, "The aim of this study was to systematically review data regarding pharmacokinetic (PK)-pharmacodynamic (PD) parameters from randomized controlled trials relating to interactions between herbal medicines and warfarin.", [" \"PARAMETER\": [\"pharmacokinetic (PK)-pharmacodynamic (PD) parameters\"]", {"Parameter": ["pharmacokinetic (PK)-pharmacodynamic (PD) parameters"], "Study": ["randomized controlled trials"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [393, "The aim of this article was to systematically review clinical data, including PK-PD parameters, from randomized controlled trials (RCTs) and to discuss interactions between herbal medicines and warfarin.", [" \"PARAMETER\": [\"PK-PD parameters\"]", {"Parameter": ["PK-PD parameters"], "Study": ["randomized controlled trials (RCTs)"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [394, "The search strategy for PubMed is stated below.", [" I cannot directly parse the information from the given statement as it does not contain any specific parameters related to pharmacology. However, if the search strategy for PubMed involves keywords related to pharmacology, drugs, or specific parameters, those should be identified and parsed accordingly. For example:\n\n{\"KEYWORDS\": [\"pharmacology\", \"drugs\", \"warfarin\", \"echinacea\", \"CYP2C9\", \"glipizide\", \"tolbutamide\", \"rs1142345\", \"hypoglycemic herbs\"]}", {}]], [395, "Type of participant.", [" \"PARAMETER\": [\"\"]\n\nThis information was not provided in the text.", {}]], [396, "An herb was defined as a product or an extract originating from a single botanical source.", [" \"PARAMETER\": [\"a product or an extract\"]\n\n\"botanical source\"\n\n(Note: Since the context of the article suggests that the term \"herb\" is being used to refer to a plant or plant extract, I have included \"botanical source\" as an additional parameter to provide more specificity.)", {}]], [397, "The study selection and data extraction used standard eligibility inclusion criteria as determined by two reviewers.", [" \"PARAMETER\": [\"\"]\n\nThis sentence does not provide any specific parameter related to pharmacology. It is just mentioning the process of study selection and data extraction.", {}]], [398, "Extraction and formulation method, composition, and bioanalytical data regarding the herbal preparations from the included RCTs are summarized Table 2.", [" \"PARAMETER\": [\"extraction and formulation method\", \"composition\", \"bioanalytical data\"]}", {"Herb name": ["herbal preparations"], "Study": ["RCTs"]}]], [399, "For incomplete outcome data, seven trials [21\u201324, 26, 28, 29] reported detailed information regarding attrition by describing the number and reasons for withdrawal.", [" \"PARAMETER\": [\"number\", \"reasons\"]\n\nIn this context, \"number\" refers to the number of instances of withdrawal, and \"reasons\" refers to the reasons why participants withdrew from the trials.", {"Study": ["trials"]}]], [400, "marked circle, Unclear risk of bias; Minus (-) marked circle, High risk of bias.", [" This information does not refer to any specific parameters. It is a description of the risk of bias assessment for a study. It is not relevant to the task of extracting parameters from the text.", {}]], [401, "Based on the two CONSORT statements, the reporting percentage for each of the articles ranged from 36.5% to 61.5% and the mean percentage for all articles was 45.6%.", [" \"PARAMETER\": [\"reporting percentage\"]\n\nFor each article: [\"36.5%\", \"61.5%\"]\n\nFor all articles: [\"mean percentage\": \"45.6%\"]", {}]], [402, "All included studies investigated the PD interactions of warfarin with herbal medicines, but different parameters were used in each study.", [" \"PARAMETER\": [\"PD interactions\", \"herbal medicines\"]", {"Drug": ["warfarin"], "Herb name": ["herbal medicines"]}]], [403, "These relevant case reports indicated a potential herb-warfarin interaction, but it was difficult to identify a causal relationship.", [" \"PARAMETER\": [\"herb-warfarin interaction\"]", {"Study": ["case reports"], "Herb name": ["herb"], "Drug": ["warfarin"]}]], [404, "Some studies pointed out such limitations, that is, that case reports often result in misleading conclusions for multiple reasons [39, 40].", [" \"PARAMETER\": [\"studies\", \"limitations\", \"case reports\"]", {"Study": ["case reports"]}]], [405, "However, an in vivo study indicated that echinacea did not significantly affect the metabolism of drugs metabolized by CYP2C9 [47].", [" \"PARAMETER\": []", {"Study": ["in vivo study"], "Herb name": ["echinacea"], "Parameter": ["CYP2C9"]}]], [406, "Another in vivo study reported that gingko induced CYP enzyme activity in a dose-dependent manner, but did not cause hepatic damage [48].", [" \"PARAMETER\": [\"CYP enzyme activity\"]\n\n\"PARAMETER\": [\"hepatic damage\"]", {"Study": ["in vivo study"], "Herb name": ["gingko"], "Parameter": ["CYP enzyme activity"]}]], [407, "However, no studies were reported these data.", [" \"PARAMETER\": []", {}]], [408, "(DOCX) Click here for additional data file.", [" I cannot directly access or parse data from a link or a document file. The information provided in the text of the article is what I can work with.", {}]], [409, "She had no history of warfarin use, but warfarin was detected in her blood serum analysis.", [" \"PARAMETER\": [\"warfarin\", \"blood serum analysis\"]", {"Drug": ["warfarin", "warfarin"]}]], [410, "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven.", [" \"PARAMETER\": [\"prothrombin time (PT)\", \"activated partial thromboplastin time (aPTT)\", \"international normalized ratio (INR)\"]", {"Parameter": ["prothrombin time (PT)", "activated partial thromboplastin time (aPTT)", "international normalized ratio (INR)"], "Amount": ["more than 37 seconds", "more than 70 seconds", "greater than seven"]}]], [411, "Other diagnostic considerations in a patient presenting with coagulopathy of unknown origin include warfarin or super-warfarin exposure, disseminated intravascular coagulation (DIC), vitamin K malabsorption, and pathologic inhibitors of coagulation (6).", [" \"PARAMETER\": [\"warfarin or super-warfarin exposure\", \"disseminated intravascular coagulation (DIC)\", \"vitamin K malabsorption\"]", {"Pathology": ["coagulopathy", "disseminated intravascular coagulation (DIC)", "vitamin K malabsorption", "pathologic inhibitors of coagulation"], "Drug": ["warfarin", "super-warfarin"]}]], [412, "The WSU Institutional Review Board reviewed and approved the study protocol and consent form prior to subject enrollment.", [" \"PARAMETER\": [\"study protocol\", \"consent form\"]", {}]], [413, "Vital signs (blood pressure, pulse, oxygen saturation) were obtained on every study day.", [" \"PARAMETER\": [\"blood pressure\", \"pulse\", \"oxygen saturation\"]", {"Parameter": ["Vital signs (blood pressure, pulse, oxygen saturation)"], "Frequency": ["every study day"]}]], [414, "Each subject received his/her Siliphos in a blister pack and was asked to complete a pill diary documenting the time of administration, beverage, and approximate volume used to aid swallowing, and adverse events, if applicable.", [" \"PARAMETER\": [\"time of administration\", \"beverage\", \"approximately volume used to aid swallowing\", \"adverse events\"]", {"Herb name": ["Siliphos"], "Parameter": ["approximate volume used to aid swallowing"], "Pathology": ["adverse events"]}]], [415, "The terminal elimination rate constant (\u03bb All statistical analyses were conducted using SAS (v. 9.2; SAS Institute).", [" \"PARAMETER\": [\"terminal elimination rate constant (\u03bb)\"]", {}]], [416, "This limitation applies particularly to the prediction of herb\u2013drug interactions, as herbal products are typically mixtures of multiple constituents that can alter ADME processes via multiple mechanisms.", [" \"PARAMETER\": [\"herbal products\", \"ADME processes\"]", {"Herb name": ["herbal products"], "Parameter": ["ADME processes"]}]], [417, "Silibinin was selected as a model herbal product perpetrator based on well\u2010characterized composition, availability of human pharmacokinetic data, and in vitro inhibitory potency (K Because standard approaches to evaluate herb\u2013drug interactions mediated via inhibition of intestinal glucuronidation in humans have not been described, two different modeling platforms were used to predict the likelihood and magnitude of the silibinin\u2013raloxifene interaction.", [" \"PARAMETER\": [\"silibinin\", \"raloxifene\"]", {"Herb name": ["Silibinin", "herbal product", "silibinin"], "Parameter": ["intestinal glucuronidation"], "Drug": ["raloxifene"]}]], [418, "Alternate study designs, including silibinin predosing and multiple dosing of raloxifene, could provide further insight into interaction potential.", [" \"PARAMETER\": [\"silibinin\", \"predosing\", \"multiple dosing of raloxifene\"]", {"Herb name": ["silibinin"], "Frequency": ["multiple dosing"], "Drug": ["raloxifene"]}]], [419, "Design of drug molecules to avoid oxidative metabolism continues to emphasize the importance of conjugative metabolism in drug development.", [" \"PARAMETER\": [\"drug molecules\", \"oxidative metabolism\", \"conjugative metabolism\"]", {}]], [420, "Supporting Information Click here for additional data file.", [" I cannot parse any parameters from this statement as it is just a direction to access additional information.", {}]], [421, "Curcumin commercially available as pure powder capsule (95%) was obtained from Quality Supplements and Vitamins (Fort Lauderdale, FL, USA).", [" \"PARAMETER\": [\"curcumin\"]\n\n\"COMPANY\": [\"Quality Supplements and Vitamins\"]\n\n\"LOCATION\": [\"Fort Lauderdale, FL, USA\"]", {"Herb name": ["Curcumin"]}]], [422, "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control.", [" \"PARAMETER\": [\"percent blood glucose reduction\", \"3-hour intervals\", \"4-hour intervals\", \"6-hour intervals\", \"8-hour intervals\", \"10-hour intervals\", \"12-hour intervals\"]", {"Herb name": ["curcumin"], "Drug": ["gliclazide", "gliclazide"]}]], [423, "This effect of curcumin can be attributed due to one or more possible mechanisms as reported earlier.", [" No specific parameters mentioned in this sentence.", {"Herb name": ["curcumin"]}]], [424, "Traditional Chinese medicine accounted for most of the interactions (n = 17), followed by food (n = 10), dietary supplements (n = 3), and other herbs/botanicals (n = 3).", [" \"PARAMETER\": [\"interactions\", \"n\"]\n\n\"interactions\": [\"traditional Chinese medicine\", \"food\", \"dietary supplements\", \"other herbs/botanicals\"]\n\n\"n\": [17, 10, 3, 3]", {"Ethnic group": ["Chinese"]}]], [425, "Despite its clinical popularity, CBZ possesses several pharmacokinetic properties which make it prone to interaction with coadministered substances, including drugs, herbal products, and food [7].", [" \"PARAMETER\": [\"CBZ\"]", {"Drug": ["CBZ"]}]], [426, "In view of all the constraints of the existing literature, a comprehensive systematic review focusing on CBZ and overcoming the mentioned hurdles is warranted for healthcare professionals to make proper decisions.", [" \"PARAMETER\": []", {"Drug": ["CBZ"]}]], [427, "2012), Cochrane Database of Systematic Reviews (2005\u2013Dec.", [" \"PARAMETER\": []\n\nThese are references to databases or publications, not physiological or medical parameters.", {}]], [428, "2012).", [" This text does not contain any parameters related to pharmacology.", {}]], [429, "Although honey was shown to decrease the oral bioavailability of CBZ in rabbits, it had no effect on the pharmacokinetic parameters of CBZ in human [63\u201365].", [" \"PARAMETER\": [\"oral bioavailability\", \"pharmacokinetic parameters\"]\n\nIn rabbits:\n- oral bioavailability\n\nIn human:\n- pharmacokinetic parameters\n\nNote: It's not clear from the text if the \"pharmacokinetic parameters\" mentioned for human refer to a specific set of parameters, so I assumed it refers to all pharmacokinetic parameters. If more context is provided, please let me know and I'll update the answer accordingly.", {"Parameter": ["oral bioavailability"], "Drug": ["CBZ", "CBZ"]}]], [430, "As regards the dietary supplement-CBZ interactions, folinic acid did not alter the plasma level of CBZ in rats [61] while nicotinamide increased CBZ plasma level and decreased its clearance in two children with epilepsy [70].", [" \"PARAMETER\": [\"plasma level\", \"clearance\"]}\n\nFor folinic acid: [\"plasma level\"]\nFor nicotinamide: [\"plasma level\", \"clearance\"]", {"Drug": ["CBZ", "folinic acid", "CBZ", "nicotinamide", "CBZ"], "Parameter": ["clearance"], "Cohort": ["two children"], "Pathology": ["epilepsy"]}]], [431, "Patients on antiepileptic therapy are usually on a long-term basis.", [" \"PARAMETER\": []", {"Pathology": ["Patients"], "Drug": ["antiepileptic therapy"]}]], [432, "In order to achieve a comprehensive literature search, a total of eleven databases were searched.", [" \"PARAMETER\": [\"eleven databases\"]", {}]], [433, "These included two conventional databases (EMBASE and MEDLINE), five other English databases (AMED, CINAHL Plus, Cochrane Database of Systematic Reviews, CENTRAL, and SciFinder Scholar) four Chinese databases.", [" \"PARAMETER\": [\"EMBASE\", \"MEDLINE\", \"AMED\", \"CINAHL Plus\", \"Cochrane Database of Systematic Reviews\", \"CENTRAL\", \"SciFinder Scholar\"]", {"Ethnic group": ["Chinese"]}]], [434, "Ispaghula husk, septilin, soybean and Xiao-cha-hu-tang reduced the plasma level of CBZ by affecting its gastric absorption.", [" \"PARAMETER\": [\"plasma level of CBZ\"]", {"Herb name": ["Ispaghula husk", "septilin", "soybean", "Xiao-cha-hu-tang"], "Drug": ["CBZ"]}]], [435, "Caution should also be paid for beverage containing alcohol.", [" \"PARAMETER\": [\"beverages containing alcohol\"]", {}]], [436, "In a randomized double-blinded control trial, Xiao-yao-san increased the incidence of CBZ-related side effects including dizziness, blurred vision, skin rash, and nausea in patients with major depression or bipolar disorder.", [" \"PARAMETER\": [\"incidence of CBZ-related side effects\", \"dizziness\", \"blurred vision\", \"skin rash\", \"nausea\"]", {"Study": ["a randomized double-blinded control trial"], "Herb name": ["Xiao-yao-san"], "Drug": ["CBZ"], "Pathology": ["dizziness", "blurred vision", "skin rash", "nausea", "major depression", "bipolar disorder"]}]], [437, "Composition of individual herbs in the included herbal formulae.", [" \"PARAMETER\": [\"individual herbs\"]\n\nor\n\n\"PARAMETER\": [\"the composition of individual herbs in the included herbal formulae\"]", {}]], [438, "Fifty percent of the informants used herbal medicines alongside their prescription drugs.", [" \"PARAMETER\": [\"fifty percent of the informants\"]\n\n\"NUMBER OF INDIVIDUALS\": [\"fifty percent\"]\n\n\"ENTITY\": [\"herbal medicines\", \"prescription drugs\"]", {}]], [439, "In identifying these possible interactions, we have highlighted the need for healthcare professionals to promote a proactive monitoring of patients' use of herbal medicines.", [" \"PARAMETER\": [\"\"]\n\nThis sentence does not provide any specific parameters related to pharmacology. It is a statement about the importance of monitoring patients' use of herbal medicines.", {}]], [440, "A significant relationship between variables was identified if p < 0.05.", [" \"PARAMETER\": [\"p\"]\n\nThis parameter refers to the significance level used to determine if there is a relationship between variables. In this case, if the p-value is less than 0.05, it is considered significant.", {}]], [441, "A summary of the background characteristics of the interviewed patients is given in Table 1.", [" I cannot directly parse the information from the text as there is no table provided in the text for reference. However, based on the context, the following parameters can be assumed to be included in Table 1:\n\n\"PARAMETER\": [\"interviewed patients\"]\n\nAssuming that Table 1 provides information about the patients, the following parameters can be assumed:\n\n\"BACKGROUND CHARACTERISTICS\": [\"interviewed patients\"]\n\nThe specific parameters within \"BACKGROUND CHARACTERISTICS\" would depend on the contents of Table 1.", {}]], [442, "This is possibly because the highest number of patients with type-2 diabetes fell within that age group.", [" \"PARAMETER\": []", {"Pathology": ["type-2 diabetes"]}]], [443, "Tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents.", [" \"PARAMETER\": [\"pharmacological management\", \"patients'\"]", {"Drug": ["hypoglycaemic agents"]}]], [444, "For all of the 12 identified plants, pharmacological evidence validating their traditional use in diabetes management have been published.", [" \"PARAMETER\": [\"the 12 identified plants\"]", {"Pathology": ["diabetes"]}]], [445, "An analysis of the drugs commonly prescribed to patients with diabetes show that most of these are substrates or modulators of known pharmacokinetic parameters commonly implicated in drug interactions.", [" \"PARAMETER\": [\"drugs commonly prescribed to patients with diabetes\", \"substrates\", \"modulators\"]", {"Pathology": ["diabetes"]}]], [446, "Healthcare practitioners who are aware of their patients' use of herbal medicines and its identity can more easily monitor them for any possible interactions using available information, such as that presented in Tables 3, 4.", [" \"PARAMETER\": [\"available information\"]\n\n\"PARAMETER\": [\"Tables 3, 4\"]", {}]], [447, "Herb\u2013drug interactions strongly challenge the clinical combined application of herbs and drugs.", [" \"PARAMETER\": [\"herb\u2013drug interactions\"]", {}]], [448, "Herbs have been used for primary health care for thousands of years before the advent of modern medicines.", [" No specific parameters were mentioned in this sentence.\n\nTherefore, the output will be an empty dictionary.\n\n{\"PARAMETER\": []}", {"Herb name": ["Herbs"], "Duration": ["for thousands of years"]}]], [449, "HepaRG cell line, derived from a hepatocellular carcinoma, could express a large panel of liver-specific enzymes [5,6,7].", [" \"PARAMETER\": [\"HepaRG cell line\"]\n\n\"PARAMETER\": [\"a large panel of liver-specific enzymes\"]\n\n[References: 5,6,7]", {"Pathology": ["carcinoma"], "Parameter": ["liver-specific enzymes"]}]], [450, "After administration, aspirin is rapidly hydrolyzed in the body with an elimination half-life of approximatly 15 min [11,12].", [" \"PARAMETER\": [\"elimination half-life\"]\n\nReferences: [11,12]\n\nNote: The exact value of the elimination half-life for aspirin is approximately 15 minutes.", {"Drug": ["aspirin"], "Parameter": ["an elimination half-life"], "Duration": ["15 min"]}]], [451, "A total of 22 compounds were identified or tentatively identified (Figure 1).", [" \"PARAMETER\": [\"\"]\n\nThis sentence does not provide any specific parameters to be extracted. It only mentions that 22 compounds were identified or tentatively identified.", {}]], [452, "There was no significant difference between BNPP (68 \u00b5g/mL) and PNS (150 \u00b5g/mL).", [" \"PARAMETER\": [\"BNPP (68 \u00b5g/mL)\", \"PNS (150 \u00b5g/mL)\"]\n\nThis statement suggests that the concentrations of BNPP and PNS mentioned do not have a significant difference. However, it's important to note that the statement only refers to the difference between these two concentrations and not their significance in relation to any other parameter or context.", {"Parameter": ["BNPP"], "Amount": ["68 \u00b5g/mL", "150 \u00b5g/mL"], "Herb name": ["PNS"]}]], [453, "Liver drug enzymes are the common sites of drug interaction in human.", [" \"PARAMETER\": [\"liver drug enzymes\"]", {"Parameter": ["Liver drug enzymes"]}]], [454, "PNS contents were determined as: notoginsenoside R UPLC-MS/MS analysis was conducted on an Ultimate 3000 UPLC system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA).", [" \"PARAMETER\": [\"notoginsenoside R\", \"UPLC-MS/MS analysis\", \"an Ultimate 3000 UPLC system\", \"an LTQ-Orbitrap Elite mass spectrometer\"]", {"Herb name": ["PNS", "notoginsenoside R"]}]], [455, "The influence test for PON was conducted by the method of Furlong et al.", [" \"PARAMETER\": [\"PON\"]", {"Parameter": ["PON"]}]], [456, "Briefly, 2 \u00d7 10 Total RNA was extracted from the cells using the Trizol (CW0581, CWbio, Beijing, China).", [" \"PARAMETER\": [\"2 \u00d7 10 Total RNA\"]\n\n\"PARAMETER\": [\"the cells\"]\n\n\"PARAMETER\": [\"using the Trizol (CW0581, CWbio, Beijing, China)\"]", {"Amount": ["2 \u00d7 10"], "Parameter": ["Total RNA"]}]], [457, "The present work provides an insight into the mechanism exploration governing HDI between aspirin and PNS.", [" \"PARAMETER\": [\"HDI (Hepatic Drug Interaction)\"]\n\n\"PARAMETER\": [\"aspirin\"]\n\n\"PARAMETER\": [\"PNS (Peripheral Nervous System]\")", {"Drug": ["aspirin"], "Herb name": ["PNS"]}]], [458, "conceived and designed the whole experiments.", [" No physiological or medical parameters were mentioned in this sentence. Therefore, there is no need to add an entry for this sentence in the format requested.", {}]], [459, "** and *** denoted result significantly different from that of the control group (p < 0.01 and p < 0.001, respectively).", [" \"PARAMETER\": [\"p value\"]\n\nNote: No specific value is mentioned in the text, but the information provided indicates that \"p < 0.01\" and \"p < 0.001\" correspond to significant differences from the control group.", {}]], [460, "However, there is hardly any data on the pharmacological safety of these two herbal medicines.", [" \"PARAMETER\": []", {}]], [461, "Inhibition of cytochrome P450 enzymes (CYPs) was quantified by commercial kits and inhibition of drug transporters by use of fluorescent probe substrates.", [" \"PARAMETER\": [\"cytochrome P450 enzymes (CYPs)\", \"drug transporters\"]", {"Target": ["cytochrome P450 enzymes (CYPs)"]}]], [462, "Neither Samento nor Banderol increased intracellular calcein fluorescence in L-MDR1 cells over-expressing human P-glycoprotein (P-gp), indicating lack of P-gp inhibition (data not shown).", [" \"PARAMETER\": []", {"Herb name": ["Samento", "Banderol"], "Target": ["P-glycoprotein (P-gp)", "P-gp"]}]], [463, "The highest inhibition was demonstrated for CYP3A4 by Samento (around 40% at a concentration of 1%) and Banderol (around 20% at a concentration of 1%) and for CYP2C19 by Banderol (about 20% at a concentration of 1%).", [" \"PARAMETER\": [\"highest inhibition\", \"CYP3A4\", \"Samento\", \"around 40%\", \"at a concentration of 1%\", \"CYP2C19\", \"Banderol\", \"about 20%\", \"at a concentration of 1%\"]", {"Target": ["CYP3A4", "CYP2C19"], "Herb name": ["Samento", "Banderol", "Banderol"]}]], [464, "To demonstrate possible influences on aryl hydrocarbon receptor (AhR), another important transcription factor regulating e.g., CYP1A, we also tested whether Samento can activate AhR and found only a minor effect compared to the positive control omeprazole (Figure 4B).", [" \"PARAMETER\": [\"aryl hydrocarbon receptor (AhR)\"]", {"Target": ["aryl hydrocarbon receptor (AhR)", "CYP1A", "AhR"], "Herb name": ["Samento"], "Drug": ["omeprazole"]}]], [465, "This study, therefore, scrutinized in vitro whether Samento and Banderol can inhibit the activity or induce the expression of important drug metabolizing enzymes and drug transporters.", [" \"PARAMETER\": [\"the activity\", \"the expression\"]\n\n\"PARAMETER (of enzymes and transporters)\": [\"important drug metabolizing enzymes and drug transporters\"]", {"Study": ["in vitro"], "Herb name": ["Samento", "Banderol"]}]], [466, "PXR activating drugs (e.g., rifampicin) or herbal preparations (e.g., St. John\u2019s Wort) consequently induce drug metabolizing enzymes, and drug transporters can deteriorate drug efficacy by reducing the bioavailability or increasing the clearance of concomitantly used drugs, being substrates of such enzymes and/or transporters [16,17].", [" \"PARAMETER\": [\"drug metabolizing enzymes\", \"drug transporters\", \"bioavailability\", \"clearance\"]", {"Target": ["PXR"], "Drug": ["rifampicin"], "Herb name": ["John\u2019s Wort"], "Parameter": ["bioavailability"]}]], [467, "BCRP inhibition was tested by flow cytometry using pheophorbide A as a specific BCRP substrate in MDCKII-BCRP cells compared to the parental cell line MDCKII as described previously [24].", [" \"PARAMETER\": [\"BCRP inhibition\", \"pheophorbide A\"]", {"Target": ["BCRP", "BCRP"]}]], [468, "Results for the positive controls rifampicin and cyclosporine A were published previously [25].", [" \"PARAMETER\": [\"rifampicin\", \"cyclosporine A\"]", {"Drug": ["rifampicin", "cyclosporine A"]}]], [469, "Therefore, Samento and Banderol were tested up to a dilution of 1% in the induction assay.", [" \"PARAMETER\": [\"dilution\"]\n\"PARAMETER\": [\"Samento\"]\n\"PARAMETER\": [\"Banderol\"]", {"Herb name": ["Samento", "Banderol"]}]], [470, "RNA was isolated using the GeneElute Mammalian Total RNA Miniprep Kit and cDNA was synthesized with the RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit according to the manufacturers\u2019 instructions.", [" \"PARAMETER\": [\"RNA\", \"cDNA\"]", {}]], [471, "Data were evaluated as described previously [28].", [" No new parameters identified in this sentence.", {}]], [472, "IC In conclusion, Samento and Banderol exhibit a completely different in vitro profile as perpetrators in herb\u2013drug interactions.", [" \"PARAMETER\": []", {"Herb name": ["Samento", "Banderol"], "Study": ["in vitro"]}]], [473, "Thanks to J. Kocher, S. Rosenzweig, C. Mueller, A. Fautsch, and T. R\u00fctzert for excellent technical assistance, to D. Ballinari (Pharmacia & Upjohn, Milano, Italy) for providing P388 and P388/dx cells, to A. H. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands) for providing MDCKII-BCRP cells, to D. Keppler (German Cancer Research Centre, Heidelberg, Germany) for providing HEK-OATP1B1 and HEK-OATP1B3 cell lines, to Z. Dvorak (Palyck\u00fd University, Olomouc, Czech Republic) for providing the AZ-AhR cells, and to D. Theile for careful proofreading of the manuscript.", [" \"PARAMETER\": []\n\nThis section is acknowledging the contributions and assistance of various individuals and institutions. No specific parameters are mentioned in this text.", {"Pathology": ["Cancer"]}]], [474, "* p < 0.05, ** p < 0.01.", [" \"PARAMETER\": []\n\nThis information indicates the level of statistical significance, it does not refer to a specific physiological or medical parameter.", {}]], [475, "Results of the reporter gene assays.", [" \"PARAMETER\": []", {}]], [476, "(a) Concentration-dependent effect of Samento and the positive control rifampicin (insert) on pregnane x receptor (PXR) activity.", [" \"PARAMETER\": [\"concentration-dependent effect\", \"pregnane x receptor (PXR) activity\"]", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["pregnane x receptor (PXR)"]}]], [477, "Effects of Samento (0.033\u20131%) and the positive control rifampicin (20 \u00b5M) on the protein expression of P-glycoprotein (P-gp) after four days of exposure.", [" \"PARAMETER\": [\"protein expression of P-glycoprotein (P-gp)\"]", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["P-glycoprotein (P-gp)"], "Duration": ["after four days"]}]], [478, "Effect of Samento on CYP2J2 mRNA decay in LS180 cells.", [" \"PARAMETER\": [\"CYP2J2 mRNA decay\"]\n\nIn LS180 cells, \"Samento\" affects the decay of \"CYP2J2 mRNA\".", {"Herb name": ["Samento"], "Target": ["CYP2J2 mRNA"]}]], [479, "Expression of CYP2J2 mRNA was quantified by RT-PCR and results normalized to \u03b22mg and to t = 0.", [" \"PARAMETER\": [\"CYP2J2 mRNA\"]\n\n\"RT-PCR\" (assay method used for quantification)\n\n\"results\" (data obtained from the experiment)\n\n\"normalized to \u03b22mg\" (reference gene used for normalization)\n\n\"t = 0\" (time point used as reference)", {"Target": ["CYP2J2 mRNA", "\u03b22mg"]}]], [480, "Drug interactions may occur between woohwangcheongsimwon suspension and bupropion.", [" \"PARAMETER\": [\"woohwangcheongsimwon suspension\", \"bupropion\"]", {"Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [481, "Its original formulation was in a tablet form.", [" \"PARAMETER\": []", {}]], [482, "It has been officially listed in the Korean Pharmaceutical Codex for a long time and an aqueous suspension has recently been developed for convenient administration [1].", [" \"PARAMETER\": [\"\"]\n\n[1]: This sentence does not contain any specific parameter. It is providing additional contextual information about the substance being discussed.", {"Ethnic group": ["Korean"], "Extraction process": ["aqueous suspension"]}]], [483, "Table 1  The major ingredients of woohwangchengonsimwon suspension (Kwang-Dong Pharmaceutical Company, Seoul, Korea) Ingredients\tQuantity in 30 ml (mg) Bovis Calculus\t14 Dioscoreae Rhizoma\t282 Glycyrrhizae Radix et Rhizoma\t202 Ginseng Radix\t97 Typhae Pollen\t100 Massa Medicata Fermentata\t100 Glycine Semen Germinatum\t70 Cinnamomi cortex\t70 Paeoniae Radix\t60 Liriopis Tuber\t60 Scutellariae Radix\t60 Angelicae Gigantis Radix\t60 Saposhnikoviae Radix\t60 Atractylodis Rhizoma Alba\t60 Bupleuri Radix\t50 Platycodonis Radix\t50 Armeniacae Semen\t50 Poria Sclerotium\t50 Cnidii Rhizoma\t50 Civet\t15 Antelopis Cornu\t35 Borneolum*\t41 Ampelopsis Radis\t30 Zingiberis Rhizoma\t30 Open in a separate window *Borneolum included 38.58 mg of borneol and isoborneol.", [" \"PARAMETER\": [\"Bovis Calculus\", \"Dioscoreae Rhizoma\", \"Glycyrrhizae Radix et Rhizoma\", \"Ginseng Radix\", \"Typhae Pollen\", \"Massa Medicata Fermentata\", \"Glycine Semen Germinatum\", \"Cinnamomi cortex\", \"Paeoniae Radix\", \"Liriopis Tuber\", \"Scutellariae Radix\", \"Angelicae Gigantis Radix\", \"Saposhnikoviae Radix\", \"Atractylodis Rhizoma Alba\", \"Bupleuri Radix\", \"Platycodonis Radix\", \"Armeniacae Semen\", \"Poria Sclerotium\", \"Cnidii Rhizoma\", \"Civet\", \"Antelopis Cornu\", \"Borneolum\"]}\n\nNote: Borneolum is mentioned twice, but the second mention includes the specific quantities of borneol and isoborneol. Therefore, I have included \"Borneolum\" in the list, but you may want to update the quantity parameter to reflect the specific quantities of borneol and isoborneol if that information is important for your analysis.", {"Herb name": ["woohwangchengonsimwon suspension", "Dioscoreae", "Glycyrrhizae", "Ginseng", "Typhae", "Massa Medicata Fermentata", "Cinnamomi", "Paeoniae", "Liriopis", "Scutellariae", "Angelicae Gigantis", "Saposhnikoviae", "Atractylodis", "Bupleuri", "Platycodonis", "Armeniacae", "Poria Sclerotium", "Cnidii", "Civet", "Borneolum", "Ampelopsis", "Zingiberis", "Borneolum", "borneol", "isoborneol"], "Herb part": ["Rhizoma", "Radix", "Rhizoma", "Radix", "Pollen", "cortex", "Radix", "Tuber", "Radix", "Radix", "Radix", "Rhizoma", "Radix", "Radix", "Rhizoma", "Radis", "Rhizoma"]}]], [484, "Subjects were also asked to abstain from taking prescription and over the counter medications for 2 weeks before and during the study period.", [" \"PARAMETER\": [\"prescription medications\", \"over the counter medications\"]", {}]], [485, "CYP2B6 genotyping  CYP2B6 genotyping was performed by pyrosequencing of polymerase chain reaction (PCR) products as described previously [13].", [" \"PARAMETER\": [\"CYP2B6 genotyping\"]", {"Target": ["CYP2B6", "CYP2B6"]}]], [486, "Safety monitoring was performed throughout the study.", [" \"PARAMETER\": []", {}]], [487, "The TurboIonSpray interface was operated in positive ion mode at 5500 V and 500\u00b0C.", [" \"PARAMETER\": [\"5500 V\", \"500\u00b0C\"] (These values are likely the operating conditions for the TurboIonSpray interface, specifically the ion spray voltage and temperature.)", {}]], [488, "The analytical data were processed using Analyst software (version 1.4, Applied Biosystems, Foster City, CA).", [" \"PARAMETER\": [\"\"]\n\n(No relevant parameters found in the text)", {}]], [489, "Geometric means were calculated for the AUC(0,\u221e), Cmax and so on of bupropion and 4-hydroxybupropion.", [" \"PARAMETER\": [\"AUC(0,\u221e)\", \"Cmax\"]}", {"Parameter": ["AUC(0,\u221e)", "Cmax"], "Drug": ["bupropion", "4-hydroxybupropion"]}]], [490, "Geometric mean ratios (GMRs) with 90% confidence intervals (CIs) were calculated after log transformation of within-subject data.", [" \"PARAMETER\": [\"geometric mean ratios (GMRs)\", \"confidence intervals (CIs)\"]", {}]], [491, "No clinically significant alterations in blood pressure, heart rate or body temperature were observed.", [" \"\"PARAMETER\"\": [\"blood pressure\", \"heart rate\", \"body temperature\"]}\n\nThese parameters were not significantly altered.", {"Parameter": ["blood pressure", "heart rate", "body temperature"]}]], [492, "Go to: Discussion  In this study, we examined the CYP2B6 inhibitory effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion.", [" \"PARAMETER\": [\"CYP2B6 inhibitory effects\", \"woohwangcheongsimwon suspension\", \"pharmacokinetics of bupropion\"]", {"Target": ["CYP2B6"], "Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [493, "The herbal reaction toward different types of statins is varied so that grapefruit or pomegranate was interacted with only some types of statins, but not with all statin types.", [" \"PARAMETER\": [\"grapefruit\", \"pomegranate\"]\n\n(Note: In this context, \"herbal reaction toward different types of statins\" refers to drug-herb interactions, so both \"herbal\" and \"statins\" are considered as entities.)", {"Drug": ["statins", "statins", "statin"], "Herb name": ["grapefruit", "pomegranate"]}]], [494, "The overexpression or somatic mutations of tyrosine kinases are dysregulated in various malignancies [3].", [" \"PARAMETER\": [\"tyrosine kinases\"]\n\nReferences:\n[3] [Citation needed]", {"Target": ["tyrosine kinases"]}]], [495, "The APG-pretreated rats showed significant inhibition of the Pgp/MDR1 protein, that is 65.38% and 69.90% inhibition, respectively, as compared to DAS alone (p < 0.05).", [" \"PARAMETER\": [\"Pgp/MDR1 protein\", \"inhibition\"]", {"Herb name": ["APG"], "Target": ["Pgp", "MDR1"], "Drug": ["DAS"]}]], [496, "The inhibitory potential of APG on BCRP/ABCG2 protein expression was investigated and shown in Figure 5A,B.", [" \"PARAMETER\": [\"BCRP/ABCG2 protein expression\"]\n\n\"PARAMETER\": [\"Figure 5A,B\"]", {"Herb name": ["APG"], "Target": ["BCRP", "ABCG2"]}]], [497, "The APG-pretreated rats showed significant inhibition of the BCPR/ABCG2 protein that is (66.77% and 41.06% inhibition, respectively) as compared to DAS only (p < 0.05).", [" \"PARAMETER\": [\"BCPR/ABCG2 protein\", \"inhibition\"]", {"Herb name": ["APG"], "Target": ["BCPR", "ABCG2"], "Drug": ["DAS"]}]], [498, "Inhibition and/or induction of drug-metabolizing enzymes (DME) and or drug transporters mediated by herbs is the most typical mechanism of herb-drug interactions, which in turn alters the pharmacokinetic disposition of the drug [24,25].", [" \"PARAMETER\": [\"drug-metabolizing enzymes (DME)\", \"drug transporters\"]", {}]], [499, "The purpose of the current study was to determine whether or not APG has a pharmacokinetic interaction with DAS, and if so, how they would interact.", [" \"PARAMETER\": [\"APG\", \"DAS\"]\n\nThe purpose of the current study was to determine the pharmacokinetic interaction between APG and DAS.", {"Herb name": ["APG"], "Drug": ["DAS"]}]], [500, "The radical alteration in the pharmacokinetic parameters of DAS 25 mg/kg P.O.", [" \"PARAMETER\": [\"pharmacokinetic parameters of DAS 25 mg/kg P.O.\"]", {"Drug": ["DAS"], "Amount": ["25 mg/kg"]}]], [501, "All animals were retained in polypropylene cages: 6 animals were caged (n = 6) per cage with a 12-h light/dark cycle, at 25 \u00b0C in humane conditions with free access to food and water and adapted to the living conditions one week prior to experiment The animals were categorized into four groups (n = 6) and fasted for 12 h before the experiment.", [" \"PARAMETER\": [\"animals\", \"polypropylene cages\", \"n = 6\", \"12-h light/dark cycle\", \"25 \u00b0C\", \"humane conditions\", \"free access to food and water\", \"living conditions\", \"one week prior to experiment\", \"four groups\", \"n = 6\"]", {"Cohort": ["four groups (n = 6)"]}]], [502, "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day.", [" \"PARAMETER\": [\"7 days\", \"Group II\", \"DAS\", \"25 mg/kg\"]\n\nExplanation:\nGroup I was administered normal saline for 7 days, while Group II was administered DAS (25 mg/kg) on the 7th day. Therefore, both the duration of treatment and the specific intervention for Group II should be included in the parameters.", {"Duration": ["for 7 days"], "Drug": ["DAS"], "Amount": ["25 mg/kg)"]}]], [503, "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days.", [" \"PARAMETER\": [\"7th day\", \"2 h after APG 40 mg/kg administration\", \"APG 40 mg/kg\"]", {"Herb name": ["APG", "APG"], "Amount": ["40 mg/kg", "40 mg/kg"], "Duration": ["for 7 days"]}]], [504, "Electrospray ionization was used to ionize samples in a positive direction.", [" \"PARAMETER\": [\"ionization\"]\n\n\"IONIZATION TECHNIQUE\": [\"electrospray ionization\"]", {}]], [505, "Further thorough in vivo studies of the APG\u2013DAS interaction in humans are warranted to support these findings.", [" No specific parameters were mentioned in this sentence.", {"Study": ["in vivo studies"], "Herb name": ["APG"], "Drug": ["DAS"]}]], [506, "and M.A.A.", [" I cannot determine the parameter for \"M.A.A.\" without additional context.", {}]], [507, "; supervision, K.M.A.", [" \"PARAMETER\": []", {}]], [508, "All authors have read and agreed to the published version of the manuscript.", [" No specific parameters mentioned in this statement.", {}]], [509, "The research was approved by the Research Ethics Committee of King Saud University College of Pharmacy Riyadh, Saudi Arabia (KSU-SE-21-58).", [" \"PARAMETER\": [\"\"]\n\n(This text does not contain any specific parameter related to pharmacology or entities related to the described entities in the article.)", {}]], [510, "All results are presented as the average \u00b1 SD.", [" \"PARAMETER\": [\"average\", \"SD\"]", {}]], [511, "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment.", [" \"PARAMETER\": [\"HEPATIC A and INTESTINAL B hepatic and intestinal BCRP/ABCG2 protein expression\"]", {"Target": ["BCRP", "ABCG2"], "Drug": ["DAS"], "Herb name": ["APG"]}]], [512, "Phytochemical-mediated modulation of cytochrome P-450 (CYP) activity may underlie many herb-drug interactions.", [" \"PARAMETER\": [\"cytochrome P-450 (CYP) activity\"]", {}]], [513, "If so, herb-mediated changes in CYP activity may take on greater clinical relevance in this population.", [" \"PARAMETER\": [\"herb-mediated changes in CYP activity\"]", {}]], [514, "Concomitant ingestion of botanical supplements with prescription medications, therefore, should be strongly discouraged in the elderly.", [" \"PARAMETER\": []", {}]], [515, "The purpose of this study was to evaluate the effect of SC extract supplementation on quadriceps muscle strength (QMS) and lactate at rest in adult women.", [" \"PARAMETER\": [\"quadriceps muscle strength (QMS)\", \"lactate at rest\"]", {"Herb name": ["SC extract"], "Parameter": ["quadriceps muscle strength (QMS)", "lactate"], "Sex": ["women"]}]], [516, "In ANOVA results, QMS (p = 0.001) and lactate level (p = 0.038) showed significant interactions.", [" \"PARAMETER\": [\"QMS\", \"lactate level\"]\n\nNote: \"p\" values are statistical parameters, but they are not typically considered as physiological or medical parameters. However, I included them here for completeness.", {"Parameter": ["lactate level"]}]], [517, "Our first hypothesis is that the supplementation of SC extract in humans can increase muscle strength.", [" \"PARAMETER\": [\"muscle strength\"]", {"Herb name": ["SC extract"], "Parameter": ["muscle strength"]}]], [518, "In the main test session, subjects performed 5 isokinetic knee extensions of the leg at an angular velocity of 60 degrees/second, and subjects recovered passively for 2 min between sets of measurements [26,27].", [" \"PARAMETER\": [\"angular velocity\", \"5 isokinetic knee extensions\", \"2 min\"]", {}]], [519, "The subject\u2019s knee joint center, measured using the femoral epicondyles as a joint center reference, was aligned with the axis of the isokinetic dynamometer.", [" \"PARAMETER\": [\"subject\u2019s knee joint center\", \"axis of the isokinetic dynamometer\"]", {}]], [520, "Plasma samples were obtained by centrifugation and stored at \u221280 \u00b0C.", [" \"PARAMETER\": [\"plasma samples\"]\n\n\"TEMPERATURE\": [\"-80 \u00b0C\"]", {}]], [521, "The mean SC extract supplementation and placebo compliance were 97.3% (90.2\u2212100%) in the SC group and 95.8% (86.7\u2013100%) in the placebo group.", [" \"PARAMETER\": [\"mean SC extract supplementation\", \"mean placebo compliance\"]", {"Herb name": ["SC extract", "SC"]}]], [522, "There were no significant differences between the groups for height, weight, or BMI at baseline (Table 1).", [" \"PARAMETER\": []", {"Parameter": ["BMI"]}]], [523, "Resting lactate level was measured at baseline and after 12 weeks, and results are presented in Figure 2.", [" \"PARAMETER\": [\"resting lactate level\"]", {"Parameter": ["lactate level"], "Duration": ["12 weeks"]}]], [524, "have shown the association between high lactate production and reduced oxidative metabolism [47].", [" \"PARAMETER\": [\"high lactate production\"]\n\n\"PARAMETER\": [\"reduced oxidative metabolism\"]", {"Parameter": ["lactate"]}]], [525, "The first clinically relevant reports of preparations of St. John's wort (SJW), a herbal medicine with anti\u2010depressant effects, interacting with other drugs, altering their bioavailability and efficacy, were published about 20 years ago.", [" \"PARAMETER\": [\"bioavailability\", \"efficacy\"]\n\nThese parameters refer to the effects of St. John's wort on other drugs, specifically in relation to their interaction and impact on their performance.", {"Study": ["reports"], "Herb name": ["St. John's wort (SJW)"], "Parameter": ["bioavailability"]}]], [526, "These interactions were caused by pregnane\u2010X\u2010receptor (PXR) activation.", [" \"PARAMETER\": [\"pregnane-X-receptor (PXR)\"]", {"Target": ["pregnane\u2010X\u2010receptor (PXR)"]}]], [527, "The most important information has been comprehensively summarized (Borrelli & Izzo, 2009; Chrubasik\u2010Hausmann, Vlachojannis, & McLachlan, 2019; Gurley, Fifer, & Gardner, 2012; Izzo, 2004; Soleymani, Bahramsoltani, Rahimi, & Abdollahi, 2017; Whitten, Myers, Hawrelak, & Wohlmuth, 2006).", [" \"PARAMETER\": []", {}]], [528, "SJW extracts as well as isolated constituents (hyperforin, hypericin, or flavonoids) have been investigated in vitro and in vivo for their interactions with a variety of potentially relevant targets for depression.", [" \"PARAMETER\": [\"SJW extracts\", \"isolated constituents\", \"hyperforin\", \"hypericin\", \"flavonoids\"]", {"Herb name": ["SJW extracts", "hyperforin", "hypericin", "flavonoids"], "Study": ["in vitro", "in vivo"], "Pathology": ["depression"]}]], [529, "The tail suspension test, which also measures changes in immobility in rodents after antidepressant treatment, was applied by several investigators (Butterweck, Christoffel, et al., 2003; Machado et al., 2008; Tian et al., 2014) and SJW extracts significantly reduced the time of immobility in this test.", [" \"PARAMETER\": [\"time of immobility in the tail suspension test\"]", {"Drug": ["antidepressant treatment,"], "Herb name": ["SJW extracts"]}]], [530, "In the network of genes involved in drug metabolism, the PXR functions as a xenobiotic receptor or \u201cxenosensor,\u201d which, after ligand binding, translocates to the nucleus, where it binds to specific PXR response elements (PXRRE) in the promotor of various genes, modulating their transcription.", [" \"PARAMETER\": [\"PXR\", \"xenobiotic receptor\", \"xenosensor\", \"ligand binding\", \"nucleus\", \"specific PXR response elements (PXRRE)\", \"promotor\", \"transcription\"]", {"Target": ["PXR", "PXR response elements (PXRRE)"]}]], [531, "For OATP2B1, we have recently shown that this transporter is not only inhibited by hyperforin but also transports this constituent of SJW (Sch\u00e4fer, Bock, & Meyer Zu Schwabedissen, 2018), thus influencing the intracellular transactivation of PXR by hyperforin (Sch\u00e4fer et al., 2019).", [" \"PARAMETER\": [\"OATP2B1\", \"intracellular transactivation of PXR\"]", {"Target": ["OATP2B1", "PXR"], "Herb name": ["hyperforin", "SJW", "hyperforin"]}]], [532, "This statement was provided even before another comprehensive pharmacokinetic interaction study was published, where no clinically relevant interactions were found for seven test drugs in concomitant application with a low\u2010hyperforin SJW extract (Zahner et al., 2019).", [" \"\"PARAMETER\"\": [\"seven test drugs\", \"a low-hyperforin SJW extract\"]\"\"\"\n\nNote: SJW stands for St. John's Wort.", {"Herb name": ["low\u2010hyperforin SJW extract"]}]], [533, "Based on the high quality clinical data, pharmacoepidemiology methods and bioinformatics or data mining could be adopt for further identification of clinical meaningful herb-drug interactions in cancer therapies.", [" \"PARAMETER\": [\"high quality clinical data\", \"pharmacoepidemiology methods\", \"bioinformatics or data mining\"]", {"Pathology": ["cancer"]}]], [534, "Although systematic reviews and meta-analysis of Lingzhi and Yunzhi as an adjunct for cancer treatment have been performed [8\u201310], these reviews mostly focused on clinical outcomes with no mechanistic explanations for the potential beneficial or harmful interactions.", [" \"\"PARAMETER\": [\"systematic reviews\", \"meta-analysis\", \"Lingzhi\", \"Yunzhi\", \"clinical outcomes\"]\"\"\"", {"Herb name": ["Lingzhi", "Yunzhi"], "Pathology": ["cancer"]}]], [535, "If the control group also received medicinal mushrooms, there should be significant dosage differences of the mushrooms in the treatment group.", [" \"PARAMETER\": [\"dosages of medicinal mushrooms\"]", {}]], [536, "Figure\u00a01 summarizes the process of database searching and literature selection.", [" \"PARAMETER\": []", {}]], [537, "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100].", [" \"PARAMETER\": [\n\"T cell apoptosis\",\n\"caspase 3 activity\",\n\"Bax expression\",\n\"efficacy\",\n\"survival\",\n\"T cells count (CD4, CD4/CD8)\",\n\"appetite\",\n\"WBC (CD3+, CD4+ T cells, NK cells)\",\n\"platelets\",\n\"phagocytic activity\",\n\"antibody production\",\n\"delayed hypersensitivity\",\n\"tumor inhibition effect\",\n\"survival time\",\n\"cytotoxicity\",\n\"metastasis\",\n\"immunosuppression\",\n\"phagocytic activity (reduced decrease)\",\n\"antibody production (reduced decrease)\",\n\"delayed hypersensitivity (reduced decrease)\",\n\"tumor inhibition and apoptotic rate\",\n\"cell cycle arrest\",\n\"caspase 3 expression and activity\",\n\"caspase 8 expression and activity\"\n]", {"Parameter": ["T cell apoptosis", "caspase 3 activity", "Bax expression", "cells count", "CD4", "CD4", "CD8", "WBC", "CD3+", "CD4+ T cells", "NK cells", "platelets", "WBC", "platelets", "bone marrow cells", "phagocytic activity", "antibody production", "caspase 3"], "Study": ["preclinical studies"], "Pathology": ["intestinal damage", "metastasis"], "Drug": ["5-FU", "5-FU"]}]], [538, "Some Yunzhi\u2013drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide and UFT) also reduced tumor recurrence [25, 38, 42, 44] and metastasis [49].", [" \"PARAMETER\": [\"tumor recurrence\", \"metastasis\"]", {"Herb name": ["Yunzhi"], "Drug": ["5-FU", "carboplatin", "cisplatin", "cyclophosphamide", "doxorubicin", "etoposide", "UFT"], "Pathology": ["tumor", "metastasis"]}]], [539, "In addition, the enhancement of the antitumor effect was shown to be achieved via the inhibition of tumor cell angiogenesis [104] or increase in the reactive oxygen species production [124].", [" \"\"PARAMETER\": [\"tumor cell angiogenesis\", \"reactive oxygen species production\"]\"\"\"", {}]], [540, "Notably, a recent study found that such synergistic effect may be due to the inhibition of tumor metabolism via down-regulating Warburg-related proteins and restoration of the gut dysbiosis induced by paclitaxel [97].", [" \"\"PARAMETER\": [\"Warburg-related proteins\", \"gut dysbiosis\"]\"\"\"", {"Pathology": ["gut dysbiosis"], "Drug": ["paclitaxel"]}]], [541, "Yunzhi could also enhance the cytotoxicity of anticancer drugs via other mechanisms, such as direct increase in the activity of cytotoxic and tumor-infiltrating lymphocytes, decrease in the activity of suppressor T cells [38, 70], and decrease and increase in superoxide dismutase (SOD) and lipid peroxide levels, respectively, in cancer cells [131].", [" \"PARAMETER\": [\"cytotoxicity\", \"activity of cytotoxic and tumor-infiltrating lymphocytes\", \"suppressor T cells\", \"superoxide dismutase (SOD)\", \"lipid peroxide levels\"]", {"Herb name": ["Yunzhi"], "Drug": ["anticancer drugs"], "Parameter": ["suppressor T cells", "superoxide dismutase (SOD)", "lipid peroxide levels"], "Pathology": ["cancer"]}]], [542, "a.", [" I cannot determine what \"a\" refers to in this context without additional information. Please provide more context or specify which parameter \"a\" refers to.", {}]], [543, "Multiple mechanisms may be involved, including upregulation of transcription factors such as T-box protein expressed in T cells (T-bet) and GATA-3, which modulate the T helper cell balance [169]; downregulation of Bax expression to reduce caspase 3 activity and T cell apoptosis [170]; and reduction of the expression of negative regulators/transcription factors of immune responses, including Forkhead box protein 3 (Foxp3) and programmed death 1 (PD-1) [171].", [" \"PARAMETER\": [\n\"T-box protein expressed in T cells (T-bet)\",\n\"GATA-3\",\n\"Bax\",\n\"caspase 3 activity\",\n\"T cell apoptosis\",\n\"Forkhead box protein 3 (Foxp3)\",\n\"programmed death 1 (PD-1)\"\n]", {"Target": ["T-box protein expressed in T cells (T-bet)", "GATA-3", "caspase 3", "T cell", "Forkhead box protein 3 (Foxp3)", "programmed death 1 (PD-1)"]}]], [544, "In summary, the aforementioned outcomes suggest that medicinal mushrooms have great potential to ameliorate the adverse effects of chemotherapeutic drugs in clinical settings.", [" \"PARAMETER\": []", {"Pathology": ["adverse effects"]}]], [545, "Table S4.", [" I cannot directly parse the information from a table without additional context. The name of the table (Table S4) does not provide enough information to determine the parameters mentioned in the article.", {}]], [546, "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All.", [" \"PARAMETER\": [\"All\"] (This is not a physiological or medical parameter, but rather a statement about the responsibility of the individuals involved in the study.)", {}]], [547, "Not applicable.", [" If there is no specific parameter mentioned in the text, the output should be an empty dictionary.\n\n{\"PARAMETER\": []}", {}]], [548, "Women diagnosed with breast cancer frequently seek complementary and alternative (CAM) treatment options that can help to cope with their disease and the side effects of conventional cancer therapy.", [" \"PARAMETER\": [\"women diagnosed with breast cancer\", \"disease\", \"side effects of conventional cancer therapy\"]\n\nNote: In this context, \"conventional cancer therapy\" refers to standard medical treatments for breast cancer, such as chemotherapy, radiation therapy, and surgery.", {"Pathology": ["breast cancer", "side effects", "cancer"]}]], [549, "Approximately 70\u201380% of all breast tumors are estrogen receptor (ER) positive [2], and hormonal therapy plays therefore an important role in the therapy of early stage and metastatic ER-positive breast cancer.", [" \"PARAMETER\": [\"early stage and metastatic ER-positive breast cancer\", \"approximately 70\u201380%\"]\n\n\"PERCENTAGE\": [\"70\u201380%\"]\n\n\"ENTITY\": [\"early stage and metastatic ER-positive breast cancer\", \"hormonal therapy\"]\n\n\"REFERENCE\": [2]\n\n\"TYPE\": [\"fact\"]\n\n\"DESCRIPTION\": [\"Approximately 70-80% of all breast tumors are estrogen receptor (ER) positive, and hormonal therapy plays therefore an important role in the therapy of early stage and metastatic ER-positive breast cancer.\"]\n\n\"NOTES\": [\"This statement is based on the given reference [2]. The percentage is approximate and may vary slightly depending on the specific population studied and the diagnostic methods used to determine ER status.\"]", {"Pathology": ["breast tumors", "ER-positive breast cancer"], "Target": ["estrogen receptor (ER)"], "Drug": ["hormonal therapy"]}]], [550, "Clinical studies have reported on the benefits of Viscum album extracts (VAE) not only in breast cancer patients but also for other types of cancer [10\u201313].", [" \"PARAMETER\": [\"Viscum album extracts (VAE)\"]\n\nReferences:\n[10\u201313]", {"Study": ["Clinical studies"], "Herb name": ["Viscum album extracts (VAE)"], "Pathology": ["breast cancer", "cancer"]}]], [551, "5\u2009mg (VAEM, host tree Malus domestica, Lot 7054/0, total mistletoe lectin concentration 306\u2009ng/mL), and Iscador Qu spec.", [" \"PARAMETER\": [\"5 mg\", \"VAEM\", \"host tree Malus domestica\", \"Lot 7054/0\", \"total mistletoe lectin concentration 306 ng/mL\", \"Iscador Qu spec\"]\n\nNote: It's unclear from the context what each parameter represents, so I've left them as is.", {"Amount": ["5\u2009mg"], "Herb name": ["VAEM", "Malus domestica", "mistletoe lectin", "Iscador Qu"]}]], [552, "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA).", [" \"PARAMETER\": [\"(E/Z)-endoxifen hydrochloride\", \"4-hydroxy-N-desmethyltamoxifen hydrochloride\", \"\u03b2-estradiol (E2)\", \"pooled human liver microsomes (HLMs)\", \"50 donors\", \"mixed gender\"]", {"Drug": ["(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride)", "dextrorphan-d"], "Target": ["\u03b2-estradiol (E2)"]}]], [553, "Significances are given relative to the VAEM untreated values (*p\u00a0<\u20090.05, **p\u00a0<\u20090.01, ***p\u00a0<\u20090.001) VAEM, as well as endoxifen, showed a concentration-dependent inhibition of proliferation (Fig.", [" 1].\"\"PARAMETER\": [\"VAEM\", \"proliferation\"]\n\n\"FIGURE\": [\"Fig. [\"]\n\n\"PARAMETER (for Fig.)\": [\"concentration-dependent inhibition\"]", {"Herb name": ["VAEM", "VAEM"], "Drug": ["endoxifen"]}]], [554, "Based on genotype combinations encoding for varying enzyme phenotypes, patients have been classified as poor, intermediate, extensive, or ultra-rapid metabolizers [32, 33].", [" \"PARAMETER\": [\"patients\", \"poor metabolizers\", \"intermediate metabolizers\", \"extensive metabolizers\", \"ultra-rapid metabolizers\"]", {}]], [555, "The metabolic activity of CYP2D6 was suggested to be associated with the long-term outcomes in breast cancer, although the studies are inconsistent [35].", [" \"PARAMETER\": [\"metabolic activity of CYP2D6\", \"long-term outcomes in breast cancer\"]", {"Target": ["CYP2D6"], "Pathology": ["breast cancer"]}]], [556, "The significant inter-individual variability of CYP2D6 activity due to genetic polymorphisms was mitigated by the use of pooled microsomes from 50 donors [41].", [" \"PARAMETER\": [\"CYP2D6 activity\"]", {"Target": ["CYP2D6"]}]], [557, "(PDF 36 kb) Figure S2.", [" I cannot extract any parameters from the given text as it only mentions the existence of a figure named \"Figure S2\".", {}]], [558, "Dextromethorphan in vitro inhibition profiles of CYP2D6 by reference inhibitor: Quinidine (0.1-1-2-5-10-100 \u03bcM).", [" \"PARAMETER\": [\"CYP2D6\", \"in vitro inhibition profiles\"]", {"Drug": ["Dextromethorphan", "Quinidine"], "Study": ["in vitro"], "Target": ["CYP2D6"]}]], [559, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" This statement is not related to parameters in the context of pharmacology.", {}]], [560, "To our knowledge, there is no available information regarding pharmacokinetic interactions between captopril and H. sabdariffa.", [" \"PARAMETER\": []", {"Drug": ["captopril"], "Herb name": ["H. sabdariffa"]}]], [561, "For derivatization of plasma captopril, a plasma sample (180\u2009\u00b5L) was first mixed with 20\u2009\u00b5L of 520\u2009ppm 2-4-dibromoacetophenone stock solution and 20\u2009\u00b5L of 5% ammonia solution, vortexed for 30 seconds, and incubated at room temperature for 30\u2009min.", [" \"PARAMETER\": [\"plasma sample\", \"2-4-dibromoacetophenone stock solution\", \"5% ammonia solution\"]", {"Drug": ["captopril"]}]], [562, "daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)", [" \"PARAMETER\": [\"daily\", \"for two weeks\", \"morning\", \"single captopril dose\", \"4.5\u2009mg/200\u2009g BW\", \"BW\", \"p.o.\"]\n\nExplanation:\n\n* \"daily\" and \"for two weeks\" indicate the frequency and duration of the treatment.\n* \"morning\" indicates the time of day when the treatment was administered.\n* \"single captopril dose\" indicates that a single dose of captopril was given.\n* \"4.5\u2009mg/200\u2009g BW\" indicates the dose of captopril in terms of milligrams per kilogram of body weight.\n* \"p.o.\" stands for \"per os,\" which means \"by mouth.\"\n\nTherefore, the entire phrase \"daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)\" refers to the administration of a single dose of captopril (4.5 mg/kg BW) every day for a period of two weeks.", {"Frequency": ["daily"], "Duration": ["for two weeks"], "Drug": ["captopril"], "Amount": ["4.5\u2009mg/200\u2009g BW"]}]], [563, "The animals were anaesthetized before blood collection process.", [" \"PARAMETER\": [\"animals\", \"before\"]\n\n\"ANESTHETIZED\": [\"animals\"]\n\n\"EVENT\": [\"blood collection process\"]\n\n\"TIME\": []\n\n\"LOCATION\": []\n\n\"METHOD\": []\n\n\"OTHERS\": []\n\n\"PARAMETER\": []\n\n\"RESULT\": []\n\n\"REFERENCE\": []\n\n\"COMMENT\": [\"The animals were anesthetized before the blood collection process.\"]", {}]], [564, "The loss of body fluid was compensated by administrating 1.0\u2009mL saline solution (p.o.)", [" \"PARAMETER\": [\"1.0 mL saline solution\"]", {}]], [565, "The within-run accuracy and precision of captopril analysis ranged from 1.56% to 14.38% (Table 3).", [" \"PARAMETER\": [\"within-run accuracy\", \"within-run precision\"]", {"Drug": ["captopril"]}]], [566, "In selectivity testing, six rats plasma was used.", [" \"PARAMETER\": [\"six rats\"]\n\nThis parameter refers to the number of rats used in selectivity testing.", {}]], [567, "In this experiment, we used 2-4-dibromoacetophenone as a derivatization agent to prevent the sulfhydryl group in captopril from binding to plasma sulfhydryl groups.", [" \"PARAMETER\": [\"2-4-dibromoacetophenone\"]", {"Drug": ["captopril"]}]], [568, "Ammonia was used during derivatization since the reaction is optimal at basic pH.", [" \"PARAMETER\": [\"ammonia\"]", {}]], [569, "The reaction was then stopped by adding formic acid [17].", [" \"PARAMETER\": [\"\"]\n\n(Formic acid is a chemical reagent and not a physiological or medical parameter.)", {}]], [570, "Two weeks of coadministration of H. sabdariffa extract is sufficient enough to affect the GSH level or the expression of the PEPT1 transporter.", [" \"PARAMETER\": [\"GSH level\", \"expression of the PEPT1 transporter\"]", {"Duration": ["Two weeks"], "Herb name": ["H. sabdariffa"], "Target": ["GSH", "PEPT1 transporter"]}]], [571, "2016; Eng et\u00a0al.", [" \"PARAMETER\": [\"\"]\n\nThis is likely a citation, and it does not provide any specific parameters.", {}]], [572, "2016).", [" This text does not contain any parameters related to pharmacology.", {}]], [573, "Water and food (laboratory rodent chow, Shanghai, China) were allowed ad libitum.", [" No specific parameters mentioned in this sentence.", {}]], [574, "The analysis was performed on an Agilent 1290 series liquid chromatography system (Agilent Technologies, Palo Alto, CA, USA).", [" \"PARAMETER\": [\"Agilent 1290 series liquid chromatography system\"]", {}]], [575, "Statistical analysis of results obtained from clinical study was performed using Student\u2019s paired t-test.", [" \"PARAMETER\": [\"results obtained from clinical study\"]\n\n\"STATISTICAL ANALYSIS\": [\"Student\u2019s paired t-test\"]", {"Study": ["clinical study"]}]], [576, "The results suggest that the herb-drug interaction between GLT and AC might occur when they were co-administered.", [" \"PARAMETER\": [\"herb-drug interaction\", \"GLT and AC\"]", {"Herb name": ["GLT"], "Drug": ["AC"]}]], [577, "HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?", [" It is important to note that the given text does not provide sufficient information to determine how this finding might change clinical pharmacology or translational science in general. The text only reports an association between a genetic variant (rs1142345) and the clinical effect of traditional hypoglycemic herbs. Further research is needed to determine the clinical implications of this finding, such as how it might affect dosing, drug interactions, or patient outcomes. Additionally, the text does not provide information on the specific herbs or active compounds that were studied, or the population demographics, which could also impact the clinical significance of this finding.", {}]], [578, "(n\u00a0=\u00a06).", [" \"PARAMETER\": []\n\nThis text does not provide any information about physiological or medical parameters.", {"Amount": ["6"]}]], [579, "wrote the manuscript.", [" I'm an AI language model and don't have the ability to write manuscripts or perform experiments. I can only help you with text-related tasks such as parsing information and providing explanations. In this case, I've helped you identify the parameters mentioned in the text. If you have any specific text-related questions, feel free to ask!\n\nRegarding the manuscript, it discusses the impact of genetic variations on the metabolism of certain drugs and herbs. The text mentions that concomitant use of echinacea with warfarin increases the apparent clearance of S-warfarin but does not have a clinically significant effect on warfarin pharmacodynamics in healthy subjects. Additionally, the text discusses how certain genetic variations, specifically rs1142345, are associated with the clinical effect of traditional hypoglycemic herbs and their impact on the metabolism of glipizide and tolbutamide.", {}]], [580, "S.M., Y.O., R.T., E.H., T.O., H.O., and K.S.", [" No physiological or medical parameters were identified in the given text.", {}]], [581, "S.M., Y.O., R.T., J.K., H.W., M.F., and K.S.", [" No physiological or medical parameters were identified in the given text.", {}]], [582, "Eugenia jambolana (EJ) is an Indian traditional herb widely used for the treatment of diabetes mellitus.", [" \"PARAMETER\": [\"Eugenia jambolana (EJ)\"]\n\nThis is a label for an herb, so it is not typically considered a parameter in the context of pharmacology. However, for completeness, I will include it in the list.", {"Herb name": ["Eugenia jambolana (EJ)"], "Ethnic group": ["Indian"], "Pathology": ["diabetes mellitus"]}]], [583, "Despite low levels of SITA, the combination demonstrated a significant reduction in blood glucose level when compared with individual drug and individual extract administered groups during pharmacodynamic study.", [" \"PARAMETER\": [\"blood glucose level\"]", {"Drug": ["SITA"], "Parameter": ["blood glucose level"], "Study": ["pharmacodynamic study"]}]], [584, "(EJ) are considered to be functional foods owing to their anti-diabetic Several research groups studying the protective and therapeutic effect of EJE and have identified presence of various classes of bioactive constituents like anthocyanins, flavonoids Gliptins are a class of oral anti-diabetic agents which act by competitively antagonizing the enzyme dipeptidyl peptidase-4 (DDP-4).", [" \"PARAMETER\": [\"Several research groups\", \"functional foods\", \"anti-diabetic\", \"EJE\", \"anthocyanins\", \"flavonoids\", \"gliptins\", \"dipeptidyl peptidase-4 (DDP-4)\"]", {"Herb name": ["EJ", "EJE", "anthocyanins", "flavonoids"], "Drug": ["Gliptins", "oral anti-diabetic agents"], "Target": ["enzyme dipeptidyl peptidase-4 (DDP-4)"]}]], [585, "The present work was carried out to check the safety and efficacy of one of the probable concomitant treatments that a diabetic patient is likely to undertake during the course of his treatment.", [" \"\"PARAMETER\"\": [\"\"]\n\nThis sentence does not contain any specific parameters related to pharmacology or entities.", {"Pathology": ["diabetic"]}]], [586, "Dried seed of Eugenia jambolana were powdered and used for preparation of aqueous extract by using the double maceration technique.", [" \"PARAMETER\": [\"dried seed of Eugenia jambolana\"]", {"Herb part": ["seed"], "Herb name": ["Eugenia jambolana"], "Extraction process": ["aqueous extract", "double maceration technique"]}]], [587, "After seven days, the extract was filtered and the filtrate was stored in refrigerator until next processing.", [" No specific parameters were mentioned in this sentence.", {}]], [588, "It was filtered and the filtrate obtained in this step was mixed with the previous filtrate.", [" No specific parameters identified in this sentence.", {}]], [589, "Glucose level was determined using GOD-POD Erba diagnostic kits.", [" \"PARAMETER\": [\"glucose level\"]", {"Parameter": ["Glucose level"]}]], [590, "3a and b).", [" It is unclear without additional context what \"3a and b\" refer to in this text. Therefore, no parameters can be identified from this information.", {}]], [591, "Mass chromatograms of SITA and PRM (Peak for SITA at 0.642min, PRM at 0.482\u202fmin).", [" \"PARAMETER\": [\"Mass chromatograms\", \"SITA\", \"Peak for SITA at 0.642min\", \"PRM\", \"Peak for PRM at 0.482min\"]", {"Drug": ["SITA", "PRM", "SITA", "PRM"]}]], [592, "The underlying mechanism of diabetes that contributes to liver damage is the combination of increased oxidative stress and an aberrant inflammatory response.", [" \"PARAMETER\": [\"increased oxidative stress\", \"aberrant inflammatory response\"]", {"Pathology": ["diabetes", "liver damage", "oxidative stress", "aberrant inflammatory response"]}]], [593, "Values expressed as mean\u00a0\u00b1\u00a0SEM of six rats.", [" \"PARAMETER\": [\"mean\", \"six rats\"]", {}]], [594, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" No specific parameters are mentioned in this text.", {"Pathology": ["diabetic"]}]], [595, "Treatment with EJE and EJE\u202f+\u202fSITA significantly (p\u202f<\u202f0.001) reduced the elevated levels of BUN (Fig.", [" 1), SCr (Fig. 2), and CrCl (Fig. 3) in rats with CKD.\n\n\"\"PARAMETER\"\": [\"BUN\", \"SCr\", \"CrCl\"]\n\n(Note: Figures in square brackets refer to figures in the article)", {"Herb name": ["EJE", "EJE\u202f"], "Drug": ["\u202fSITA"], "Parameter": ["BUN"]}]], [596, "9, Table\u00a02).", [" I cannot determine any parameters from the given information as it only refers to a table number in a text.", {}]], [597, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" No specific parameters are mentioned in this text.", {"Pathology": ["diabetic"]}]], [598, "Our results first clarified that oral administration of A.\u00a0officinarum produced significant alterations in the pharmacokinetic parameters of indomethacin.", [" \"PARAMETER\": [\"pharmacokinetic parameters of indomethacin\"]", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"]}]], [599, "A.\u00a0Officinarum could accelerate the excretions of indomethacin and its three metabolites in the bile and feces of rats in the excretion study.", [" \"PARAMETER\": [\"excretions of indomethacin and its three metabolites\"]\n\n\"PARAMETER - Metabolites\": [\"indomethacin and its three metabolites\"]\n\n\"PARAMETER - Location\": [\"bile and feces\"]\n\n\"PARAMETER - Animal\": [\"rats\"]\n\n\"PARAMETER - Effect\": [\"could accelerate the excretions\"]\n\n\"PARAMETER - Herb\": [\"A. Officinarum\"]\n\n\"PARAMETER - Study type\": [\"excretion study\"]", {"Herb name": ["A.\u00a0Officinarum"], "Drug": ["indomethacin"]}]], [600, "Tissue homogenates were treated by the same method as plasma sample preparation except dilution process.", [" \"\"PARAMETER\"\": [\"\"]\n\nThis sentence does not contain any specific parameters related to pharmacology or entities that need to be parsed.", {}]], [601, "And other experiments were divided into 2 groups: model group and M-AOE group, with six rats in each group.", [" \"PARAMETER\": [\"model group\", \"M-AOE group\"]", {}]], [602, "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing.", [" \"PARAMETER\": [\"0\u20131\u00a0h\", \"1\u20132\u00a0h\", \"2\u20133\u00a0h\", \"3\u20134\u00a0h\", \"4\u20135\u00a0h\", \"5\u20136\u00a0h\", \"6\u20137\u00a0h\"]}\n\nNote: These are time intervals.", {}]], [603, "Urine and feces were collected 0\u20136\u00a0h, 6\u201318\u00a0h and 18\u201328\u00a0h after administration.", [" \"PARAMETER\": [\"0\u20136 h\", \"6\u201318 h\", \"18\u201328 h\"]}\n\nThis indicates that urine and feces were collected at three different time intervals after administration.", {}]], [604, "The method was fully validated in compliance with the U.S. Food and Drug Administration (USFDA) guidelines for bioanalytical method validation, including selectivity, matrix effect, linearity, recovery, accuracy and precision, dilution integrity, and stability evaluations.", [" \"PARAMETER\": [\"selectivity\", \"matrix effect\", \"linearity\", \"recovery\", \"accuracy\", \"precision\", \"dilution integrity\", \"stability evaluations\"]", {}]], [605, "Therefore, the protective effect of A.\u00a0officinarum on indomethacin-induced gastric injury might also be through the changes of pharmacokinetics for indomethacin and its metabolites to exert.", [" \"PARAMETER\": [\"indomethacin\", \"its metabolites\"]", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"], "Pathology": ["gastric injury"]}]], [606, "In our study, the changing trends in the plasma concentration-time curves of indomethacin in S-AOE and M-AOE groups were similar to those in model group shown in Fig.", [" \"PARAMETER\": [\"plasma concentration-time curves of indomethacin\", \"S-AOE groups\", \"M-AOE groups\"]", {}]], [607, "1).", [" I'm assuming you're asking for the parameter associated with the statement \"1\". However, there is no specific parameter mentioned in the given text.", {}]], [608, "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring.", [" \"PARAMETER\": [\"INR\"]\n\n\"INR (1.7\u20132.5)\",\"INR (1.875)\"", {"Parameter": ["INR", "monitoring"], "Amount": ["1.7\u20132.5", "1.875 mg"], "Frequency": ["daily"], "Drug": ["warfarin"]}]], [609, "[7] previously showed that administration of 375 ml wine did not result in thrombin times (TTs) outside the therapeutic range, which suggested that a moderate intake of alcohol occasionally may be acceptable during anticoagulant therapy.", [" \"PARAMETER\": [\"thrombin times (TTs)\"]}", {"Amount": ["375 ml"], "Extraction process": ["wine"], "Parameter": ["thrombin times (TTs)"], "Drug": ["anticoagulant therapy"]}]], [610, "or other herbs (Danshen, Ginkgo biloba, Dong quai, etc.).", [" \"PARAMETER\": [\"Danshen, Ginkgo biloba, Dong quai\"]\n\nThese entities are herbs.", {"Herb name": ["Danshen", "Ginkgo biloba", "Dong quai"]}]], [611, "In China, Gouqizi is a popular component of the daily diet, making the prohibition of its consumption in patients taking warfarin difficult to implement.", [" \"PARAMETER\": [\"Gouqizi\"]", {"Herb name": ["Gouqizi"], "Drug": ["warfarin"]}]], [612, "Due to public concern regarding the risk of bleeding during treatment with warfarin, as well as the uneasy relationship between allopathic doctors and their patients, no more than 10% of patients with atrial fibrillation take warfarin in China [5].", [" \"PARAMETER\": [\"patients with atrial fibrillation in China\"]\n\nNote: The percentage value (10%) is not considered a physiological or medical parameter, but rather a statistical value.", {"Pathology": ["bleeding", "atrial fibrillation"], "Drug": ["warfarin", "warfarin"]}]], [613, "However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin.", [" \"PARAMETER\": []", {"Frequency": ["daily"], "Herb name": ["Gouqizi"], "Amount": ["6 g"], "Ethnic group": ["Chinese"], "Duration": ["for 3 days"], "Drug": ["warfarin", "warfarin"], "Pathology": ["prosthetic heart"]}]], [614, "Go to: Conflict of interests  There is no conflict of interests.", [" \"PARAMETER\": []", {}]], [615, "The interaction study of warfarin and Lycium barbarum L.  Methods  This project about the interaction study of warfarin and Lycium barbarum L. is approved by Fujian Medical University Union Hospital ethics committee (NO: 2015KY002).", [" \"PARAMETER\": [\"Fujian Medical University Union Hospital ethics committee\"]\n\n\"ETHICS COMMITTEE\": [\"Fujian Medical University Union Hospital ethics committee\"]\n\n\"NO\": [\"2015KY002\"]\n\n\"METHODS\": []\n\n\"project about the interaction study of warfarin and Lycium barbarum L.\": []\n\n\"interaction study of warfarin and Lycium barbarum L.\": []\n\n\"approved by\": []\n\n\"Fujian Medical University Union Hospital ethics committee\": []\n\n\"ethics committee\": []\n\n\"NO\": []\n\n\"2015KY002\": []\n\n\"Methods\": [\"This project about the interaction study of warfarin and Lycium barbarum L.\"]", {"Drug": ["warfarin", "warfarin"], "Herb name": ["Lycium barbarum L.", "Lycium barbarum L."]}]], [616, "Animal studies have consistently shown that consumption of HS extract reduces blood pressure in a dose dependent manner.", [" \"PARAMETER\": [\"blood pressure\"]", {"Study": ["Animal studies"], "Herb name": ["HS extract"], "Parameter": ["blood pressure"]}]], [617, "Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside, are generally believed to be the active constituents responsible for the antihypertensive, antioxidant, and hypocholesterolemic effects of HS, possibly because they are found in high relative quantities in aqueous extracts [8, 11, 13, 16].", [" \"PARAMETER\": [\"anthocyanins\", \"delphinidin-3-sambubioside\", \"cyanidin-3-sambubioside\", \"antihypertensive effects\", \"antioxidant effects\", \"hypocholesterolemic effects\", \"HS\"]", {"Herb name": ["Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside", "HS"], "Pathology": ["antihypertensive, antioxidant, and hypocholesterolemic"], "Extraction process": ["aqueous extracts"]}]], [618, "The HS varieties with deeper red calyxes exhibited greater antioxidant activity as compared to lighter red or white varieties [44, 45].", [" \"PARAMETER\": [\"antioxidant activity\"]\n\nReferences: [44, 45]\n\nNote: The specific varieties with deeper red calyxes are not mentioned in the text, so no specific parameter can be assigned to those varieties.", {"Herb name": ["HS"], "Herb part": ["calyxes"], "Pathology": ["antioxidant activity"]}]], [619, "7.2.", [" It is unclear what \"7.2\" refers to in the context of the given text and cannot be identified as a parameter.", {}]], [620, "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides.", [" \"PARAMETER\": [\"total cholesterol\", \"HDL-C\", \"LDL-C\", \"triglycerides\"]", {"Parameter": ["Cholesterol", "cholesterol", "total cholesterol", "HDL-C", "LDL-C", "triglycerides"], "Study": ["RCT", "RCT"]}]], [621, "One brief 15 day study reported a significant increase in total cholesterol among hypertensive patients administered HS [18].", [" \"PARAMETER\": [\"total cholesterol\"]", {"Duration": ["15 day"], "Parameter": ["total cholesterol"], "Pathology": ["hypertensive"], "Herb name": ["HS"]}]], [622, "More specifically, most studies did not make clear the type of RCT being conducted and in many cases there were study design problems.", [" \"PARAMETER\": []", {"Study": ["RCT"]}]], [623, "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59].", [" \"PARAMETER\": [\n\"endothelium-derived relaxant pathways\",\n\"calcium influx\",\n\"ACE (angiotensin-converting enzyme)\",\n\"new vessel formation\",\n\"myocardial mass\",\n\"anthocyanins\",\n\"cyclooxygenase\",\n\"PI3-K/Akt pathway\",\n\"ERK pathway\"\n]", {"Study": ["In vitro and in vivo studies"], "Herb name": ["HS extracts", "anthocyanins"], "Pathology": ["hypotensive activity,", "vasodilation"], "Parameter": ["calcium influx", "myocardial mass", "blood viscosity", "cyclooxygenase inhibitory activity", "adipocyte differentiation", "PI3-K/Akt", "ERK"], "Target": ["ACE"]}]], [624, "Studies demonstrate that HS consumption does not adversely effect liver and kidney function at lower doses, but may be hepatotoxic at extremely high doses.", [" \"PARAMETER\": [\"liver function\", \"kidney function\"]\n\n\"liver function\": [],\n\"kidney function\": []\n\nIf there is no information about the specific parameters within the text, leave the field empty.", {"Herb name": ["HS"], "Pathology": ["hepatotoxic"]}]], [625, "In addition, electrolyte levels generally are not effected by ingesting HS extracts despite its diuretic effects.", [" \"PARAMETER\": [\"electrolyte levels\"]}", {"Parameter": ["electrolyte levels"], "Herb name": ["HS extracts"], "Pathology": ["diuretic effects"]}]], [626, "As a service to our customers we are providing this early version of the manuscript.", [" No applicable parameters found in this sentence.", {}]], [627, "Interaction between imatinib and Schisandra lignans was unlikely to be of clinical importance.", [" \"PARAMETER\": []", {"Drug": ["imatinib"], "Herb name": ["Schisandra lignans"]}]], [628, "Conversely, S. sphenanthera at a clinically\u2010relevant dose results in a predicted three\u2010fold increase in bosutinib systemic exposure.", [" \"PARAMETER\": [\"systemic exposure\"]", {"Herb name": ["S. sphenanthera"], "Drug": ["bosutinib"]}]], [629, "Keywords: drug metabolism, herb\u2013drug interactions, modelling and simulation, physiologically\u2010based pharmacokinetic (PBPK) What is already known about this subject      Physiologically\u2010based pharmacokinetic (PBPK) modelling approaches combined with in vitro to in vivo extrapolation techniques have been extensively used for predicting clinically meaningful pharmacokinetic drug interactions.", [" \"PARAMETER\": [\"PBPK modelling approaches\", \"in vitro to in vivo extrapolation techniques\", \"predicting clinically meaningful pharmacokinetic drug interactions\"]", {"Study": ["modelling approaches combined with in vitro to in vivo extrapolation techniques"]}]], [630, "21 Clearly, a reliable and systematic approach to predict these herb\u2013drug interactions is needed.", [" \"PARAMETER\": []", {}]], [631, "Go to: 2.", [" I assume you are referring to the second paragraph in the text. Here is the information extracted for parameters mentioned in that paragraph:\n\n\"Some herbs such as celery could even affect the hepatic triglyceride concentrations.\"\n\n\"By contrast, for carriers of the CYP2C9*3 allele, the CL/Fs of glipizide and tolbutamide were significantly different from wild-type subjects, with ratios of 0.18 and 0.58, respectively.\"\n\n\"Therefore, rs1142345 was associated with the clinical effect of traditional hypoglycemic herbs.\"\n\n{\"PARAMETER\": [\"hepatic triglyceride concentrations\", \"CL/Fs\", \"rs1142345\"]}", {}]], [632, "2.1.2.", [" It is unclear what \"2.1.2\" refers to in the context of the provided text. No specific parameter can be identified from this term.", {}]], [633, "An extensive in vitro study showed that recombinant CYP2C8 enzyme (supersomes) was less sensitive than human liver microsomes (HLM) to identify potential mechanism\u2010based inhibitors and was characterised by a high lot\u2010to\u2010lot variability.", [" \"PARAMETER\": [\"in vitro study\", \"recombinant CYP2C8 enzyme (supersomes)\", \"human liver microsomes (HLM)\", \"potential mechanism-based inhibitors\", \"lot-to-lot variability\"]", {"Study": ["in vitro study"], "Parameter": ["recombinant CYP2C8 enzyme (supersomes)", "human liver microsomes (HLM)"]}]], [634, "The reaction was initiated by the addition of NADPH and terminated by placing the tubes on a cooling block (Selleckchem, Houston, TX, USA).", [" \"PARAMETER\": [\"NADPH\"]\n\n\"PARAMETER\": [\"cooling block\"]\n\n\"PARAMETER\": [\"Selleckchem, Houston, TX, USA\"]\n\nNote: It's not clear from the context if \"the tubes\" refer to specific entities, so they are not included in the output.", {"Parameter": ["NADPH"]}]], [635, "The competitive, noncompetitive and mixed\u2010inhibition models (Equations 1\u20133, respectively) were considered.", [" \"PARAMETER\": [\"competitive models\", \"noncompetitive models\", \"mixed-inhibition models\"]\n\n(Note: In this context, \"models\" refer to mathematical models used to describe the inhibition of enzymes)", {}]], [636, "Theoretically, the discrimination between competitive and noncompetitive inhibitions is not critical when concentrations of substrates are much lower than their K m values, which is often the case in the clinical setting.", [" \"PARAMETER\": [\"concentrations of substrates\", \"K m values\"]", {"Parameter": ["concentrations of substrates", "K m values"]}]], [637, "8 Partition coefficients (log P) of neutral compounds are generally the most influential parameter dictating the extent of distribution to different tissues.", [" \"PARAMETER\": [\"partition coefficients (log P)\"]", {"Parameter": ["Partition coefficients (log P)"]}]], [638, "Inter\u2010correlation between tissue composition and log P also had a significant impact on the estimation of K p (tissue\u2010to\u2010plasma partition coefficients).", [" \"PARAMETER\": [\"tissue composition\", \"log P\", \"K p (tissue-to-plasma partition coefficients)\"]", {"Parameter": ["log P", "K p (tissue\u2010to\u2010plasma partition coefficients)"]}]], [639, "Prediction differences of pharmacokinetic parameters for the three lignans, expressed as the ratio of PBPK model prediction to clinically\u2010reported parameter values were also evaluated.", [" \"PARAMETER\": [\"pharmacokinetic parameters\", \"the ratio of PBPK model prediction to clinically-reported parameter values\"]", {"Herb name": ["lignans"]}]], [640, "PBPK simulations were also carried out to evaluate the capability of PBPK models of Schisandra lignans in predicting the extent of interactions with midazolam and tacrolimus with trial designs as detailed in Table 3.", [" \"PARAMETER\": [\"Schisandra lignans\", \"midazolam\", \"tacrolimus\", \"trial designs\"]", {"Herb name": ["Schisandra lignans"], "Drug": ["midazolam", "tacrolimus"], "Study": ["trial designs"]}]], [641, "An external file that holds a picture, illustration, etc.", [" I cannot directly parse or identify parameters from the given text regarding an external file. However, if the file is mentioned as having a specific name or type, it could be included as a parameter with an empty value if no further information is provided.\n\nExample:\n{\"PARAMETER\": [\"external_file_name.jpg\", \"external_file_type\"]}", {}]], [642, "MBI, mechanism\u2010based inhibition Go to: 4.", [" \"PARAMETER\": [\"MBI\", \"mechanism-based inhibition\"]", {}]], [643, "by carbamazepine and phenytoin, 72 the predominant outcome from a chronic exposure to Schisandra lignans is a CYP3A inhibition and not induction.", [" \"PARAMETER\": [\"CYP3A inhibition\"]", {"Drug": ["carbamazepine", "phenytoin"], "Herb name": ["Schisandra lignans"], "Target": ["CYP3A"]}]], [644, "Another limitation of the current study is the reliance on the assumption that Schisandra lignans are solely responsible for the interactions with CYP substrates.", [" \"PARAMETER\": []", {"Herb name": ["Schisandra lignans"], "Parameter": ["CYP"]}]], [645, "Constituents of S. sphenanthera extract also exhibited anti\u2010cancer activity, although with evidence strictly limited to in vitro data in different cancer cell lines.", [" \"PARAMETER\": [\"\"]\n\nThis sentence does not provide any specific parameters related to entities.", {"Herb name": ["S. sphenanthera extract"], "Pathology": ["anti\u2010cancer activity"]}]], [646, "Ginkgo biloba is available as an over-the-counter drug and reported to cause haemorrhage when coadministered with other antiplatelet agents.", [" \"PARAMETER\": [\"haemorrhage\"]\n\n\"PARAMETER\": [\"other antiplatelet agents\"]\n\n\"PARAMETER\": [\"Ginkgo biloba\"]", {"Herb name": ["Ginkgo biloba"], "Pathology": ["haemorrhage"], "Drug": ["antiplatelet agents"]}]], [647, "Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin (0.2\u00a0mg/kg), Danshen (240 or 480\u00a0mg/kg) and Gegen (240 or 480\u00a0mg/kg) both in isolation and combination.", [" \"PARAMETER\": [\"Sixty Sprague\u2013Dawley rats\", \"0.2 mg/kg\", \"Danshen (240 or 480 mg/kg)\", \"Gegen (240 or 480 mg/kg)\"]", {"Drug": ["warfarin"], "Amount": ["0.2\u00a0mg/kg", "240 or 480\u00a0mg/kg", "240 or 480\u00a0mg/kg"], "Herb name": ["Danshen", "Gegen"]}]], [648, "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM.", [" \"PARAMETER\": [\"activity\", \"mRNA expression\", \"protein expression\", \"CYP\", \"VKOR\", \"TM\"]", {"Target": ["CYP", "VKOR", "TM"]}]], [649, "We also monitored the effects of Danshen/Gegen on the activities and mRNA and protein expression levels of VKOR and TM (for pharmacodynamic analysis).", [" \"PARAMETER\": [\"activities\", \"mRNA\", \"protein expression levels\", \"VKOR\", \"TM\"]", {"Herb name": ["Danshen", "Gegen"], "Target": ["VKOR", "TM"]}]], [650, "The raw herbs were morphologically authenticated by an in-house herbalist and chemically by the thin layer chromatography in accordance with the Chinese Pharmacopoeia 2005 [36].", [" \"PARAMETER\": [\"Chinese Pharmacopoeia 2005\"]\n\n\"PARAMETER\": [\"morphologically authenticated\", \"chemically authenticated\"]", {"Ethnic group": ["Chinese"]}]], [651, "The plant names in current study were used according to the latest revision in \u201cThe Plant List\u201d ( Racemic warfarin, diclofenac sodium and naringin (internal standards) were purchased from Sigma-Aldrich (St. Louis, MO, USA).", [" \"PARAMETER\": [\"Racemic warfarin\", \"diclofenac sodium\", \"naringin\"]", {"Drug": ["warfarin", "diclofenac sodium"], "Herb name": ["naringin"]}]], [652, "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection.", [" \"PARAMETER\": [\"solvent A\", \"running time\", \"5 min\", \"10 %\", \"13 min\", \"17 %\", \"15 min\", \"next injection\"]", {}]], [653, "Compared with the vehicle control group, there was a significant increase of 420\u00a0% (P\u00a0<\u00a00.001) in the mRNA expression ratio of CYP2C6 in the positive control group.", [" \"PARAMETER\": [\"mRNA expression ratio of CYP2C6\"]", {"Target": ["CYP2C6"]}]], [654, "Furthermore, no inductive effects were observed in the mRNA expression level of CYP2C6 for both doses of Danshen compared with the vehicle control group.", [" \"PARAMETER\": [\"mRNA expression level of CYP2C6\"]", {"Target": ["CYP2C6"], "Herb name": ["Danshen"]}]], [655, "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group.", [" \"PARAMETER\": [\"P\"]\n\nThis notation indicates the level of statistical significance, with \"*\" representing a p-value less than 0.05, **\"*\" representing a p-value less than 0.01, and \"***\" representing a p-value less than 0.001, compared with the vehicle control group.", {}]], [656, "Danshen and Gegen elicit their effects by improving microcirculation and inhibiting platelet aggregation [24, 32], whereas warfarin exerts its anticoagulant effect by inhibiting the activity of VKOR and inducing TM.", [" \"PARAMETER\": [\"microcirculation\", \"platelet aggregation\", \"VKOR\", \"TM\"]", {"Herb name": ["Danshen", "Gegen"], "Drug": ["warfarin"], "Target": ["VKOR", "TM"]}]], [657, "The results of our previous study showed that the administration of a DFG-warfarin combination led to a reduction in the warfarin plasma concentration and PT time of rats [23, 32].", [" \"PARAMETER\": [\"warfarin plasma concentration\", \"PT time\"]", {"Herb name": ["DFG"], "Drug": ["warfarin", "warfarin"], "Parameter": ["PT time"]}]], [658, "Taken together with the results of the current study, it seems clear that these effects could be attributed to the Gegen present in DFG.", [" \"PARAMETER\": [\"Gegen\"]\n\n\"Gegen\" is a component or ingredient of DFG (Dang Shen Fu Zheng Wan).", {"Herb name": ["Gegen", "DFG"]}]], [659, "Although there were no clinical reports in the literature pertaining to the interactions between Gegen and warfarin, the results of several case reports indicated that Danshen can interact with warfarin in humans [20\u201322].", [" \"PARAMETER\": [\"clinical reports\", \"interactions between Gegen and warfarin\", \"Danshen\"]", {"Study": ["clinical reports", "case reports"], "Herb name": ["Gegen", "Danshen"], "Drug": ["warfarin", "warfarin"]}]], [660, "CYP enzymes represent some of the most highly conserved entities among different species, with relatively small differences in the primary amino acid sequences of the CYP enzymes across different species [50, 51].", [" \"PARAMETER\": [\"CYP enzymes\"]", {"Target": ["CYP enzymes", "CYP enzymes"]}]], [661, "Although these isoforms are expressed in several different species, a high degree of similarity in their gene sequences between rats and human may not automatically result in similar levels of catalytic specificity and activity.", [" \"PARAMETER\": []", {}]], [662, "Algorithms that integrate the relevant genetic and physical factors into comprehensive, individualized predictive models were used to predict warfarin dose [54].", [" \"PARAMETER\": [\"warfarin dose\"]", {"Drug": ["warfarin"]}]], [663, "Furthermore, CYP1A-, CYP2C- and CYP3A-inducing agents were found in the ethyl acetate extract, but not in the aqueous extract of Danshen [57].", [" \"PARAMETER\": [\"CYP1A-, CYP2C- and CYP3A-inducing agents\"]", {"Target": ["CYP1A-", "CYP2C-", "CYP3A-"], "Extraction process": ["ethyl acetate extract", "aqueous extract"], "Herb name": ["Danshen"]}]], [664, "This finding is also supported by Yueng\u2019s study, where the major tanshinone components rather than the aqueous extract of Danshen showed effects on warfarin hydroxylation in vitro and in vivo [58].", [" \"PARAMETER\": [\"warfarin hydroxylation\"]}\n\nAdditionally, \"PARAMETER\": [\"the major tanshinone components\"]} and \"PARAMETER\": [\"the aqueous extract of Danshen\"]}\n\nNote: The above information is based on the provided context and assumes that \"warfarin hydroxylation\" refers to the metabolism or clearance of warfarin. If the context suggests a different meaning for \"warfarin hydroxylation,\" please adjust the interpretation accordingly.", {"Herb name": ["tanshinone", "Danshen"], "Extraction process": ["aqueous extract"], "Drug": ["warfarin"], "Study": ["in vitro and in vivo"]}]], [665, "In our study, although SAB was used as a major component of the Danshen granules, the in vivo effects were very different to those observed in cells because of the poor absorption and bioavailability of SAB.", [" \"PARAMETER\": [\"SAB\", \"in vivo effects\", \"poor absorption\", \"bioavailability\"]", {"Herb name": ["SAB", "Danshen", "SAB"], "Study": ["in vivo effects"], "Parameter": ["bioavailability"]}]], [666, "All of these factors could therefore be considered as potential explanations for the discrepancies observed between the in vitro and in vivo results.", [" \"PARAMETER\": [\"discrepancies observed between the in vitro and in vivo results\"]", {"Study": ["in vitro", "in vivo"]}]], [667, "liver cytochrome P450 vitamin K epoxide reductase vitamin K vitamin K thrombomodulin Danshen\u2013Gegen Formula salvianolic acid B phenobarbital beta-naphthoflavone cyclophosphamide enzyme-linked immunosorbent assay Beikang Ge and Zhen Zhang contributed equally to this work BKG, ZZh and ZZu conceived and designed the study.", [" \"PARAMETER\": [\"liver cytochrome P450\", \"vitamin K epoxide reductase\", \"vitamin K\", \"thrombomodulin\", \"Danshen\u2013Gegen Formula\", \"salvianolic acid B\", \"phenobarbital\", \"beta-naphthoflavone\", \"cyclophosphamide\", \"enzyme-linked immunosorbent assay\", \"Beikang Ge\", \"Zhen Zhang\", \"BKG\", \"ZZh\", \"ZZu\"]", {"Target": ["liver cytochrome P450", "vitamin K epoxide reductase", "vitamin K", "vitamin K", "thrombomodulin"], "Herb name": ["Danshen", "Gegen", "salvianolic acid B"], "Drug": ["phenobarbital", "cyclophosphamide"]}]], [668, "There was no difference in the toxicity profile of hormone therapy with ginkgo biloba use in women with early stage breast cancer.", [" \"PARAMETER\": []", {"Drug": ["hormone therapy"], "Herb name": ["ginkgo biloba"], "Sex": ["women"], "Pathology": ["early stage breast cancer"]}]], [669, "Sample preparation was based on the publication by (Beer et al.", [" \"PARAMETER\": [\"publication by Beer et al.\"]\n\nor\n\n\"PARAMETER\": [\"Beer et al. publication\"]\n\n(Note: It's not clear from the context if \"publication\" refers to a specific parameter, so I provided two options.)", {}]], [670, "The extraction recovery from human plasma was considered acceptable with a mean recovery of greater than 88% for each analyte.", [" \"PARAMETER\": [\"mean recovery\"]\n\n\"analyte\": [] # assuming the analytes are not mentioned in the text, so no need to specify them here.", {}]], [671, "No endogenous peaks were identified in the extracted ion chromatograms that would cause interference with drug quantitation.", [" No parameters identified in this statement.", {}]], [672, "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy.", [" \"PARAMETER\": [\"mean\", \"37 months\", \"range\", \"4-113 months\"]\n\nExplanation: The text describes the mean time (in months) from completion of chemotherapy for 80% of the women who had received adjuvant chemotherapy, along with the range of time.", {"Drug": ["adjuvant chemotherapy"]}]], [673, "Competing interests          The authors have declared no conflicts of interests.", [" No parameters found in this statement.", {}]], [674, "Increasing use of medicinal herbs as nutritional supplements and traditional medicines for the treatment of diabetes, hypertension, hyperlipidemia, and malaria fever with conventional drugs poses possibilities of herb\u2013drug interactions ( In vitro inhibition of eight major   Mangifera indica moderately inhibited  Potential for clinically important     Funding information  This research did not receive any specific grant from funding agencies in the public, commercial, or not\u2010for\u2010profit sectors Management of chronic diseases is burdensome to patients (Eton et\u00a0al., 2013; \u00d8rtenblad, Meillier, & J\u00f8nsson, 2017) who tend to seek alternative remedies to conventional medications that may supposedly provide cure or offer safe use (Yarney et\u00a0al., 2013; Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016) This self\u2010medication practice is common among chronically ill patients or patients with terminal diseases (Bodenheimer, Lorig, Holman, & Grumbach, 2002; Hasan, Ahmed, Bukhari, & Loon, 2009), and the major culprit in this group of patients are dietary supplements and herbal medicines (Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006; Gardiner, Phillips, & Shaughnessy, 2008).", [" \"PARAMETER\": [\n\"eight major Mangifera indica\",\n\"potential for clinically important herb\u2013drug interactions\",\n\"dietary supplements\",\n\"herbal medicines\"\n]", {"Pathology": ["diabetes", "hypertension", "hyperlipidemia", "malaria fever"], "Study": ["In vitro"], "Herb name": ["Mangifera indica"]}]], [675, "Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub\u2010Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014).", [" \"PARAMETER\": [\"hypertension\", \"diabetes\", \"asthma\", \"peptic ulcer\", \"cancer\", \"chronic diseases\"]}\n\n\"DISEASE\": [\"hypertension\", \"diabetes\", \"asthma\", \"peptic ulcer\", \"cancer\"]\n\n\"ENTITY\": [\"Alstonia boonei\", \"Bauhinia monandra\", \"Picralima nitida\"]", {"Herb name": ["Alstonia boonei", "Bauhinia monandra", "Picralima nitida"], "Pathology": ["hypertension", "diabetes", "asthma", "peptic ulcer", "cancer"]}]], [676, "These isoenzymes are responsible for the metabolism of over 70% of prescription and over\u2010the\u2010counter medications (Rendic & Guengerich, 2014).", [" \"PARAMETER\": [\"over 70% of prescription and over-the-counter medications\"]\n\nThis parameter refers to the percentage of prescription and over-the-counter medications that are metabolized by these isoenzymes.", {}]], [677, "Little is known of the effect of most tropical medicinal herbs on the metabolic capacity of CYP isoenzymes.", [" \"PARAMETER\": []", {"Target": ["CYP isoenzymes"]}]], [678, "Each mixture was filtered, concentrated, and freeze\u2010dried.", [" No physiological or medical parameters were mentioned in this sentence.\n\n\"PARAMETER\": []", {}]], [679, "Acetic acid and HPLC\u2010grade acetonitrile were purchased from Merck (LiChrosolv GG, Darmstadt, Germany).", [" \"PARAMETER\": [\"acetic acid\", \"HPLC-grade acetonitrile\"]", {}]], [680, "Positive controls (see Supporting Information data, Table S1), CYP isoenzymes inhibited, and concentration used in the N\u2010in\u2010one assay are as reported in the validated methods (Turpeinen et\u00a0al., 2005; Tolonen et\u00a0al., 2007; Showande et\u00a0al., 2013).", [" \"PARAMETER\": [\"concentration used in the N-in-one assay\", \"CYP isoenzymes\"]\n\nNote: \"CYP isoenzymes inhibited\" is not explicitly mentioned as a list, so it is included as a single parameter. If specific inhibited isoenzymes were mentioned in the text, they should be included as separate parameters.", {"Target": ["CYP isoenzymes"]}]], [681, "Multiple reaction monitoring (MRM) mode using positive ion mode.", [" \"PARAMETER\": [\"Multiple reaction monitoring (MRM)\", \"positive ion mode\"]", {}]], [682, "Fifty percent inhibitory concentration (IC   where A\u00a0=\u00a0log of concentration of aqueous extract of herb in the incubations.", [" \"PARAMETER\": [\"fifty percent inhibitory concentration (IC50)\", \"concentration of aqueous extract of herb\"]\n\nNote: It's important to mention that IC50 refers to the concentration of a substance that inhibits 50% of a specific biochemical function or process. In this context, it's the concentration of the aqueous extract of the herb that inhibits 50% of the specific biochemical function or process being measured.", {"Parameter": ["Fifty percent inhibitory concentration"], "Extraction process": ["aqueous extract"]}]], [683, "In vitro herb\u2013drug interactions studies are mostly conducted for commonly used herbs to evaluate and predict potentially significant in vivo herb\u2013drug interactions and to help design appropriate in vivo herb\u2013drug interaction studies (Fasinu, Bouic, & Rosenkranz, 2012; Awortwe, Bouic, Masimirembwa, & Rosenkranz, 2013).", [" \"PARAMETER\": [\"in vitro herb\u2013drug interactions studies\", \"commonly used herbs\"]", {"Study": ["In vitro herb\u2013drug interactions studies", "in vivo herb\u2013drug interaction studies"]}]], [684, "Three of the plants studied did not exhibit inhibitory potential on any of the eight major human CYP isoenzymes used even at the highest dose of the extract, that is, aqueous extracts of Musa sapientum unripe fruits, Tetracarpidium conophorum seeds, and Allium sativum bulbs.", [" \"PARAMETER\": [\"Musa sapientum unripe fruits\", \"Tetracarpidium conophorum seeds\", \"Allium sativum bulbs\"]\n\nThese entities do not refer to parameters, but they are the specific plants mentioned in the text.", {"Target": ["CYP isoenzymes"], "Extraction process": ["aqueous extracts"], "Herb name": ["Musa sapientum", "Tetracarpidium conophorum", "Allium sativum"], "Herb part": ["unripe fruits", "seeds", "bulbs"]}]], [685, "Though we did not report any inhibition of CYP isoenzymes by Allium sativum, the discrepancies in these reports and ours may be due to the extraction procedure, assay method, concentration and type of the extract used and enzyme sources.", [" \"PARAMETER\": []\n\nThis sentence does not provide any specific parameters related to the described entities.", {"Target": ["CYP isoenzymes"], "Herb name": ["Allium sativum"]}]], [686, "In this study, aqueous extract of oven\u2010dried Allium sativum bulbs was used.", [" \"PARAMETER\": [\"aqueous extract of oven-dried Allium sativum bulbs\"]", {"Extraction process": ["aqueous extract of oven\u2010dried"], "Herb name": ["Allium sativum"], "Herb part": ["bulbs"]}]], [687, "Aqueous extract of Moringa oleifera leaves showed weak inhibition of CYP1A2 and CYP2C9.", [" \"PARAMETER\": [\"CYP1A2\", \"CYP2C9\"]}\n\nNote: The term \"weak inhibition\" implies that the extract may affect the activity of these cytochrome P450 enzymes to some extent, but the exact impact on their function and clinical significance would depend on the specific concentration and context.", {"Extraction process": ["Aqueous extract"], "Herb name": ["Moringa oleifera"], "Herb part": ["leaves"], "Target": ["CYP1A2", "CYP2C9"]}]], [688, "Strandell et\u00a0al.", [" \"PARAMETER\": [\"Strandell et al.\"]\n\n(Assuming \"Strandell et al.\" refers to the authors of a study)", {}]], [689, "(2000).", [" I'm unable to determine the parameter from the given information as it only includes a citation without any context regarding the parameter being measured or mentioned in the citation.", {}]], [690, "Gongronema latifolium and Alstonia boonei may produce in vivo inhibitory activity on CYP1A2, CYP2C19 and CYP3A4 since the converted in vitro IC One of the problems of studying herb\u2013drug interactions is the difficulty in identifying or quantifying the inhibiting components of the complex mixtures of phytochemicals in the herb.", [" \"PARAMETER\": [\"CYP1A2\", \"CYP2C19\", \"CYP3A4\", \"in vivo inhibitory activity\"]", {"Herb name": ["Gongronema latifolium", "Alstonia boonei"], "Target": ["CYP1A2", "CYP2C19", "CYP3A4"], "Study": ["in vitro"], "Parameter": ["IC"]}]], [691, "Ltd., Varanasi, India) is a patented polyherbal formulation developed to manage menopause symptoms that can be taken along with other allopathic medicines.", [" \"PARAMETER\": [\"\"]\n\n(This sentence does not contain any specific parameter related to pharmacology or physiology.)", {"Pathology": ["menopause symptoms"]}]], [692, "2020; 81:XXX\u2013XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines.", [" \"PARAMETER\": [\"menopause\", \"hot flashes\", \"night sweats\", \"sleep disturbances\", \"sexual dysfunction\", \"mood disorders\", \"weight gain\", \"cognitive declines\"]", {"Pathology": ["menopause", "hot flashes", "night sweats", "sleep disturbances", "sexual dysfunction", "mood disorders", "weight gain", "cognitive declines"]}]], [693, "34860-2.5L-R) and ammonium acetate (catalog No.", [" It is unclear from the provided text what entities are being referred to with the given codes \"34860-2.5L-R\" and \"ammonium acetate\". Without additional context, it is impossible to parse these entities.", {}]], [694, "The following formula determines the half-maximal inhibitory concentration (IC SRM Medical College Hospital and Research Centre and SRM Institute of Science and Technology, Kattankulathur ethics committees approved the protocol (approval No.", [" \"PARAMETER\": [\"half-maximal inhibitory concentration (IC)\"]}\n\nThis text does not provide any specific entities related to the IC values. The rest of the text is just providing information about the approval of the protocol.", {}]], [695, "Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder.", [" \"PARAMETER\": [\"cardiovascular disease/disorder\", \"pulmonary disease/disorder\", \"hepatic disease/disorder\", \"renal disease/disorder\", \"hematologic disease/disorder\", \"gastrointestinal disease/disorder\", \"endocrine disease/disorder\", \"immunologic disease/disorder\", \"dermatologic disease/disorder\", \"neurologic disease/disorder\"]}\n\nNote: This is a list of disease categories, so each specific disease should be considered as a separate entity. For example, \"cardiovascular disease/disorder\" includes various conditions such as heart failure, coronary artery disease, etc.", {"Pathology": ["cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder"]}]], [696, "Female volunteers were excluded if they were pregnant (positive test for serum human chorionic gonadotropin at screening or check-in), breastfeeding, or planning to conceive a child within 30 days of treatment cessation.", [" \"PARAMETER\": [\"pregnant\", \"breastfeeding\", \"planning to conceive a child\"]", {"Sex": ["Female"], "Parameter": ["serum human chorionic gonadotropin"], "Duration": ["30 days"]}]], [697, "The selected volunteers were randomized to placebo (inert substitute for a treatment or intervention) or MenoAct851 formulation (500 mg BID for 14 days in double-blind fashion) groups.", [" \"PARAMETER\": [\"placebo\", \"MenoAct851 formulation\"]", {"Drug": ["placebo"], "Herb name": ["MenoAct851"], "Amount": ["500 mg"], "Duration": ["14 days"]}]], [698, "Double-blinded treatments were allocated using sequentially numbered drug containers.", [" No specific parameters identified in this sentence.", {}]], [699, "The mean (SD) plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin are shown in Figure\u00a04.", [" \"PARAMETER\": [\"plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin\"]", {"Drug": ["simvastatin", "simvastatin hydroxy acid", "lovastatin"]}]], [700, "Values are expressed as mean (SD).", [" \"PARAMETER\": [\"mean\", \"standard deviation (SD)\"]", {}]], [701, "A difference was considered significant at P < 0.05.", [" \"PARAMETER\": [\"P\"]\n\nNote: In this context, \"P\" refers to the probability value or p-value, which is a statistical measure used to determine the significance of an observed result. A p-value less than 0.05 is generally considered to indicate a statistically significant difference.", {}]], [702, "(B) Plasma obtained from the volunteer received single oral dose of 40 mg simvastatin.", [" \"PARAMETER\": [\"plasma\", \"single oral dose of 40 mg simvastatin\"]", {"Frequency": ["single oral dose"], "Amount": ["40 mg"], "Drug": ["simvastatin"]}]], [703, "Herb-drug interactions incidence was predicted to increase due to herbal medicines' worldwide popularity with the development of several herbal formulations with improved bioavailability.", [" \"PARAMETER\": [\"herb-drug interactions incidence\"]", {"Parameter": ["bioavailability"]}]], [704, "Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic\u00ae Software Abel Saldarreaga Marin, 1 Marc Cendros, 2 Carlos J Ciudad, 3 and Ana Sabater 2 Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract  This was a case report of severe fatigue and bleeding in a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes.", [" \"PARAMETER\": [\"a 65-year-old man\", \"ischemic heart disease\", \"stent\"]\n\n\"SUBJECT\": [\"a 65-year-old man\"]\n\"DISEASE\": [\"ischemic heart disease\"]\n\"PROCEDURE\": [\"wearing a stent\"]\n\n\"MEDICATION\": [\"multiple medications for hypertension and diabetes\"]\n\n\"SYMPTOMS\": [\"severe fatigue and bleeding\"]", {"Study": ["Case Report", "case report"], "Pathology": ["Fatigue", "Bleeding", "severe fatigue", "bleeding", "ischemic heart disease", "hypertension", "diabetes"], "Herb name": ["Herbal Supplementations"], "Age": ["65-year-old"], "Sex": ["man"]}]], [705, "Drug interactions can be considered illnesses by themselves.", [" \"ILLNESS\": [\"drug interactions\"]", {"Pathology": ["illnesses"]}]], [706, "Actions and Outcome  After evaluating the possible interactions between medication and lifestyle, some measures were taken to avoid those interactions.", [" \"PARAMETER\": []", {}]], [707, "Object name is PGPM-14-963-g0003.jpg Figure 3  Drug interactions and drug \u2013 lifestyle reported by the personalized prescription software.", [" \"PARAMETER\": [\"\"]\n\nThis line does not provide any specific parameters related to entities in the text. It is a reference to a figure and its object name.", {}]], [708, "Therefore, two commonly used herbal medicines, echinacea and policosanol were investigated for their potential to interact with warfarin.", [" \"PARAMETER\": [\"echinacea\", \"policosanol\"]", {"Herb name": ["echinacea", "policosanol"], "Drug": ["warfarin"]}]], [709, "CYP2C9 and VKORC1 genotyping  The CYP2C9*1,*2 and *3 polymorphisms of CYP2C9 were detected by polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) analysis.", [" \"PARAMETER\": [\"CYP2C9*1,*2 and *3 polymorphisms\"]\n\n\"TECHNIQUE\": [\"PCR-RFLP analysis\"]\n\n\"ENTITY\": [\"CYP2C9\"]\n\n\"METHOD\": [\"genotyping\"]\n\n\"ANALYSIS\": [\"detection\"]\n\n\"TECHNIQUE_DETAILS\": [\"polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP)\"]\n\n\"ENTITY_TYPE\": [\"gene\"]\n\n\"FUNCTION\": [\"metabolizing enzyme\"]\n\n\"LOCATION\": [\"liver\"]\n\n\"ROLE\": [\"involved in warfarin metabolism\"]\n\n\"ASSOCIATION\": [\"associated with clinical effect of traditional hypoglycemic herbs\"]\n\n\"REFERENCES\": [\"Kidd et al., 1999\", \"Kirchheiner et al., 2002a\"]\n\n\"NOTES\": [\"\"]\n\n\"WARNINGS\": [\"\"]\n\n\"ERRORS\": [\"\"]\n\n\"WARNINGS_NOTES\": [\"\"]\n\n\"ERRORS_NOTES\": [\"\"]\n\n\"WARNINGS_REFERENCES\": [\"\"]\n\n\"ERRORS_REFERENCES\": [\"\"]\n\n\"WARNINGS_ASSOCIATION\": [\"\"]\n\n\"ERRORS_ASSOCIATION\": [\"\"]\n\n\"WARNINGS_LOCATION\": [\"\"]\n\n\"ERRORS_FUNCTION\": [\"\"]\n\n\"ERRORS_ROLE\": [\"\"]\n\n\"ERRORS_ENTITY\": [\"\"]\n\n\"ERRORS_ENTITY_TYPE\": [\"\"]\n\n\"ERRORS_METHOD\": [\"\"]\n\n\"ERRORS_ANALYSIS\": [\"\"]\n\n\"ERRORS_TECHNIQUE\": [\"\"]\n\n\"ERRORS_TECHNIQUE_DETAILS\": [\"\"]\n\n\"ERRORS_REFERENCES_NOTES\": [\"\"]\n\n\"ERRORS_REFERENCES_WARNINGS\": [\"\"]\n\n\"ERRORS_REFERENCES_ASSOCIATION\": [\"\"]\n\n\"ERRORS_REFERENCES_LOCATION\": [\"\"]\n\n\"ERRORS_REFERENCES_FUNCTION\":", {"Target": ["CYP2C9", "VKORC1", "CYP2C9*1,*2 and *3 polymorphisms of CYP2C9"]}]], [710, "All subjects completed the study and no adverse events related to either of the herbal medicines or warfarin were reported.", [" No PARAMETER found.", {"Pathology": ["adverse events"], "Drug": ["warfarin"]}]], [711, "Table 3  Platelet aggregation (Ohms) after 2 weeks of echinacea and policosanol pre-treatment (n= 12) \tControl\tPolicosanol treatment\tEchinacea treatment Agonist\tMean (95% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI) ADP*\t7.8 (5.5, 10.0)\t6.8 (4.9, 8.8)\t0.92 (0.64, 1.30)\t7.5 (4.1, 10.8)\t0.84 (0.59, 1.19) Arachidonic acid\t11.0 (9.6, 12.5)\t11.2 (9.4, 12.9)\t1.00 (0.82, 1.23)\t12.1 (9.3, 15.0)\t1.06 (0.86, 1.30) Collagen\t13.0 (11.5, 14.6)\t14.9 (12.6, 17.2)\t1.13 (0.93, 1.37)\t15.8 (12.2, 19.5)\t1.17 (0.97, 1.42) Open in a separate window *Adenosine diphosphate.", [" \"PARAMETER\": [\n\"Platelet aggregation\",\n\"ADP (Adenosine diphosphate)\",\n\"Mean (95% CI)\",\n\"Geometric mean ratio to control (90% CI)\"\n]\n\nFor each agonist (ADP, Arachidonic acid, Collagen):\n- \"Platelet aggregation\"\n- \"ADP (Adenosine diphosphate)\"\n- \"Mean (95% CI) for Control, Policosanol treatment, and Echinacea treatment\"\n- \"Geometric mean ratio to control (90% CI) for Policosanol treatment and Echinacea treatment\"", {"Parameter": ["Platelet aggregation"], "Herb name": ["echinacea", "policosanol", "Policosanol", "Echinacea"]}]], [712, "Trough plasma concentrations of the major echinacea alkamide tetraene ranged from 1 to 23 ng ml\u22121, and the Cmax was found to range from 13 to 65 ng ml\u22121.", [" \"PARAMETER\": [\"trough plasma concentrations\", \"Cmax\", \"major echinacea alkamide tetraene\"]", {"Herb name": ["echinacea alkamide tetraene"], "Parameter": ["Cmax"]}]], [713, "Interestingly, this effect on the pharmacokinetics of (S)-warfarin was not associated with a significant effect on warfarin pharmacodynamics.", [" \"PARAMETER\": [\"warfarin pharmacodynamics\"]}\n\nIn this context, \"pharmacodynamics\" refers to the study of the biochemical and physiological effects of drugs on the body. So, in this sentence, there is no mention of any specific parameters related to warfarin pharmacodynamics.", {"Drug": ["(S)-warfarin", "warfarin"]}]], [714, "Gorski et al.", [" \"PARAMETER\": [\"Gorski et al.\"]\n\n(Assuming \"Gorski et al.\" is a reference to a specific study or authors)", {}]], [715, "The reason for the discrepancy with previous studies remains unclear.", [" \"PARAMETER\": []", {}]], [716, "A survey of cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies in Kingston, and two earlier surveys of Jamaican prescription drug users identified high levels of herb-drug use (80% [4] 80% [5] and 81% [6], respectively), while awareness of such herb-drug use amongst health care professionals was low across all four surveys (13% [5], 15% [4], 18% [6] and 19% [3], respectively).", [" \"PARAMETER\": [\"80%\", \"80%\", \"81%\"] (percentage of herb-drug use among cancer patients and prescription drug users)\n\n\"PARAMETER\": [\"13%\", \"15%\", \"18%\", \"19%\"] (percentage of awareness of herb-drug use among healthcare professionals)", {"Pathology": ["cancer"], "Ethnic group": ["Jamaican"]}]], [717, "Clinical studies of some of the most commonly researched plants include garlic (Allium sativum), St. John\u2019s wort (Hypericum perforatum), Panax ginseng, and Ginkgo biloba [9].", [" \"PARAMETER\": [\"garlic (Allium sativum)\", \"St. John\u2019s wort (Hypericum perforatum)\", \"Panax ginseng\", \"Ginkgo biloba\"]", {"Study": ["Clinical studies"], "Herb name": ["garlic (Allium sativum)", "St. John\u2019s wort (Hypericum perforatum)", "Panax ginseng", "Ginkgo biloba"]}]], [718, "Key phytochemicals were individually assessed for their impact on CYP1A2 activity.", [" \"PARAMETER\": [\"CYP1A2 activity\"]", {"Target": ["CYP1A2"]}]], [719, "The IC It was not possible to determine the IC In vitro CYP assays offer an accurate, and relatively inexpensive, first stage assessment tool for gauging the potential for herb-drug interactions.", [" \"PARAMETER\": [\"IC\", \"in vitro CYP assays\"]", {"Study": ["In vitro CYP assays"]}]], [720, "\u03b2-Sitosterol, cadina-4,10(15)-dien-3-one and a mix of five lignans comprised of dehydropodophyllotoxin, deoxydehydropodophyllotoxin, 4\u2032-demethyldesoxypodophyllotoxin, 5\u2032-methoxydehydropodophyllotoxin, and dehydro-b-peltatin methyl ether were supplied by the Department of Chemistry, University of the West Indies, Mona Campus, Jamaica.", [" \"PARAMETER\": [\"\u03b2-Sitosterol\", \"cadina-4,10(15)-dien-3-one\", \"dehydropodophyllotoxin\", \"deoxydehydropodophyllotoxin\", \"4\u2032-demethyldesoxypodophyllotoxin\", \"5\u2032-methoxydehydropodophyllotoxin\", \"dehydro-b-peltatin methyl ether\"]", {"Herb name": ["\u03b2-Sitosterol", "cadina-4,10(15)-dien-3-one", "lignans", "dehydropodophyllotoxin", "deoxydehydropodophyllotoxin", "4\u2032-demethyldesoxypodophyllotoxin", "5\u2032-methoxydehydropodophyllotoxin", "dehydro-b-peltatin methyl ether"]}]], [721, "The resulting liquor was suction-filtered through type 1 Whatman filter paper and stored in a sealed darkened glass container.", [" No specific parameters identified in this sentence.", {"Extraction process": ["liquor"]}]], [722, "The following chromatographic methods were employed.", [" I. \"METHOD\": [\"chromatographic methods\"]\n\nOR\n\n\"PARAMETER\": [\"\"]\n{\"CHROMATOGRAPHIC METHODS\": []}\n\nI chose the first option as it is clearer in this context, but the second option could also be used.", {}]], [723, "High resolution LC-MS was conducted using a Waters LCT Time of Flight Mass Spectrometer (Waters Micromass Ltd., Wilmslow, UK), with a Waters Alliance 2690 HPLC and Mass Lynx V4.1 software using similar HPLC conditions to those described above.", [" \"PARAMETER\": [\"Waters LCT Time of Flight Mass Spectrometer\", \"Waters Alliance 2690 HPLC\", \"Mass Lynx V4.1 software\"]", {}]], [724, "[15] to screen natural products for cytochrome P450 inhibition potential with a particular emphasis on the P450 enzymes, CYPs 1A1, 1A2, 1B1, 3A4 and 2D6.", [" \"PARAMETER\": [\"cytochrome P450 enzymes\", \"CYPs 1A1, 1A2, 1B1, 3A4 and 2D6\"]", {"Target": ["cytochrome P450", "P450 enzymes", "CYPs 1A1, 1A2, 1B1, 3A4 and 2D6"]}]], [725, "[35].", [" It is unclear what entity is referred to by \"[35]\" in the context of the given text. Without additional information, it cannot be parsed as a parameter.", {}]], [726, "100 \u00b5L of various concentrations of the extracts, and the ascorbic acid control, in methanol, were added to 100 \u00b5L of a 0.02% (w/v) stock solution of the free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) in methanol.", [" \"PARAMETER\": [\"2,2-diphenyl-1-picrylhydrazyl (DPPH)\", \"methanol\", \"0.02% (w/v)\"]\n\nNote: It's not clear from the text if \"various concentrations of the extracts\" refers to specific entities, so I left it out of the PARAMETER list.", {}]], [727, "Structures of phytochemicals identified in the aqueous extract of H. verticillata (aerial, dried).", [" \"PARAMETER\": [\"structures of phytochemicals\"]\n\"PARAMETER\": [\"aqueous extract of H. verticillata (aerial, dried)\"]", {"Extraction process": ["the aqueous extract"], "Herb name": ["H. verticillata"], "Herb part": ["aerial"]}]], [728, "The pharmacokinetic data revealed that curcumin-treated animals had significantly (p \u2264 0.05) higher area under the plasma concentration-time curve and area under the first moment of plasma drug concentration-time curve.", [" \"PARAMETER\": [\"area under the plasma concentration-time curve\", \"area under the first moment of plasma drug concentration-time curve\"]", {"Herb name": ["curcumin"], "Parameter": ["area under the plasma concentration-time curve", "area under the first moment of plasma drug concentration-time curve"]}]], [729, "Worse than the Disease?", [" It is not clear from the provided context what \"Worse than the Disease?\" refers to in terms of parameters. Please provide additional context for parsing.", {"Pathology": ["the Disease"]}]], [730, "An external file that holds a picture, illustration, etc.", [" I cannot directly parse or identify parameters from the given text regarding an external file. However, if the file is mentioned as having a specific name or type, it could be included as a parameter with an empty value if no further information is provided.\n\nExample:\n{\"PARAMETER\": [\"external_file_name.jpg\", \"external_file_type\"]}", {}]], [731, "Five days after presentation, her symptoms had completely resolved.", [" No physiological or medical parameters were mentioned in this sentence.\n\n\"PARAMETER\": []", {}]], [732, "The naturopathic literature from which most information about rashes caused by Lomatium is drawn do not indicate a well-studied treatment of the rash aside from supportive care and cessation of Lomatium ingestion.", [" \"PARAMETER\": [\"rashes caused by Lomatium\"]", {"Pathology": ["rashes", "the rash"], "Herb name": ["Lomatium", "Lomatium"]}]], [733, "In our patient, the rash was refractory to glucocorticoids and only resolved once her exposure to the extract ceased, although antihistamines were helpful to reduce pruritis.", [" \"PARAMETER\": [\"\"]\n\n(No specific parameters mentioned in the text)", {"Pathology": ["the rash", "pruritis"], "Drug": ["glucocorticoids", "antihistamines"]}]], [734, "To explore more, we would like to investigate the interactions between OS and selected single herbs from these Wen Bing formulas.", [" \"PARAMETER\": []", {"Drug": ["OS"], "Herb name": ["Wen Bing formulas"]}]], [735, "A commercially available, standardized and purified Radix Scutellariae extract (RS) was obtained from Shanghai U-sea Biotech Co., Ltd. (Shanghai, China) with a batch number of 110208 and a quality of control standard number of WS-10001-(HD-0989)-2002.", [" \"PARAMETER\": [\"Radix Scutellariae extract\", \"batch number (110208)\", \"quality of control standard number (WS-10001-(HD-0989)-2002)\"]", {"Herb name": ["Radix Scutellariae extract (RS)"]}]], [736, "Albuterol (as internal standard) was purchased from Sigma-Aldrich Chem.", [" \"PARAMETER\": [\"Albuterol\"]\n\n\"PARAMETER\": [\"Sigma-Aldrich Chem.\"]\n\n(Note: In this context, \"Albuterol\" is likely a drug used as an internal standard, and \"Sigma-Aldrich Chem.\" is the supplier of that drug.)", {}]], [737, "Hygromycin B, glycyl-sarcosine (Gly-Sar) and thiazolyl blue tetrazolium bromide (MTT) were purchased from Sigma-Aldrich Chem.", [" \"PARAMETER\": [\"Hygromycin B\", \"glycyl-sarcosine (Gly-Sar)\", \"thiazolyl blue tetrazolium bromide (MTT)\"]", {}]], [738, "The reaction was terminated by adding 5\u202f\u03bcL of 8\u202fmg/mL dichlorvos and then mixed with 600\u202f\u03bcL PBS.", [" \"PARAMETER\": [\"\"]\n\nNo entities were identified in this text.", {}]], [739, "At 30\u202fmin following the 8PM dose on Day 5, the rats were anesthetized and about 10\u202fmL of blood were collected from rats\u2019 inferior vena for determination of antiviral activity.", [" \"PARAMETER\": [\"10 mL of blood\"]\n\n\"PARAMETER\": [\"determination of antiviral activity\"]\n\n\"PARAMETER\": [\"inferior vena\"]\n\n\"PARAMETER\": [\"rats\"]\n\n\"PARAMETER\": [\"following the 8PM dose on Day 5\"]\n\n\"PARAMETER\": [\"anesthetized\"]\n\n\"PARAMETER\": [\"about\"]\n\n\"PARAMETER\": [\"10 mL\"]\n\n\"PARAMETER\": [\"blood\"]\n\n\"PARAMETER\": [\"for determination of antiviral activity\"]\n\n\"PARAMETER\": [\"inferior vena\"]\n\n\"PARAMETER\": [\"rats\"]\n\n\"PARAMETER\": [\"following the 8PM dose on Day 5\"]\n\n\"PARAMETER\": [\"anesthetized\"]\n\n\"PARAMETER\": [\"about\"]\n\n\"PARAMETER\": [\"10 mL\"]\n\n\"PARAMETER\": [\"blood\"]\n\n\"PARAMETER\": [\"collected\"]\n\n\"PARAMETER\": [\"determination of antiviral activity\"]\n\n\"PARAMETER\": [\"inferior vena\"]\n\n\"PARAMETER\": [\"rats\"]\n\n\"PARAMETER\": [\"following the 8PM dose on Day 5\"]\n\n\"PARAMETER\": [\"anesthetized\"]\n\nThis is a repetition of the same information, so I'll just include it once in the final result.\n\n\"PARAMETER\": [\"10 mL of blood\", \"determination of antiviral activity\", \"inferior vena\", \"rats\", \"following the 8PM dose on Day 5\", \"anesthetized\"]", {}]], [740, "The incubation system for rat plasma contains 1\u202f\u03bcg/mL of OS and 10% rat plasma since the super-fast reaction rate of 100% rat plasma resulted in no discrimination for nearly all the studied herb/herbal components.", [" \"PARAMETER\": [\"1 \u03bcg/mL of OS\", \"10% rat plasma\"]", {}]], [741, "The formation rate of OSA could be significantly suppressed by all the herb/herbal components.", [" \"PARAMETER\": [\"formation rate of OSA\"]", {"Drug": ["OSA"]}]], [742, "Results from RLM and hCE1 showed a similar trend for the ten marker components (Figs.", [" 1 and 2).{\"PARAMETER\": [\"ten marker components\"]}", {}]], [743, "S4, the P The above in-vitro experiments suggested that there should be some potential HDI between OS and these anti-influenza herbs/herbal components during absorption and metabolism.", [" \"PARAMETER\": [\"HDI (herb-drug interaction)\", \"absorption and metabolism\"]", {"Study": ["in-vitro experiments"], "Drug": ["OS"]}]], [744, "The results suggested that co-administration with RS could significantly increase the systemic exposure of OS and decrease that of OSA (Fig.", [" 1].\n\n\"PARAMETER\": [\"systemic exposure\", \"OS\", \"OSA\"]\n\n[1]: It is assumed that Fig. refers to a figure in the article, but without access to the article itself, it is impossible to provide the exact reference.", {"Herb name": ["RS"], "Drug": ["OS", "OSA"]}]], [745, "This can further be verified by the lowered OSA/OS ratio in rat urine samples after co-administration with RS (Fig.", [" 1).\n\n\"\"PARAMETER\"\": [\"OSA/OS ratio\"]\n\n[1]: {\"PARAMETER\": [\"rat urine samples\", \"after co-administration with RS\"]}", {"Drug": ["OSA", "OS"], "Herb name": ["RS"]}]], [746, "S8).", [" I cannot determine the parameter for the abbreviation \"S8\" without additional context.", {}]], [747, "In our current study, a screening platform based on microsomes, enzymes, cells and influenza viruses have for the first time been developed and utilized to screen potential interaction between OS and anti-influenza herb/herbal components.", [" \"PARAMETER\": [\"screening platform\", \"microsomes\", \"enzymes\", \"cells\", \"OS\", \"anti-influenza herb/herbal components\"]", {"Drug": ["OS"]}]], [748, "The metabolic inhibition studies performed in rat plasma suggested that all the herbal extracts (500\u202f\u03bcg/mL) and all the herbal components (100\u202f\u03bcg/mL) could inhibit the hydrolysis of OS in rat plasma, but the % inhibition rate varied between herbs/herbal components.", [" \"PARAMETER\": [\"hydrolysis of OS\"]\n\n\"PARAMETER - Herbal extracts\": [\"% inhibition rate\"]\n\n\"PARAMETER - Herbal components\": [\"% inhibition rate\"]", {"Amount": ["500\u202f\u03bcg/mL", "100\u202f\u03bcg/mL"], "Drug": ["OS"]}]], [749, "The hydrolase activities in rat plasma may be originated from more than one kind of enzymes (not only hCE1) and the inhibition activities of these herbal components to each kind of hydrolysis enzymes are different.", [" \"PARAMETER\": [\"hydrolase activities in rat plasma\", \"the inhibition activities of these herbal components\"]", {"Target": ["hCE1"]}]], [750, "After such a normalization, the absolute z-score of an herb/herbal component effect on OS would be proportional to its level of HDI relevancy with OS.", [" \"PARAMETER\": [\"OS\", \"herb/herbal component effect\", \"level of HDI relevancy\"]", {"Drug": ["OS", "OS"]}]], [751, "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats.", [" \"PARAMETER\": [\n\"BIO\",\n\"elimination rate (CL)\",\n\"systemic exposure (AUC)\"\n]\n\n\"BIO\": [],\n\"elimination rate (CL)\": [],\n\"systemic exposure (AUC)\": []\n\n# Explanation:\n# The text mentions that the elimination rate (CL) and systemic exposure (AUC) of OS increased after co-administration with RS, but no specific values are provided for these parameters. Therefore, they are left empty in the output. However, the text does mention that the BIO (biological availability) of OS increased by 62%. This information is included in the output under the \"BIO\" parameter.", {"Herb name": ["RS", "RS", "RS"], "Parameter": ["BIO", "AUC"], "Drug": ["OS", "OS"], "Study": ["in-vitro screening", "in-vivo", "ex-vivo"]}]], [752, "Radix Isatidis (Root of Isatis indigotica Fort., Banlangen).", [" \"PARAMETER\": [\"Radix Isatidis\", \"Root of Isatis indigotica\", \"Isatis indigotica\"]\n\nThese are all different names for the same entity, which is a traditional herb.", {"Herb name": ["Radix Isatidis", "Isatis indigotica Fort"], "Herb part": ["Root"]}]], [753, "Fructus Arctii (Fruit of Arctium lappa L., Niubangzi).", [" \"PARAMETER\": [\"Fructus Arctii\", \"Fruit of Arctium lappa L.\", \"Niubangzi\"]", {"Herb name": ["Fructus Arctii", "Arctium lappa L."], "Herb part": ["Fruit"]}]], [754, "30%\u201370% of clinical breast cancer patients use natural products, which may increase the likelihood of drug interactions.", [" \"PARAMETER\": [\"clinical breast cancer patients\"]\n\n\"PARAMETER\": [\"the likelihood of drug interactions\"]", {"Pathology": ["breast cancer"]}]], [755, "Conclusion: There is evidence for potential interactions of various natural products with TAM in pre-clinical studies, although the relevant clinical evidence is still lacking.", [" \"PARAMETER\": [\"TAM\"]", {"Herb name": ["natural products"], "Drug": ["TAM"], "Study": ["pre-clinical studies"]}]], [756, "Of all the cancer patients, breast cancer patients, in particular, are more likely to turn to complementary and alternative medicine (CAM) treatment (Wanchai et al., 2010).", [" \"PARAMETER\": [\"breast cancer patients\"]\n\n\"PARAMETER\": [\"cancer patients\"]\n\n\"PARAMETER\": [\"complementary and alternative medicine (CAM)\"]", {"Pathology": ["cancer", "breast cancer"]}]], [757, "), dried orange peel (Citrus aurantium L.), Anemarrhena (Anemarrhena asphodeloides Bunge), Phellodendron bark (Phellodendron amurense Rupr.", [" \"PARAMETER\": [\"dried orange peel (Citrus aurantium L)\", \"Anemarrhena (Anemarrhena asphodeloides Bunge)\", \"Phellodendron bark (Phellodendron amurense Rupr.)\"]", {"Herb name": ["dried orange peel (Citrus aurantium L.)", "Anemarrhena (Anemarrhena asphodeloides Bunge)", "Phellodendron bark (Phellodendron amurense Rupr."]}]], [758, "), Licorice (Glycyrrhiza glabra L.), Ginger (Zingiber officinale Roscoe), Lilyturf (Ophiopogon japonicus (Thunb.)", [" \"PARAMETER\": [\"Licorice (Glycyrrhiza glabra L.)\", \"Ginger (Zingiber officinale Roscoe)\", \"Lilyturf (Ophiopogon japonicus (Thunb.)\"]\n\nThese are the names of the herbs mentioned in the text.", {"Herb name": ["Licorice (Glycyrrhiza glabra L.)", "Ginger (Zingiber officinale Roscoe)", "Lilyturf (Ophiopogon japonicus (Thunb.)"]}]], [759, "The key mechanisms of action of anti-cancer drugs involve apoptosis, autophagy, and cell cycle arrest (Chen and Karantza-Wadsworth, 2009; Wang et el., 2011; Kon et al., 2013).", [" \"PARAMETER\": [\"apoptosis\", \"autophagy\", \"cell cycle arrest\"]}", {"Pathology": ["anti-cancer", "apoptosis, autophagy, and cell cycle arrest"]}]], [760, "A recent study has shown that the combined use of HES, PIP, and BV with TAM showed an enhanced anti-proliferative effect on MCF7 and T47D and can significantly increase cell apoptosis (Khamis et al., 2018).", [" \"PARAMETER\": [\"enhanced anti-proliferative effect\", \"MCF7 and T47D\", \"cell apoptosis\"]", {"Herb name": ["HES", "PIP", "BV"], "Drug": ["TAM"], "Pathology": ["anti-proliferative effect", "apoptosis"]}]], [761, "When combined with TAM, it exhibits a significant synergistic inhibitory effect on MCF-7 and T-47D cell growth (Cho et al., 2010).", [" \"PARAMETER\": [\"significant synergistic inhibitory effect\", \"MCF-7 and T-47D cell growth\"]", {"Drug": ["TAM"], "Parameter": ["MCF-7 and T-47D cell growth"]}]], [762, "Mistletoe (Viscum album L.) derived medicinal preparations are widely used and registered as medicines in many European countries.", [" \"PARAMETER\": [\"Mistletoe (Viscum album L.)\"]", {"Herb name": ["Mistletoe (Viscum album L.)"], "Ethnic group": ["European"]}]], [763, "In a study involving TAM-resistant cell line MCF-7 tam-R, while 10 Evn-50 is an ethyl acetate extract of Vitex negundo L. When used in combination with TAM to treat TAM-resistant MCF-7/TAM-R cells, it significantly reduces cell viability, inhibits cell growth, induces apoptosis, and reverses TAM resistance of MCF-7/TAM-R cells (Hu et al., 2012).", [" \"PARAMETER\": [\"cell viability\", \"cell growth\", \"apoptosis\"]", {"Drug": ["TAM", "TAM", "TAM", "TAM"], "Herb name": ["10 Evn-50", "Vitex negundo L."], "Extraction process": ["ethyl acetate extract"], "Parameter": ["cell viability", "cell growth"]}]], [764, "Jaeumkanghwa soup (JEKHT) is a compound composed of 12 traditional herbs (Jung et al., 2010).", [" \"PARAMETER\": [\"Jaeumkanghwa soup\", \"12 traditional herbs\"]", {"Herb name": ["Jaeumkanghwa soup (JEKHT)"]}]], [765, "Jiawei Xiaoyao San (JWXYS) is a very common Chinese herbal formula used by the Chinese for thousands of years (Chen et al., 2014).", [" \"PARAMETER\": [\"Jiawei Xiaoyao San (JWXYS)\"]\n\nThis refers to a specific Chinese herbal formula. No physiological or medical parameters are mentioned in this context.", {"Herb name": ["Jiawei Xiaoyao San (JWXYS)"], "Ethnic group": ["Chinese", "Chinese"], "Duration": ["for thousands of years"]}]], [766, "The protective effect is dose-dependent (Rahate and Rajasekaran, 2015).", [" \"PARAMETER\": [\"dose-dependent\"]\n\nThis parameter refers to the relationship between the magnitude of the effect and the amount or dose of a substance or treatment. In this context, the protective effect of traditional hypoglycemic herbs is dependent on the dose.", {"Pathology": ["protective effect"]}]], [767, "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b).", [" \"PARAMETER\": [\n\"antioxidant enzymes\",\n\"activity of sGPT and sGOT\",\n\"glutathione\",\n\"TBARS\",\n\"liver transaminases\"\n]", {"Herb name": ["DDB"], "Pathology": ["the oxidative stress", "liver injury"], "Drug": ["TAM"], "Parameter": ["antioxidant enzymes", "the activity of sGPT and sGOT", "glutathione concomitant", "TBARS", "liver transaminases"]}]], [768, "Studies have shown that just the monitoring of protein expression levels is insufficient in understanding transcription activity in vitro (Gord\u00e2n et al., 2009).", [" \"PARAMETER\": [\"protein expression levels\"]\n\n\"PARAMETER\": [\"transcription activity\"]\n\n\"PARAMETER\": [\"in vitro\"]\n\n\"PARAMETER\": [\"studies\"]\n\n\"PARAMETER\": [\"monitoring\"]\n\n\"PARAMETER\": [\"just the monitoring of protein expression levels\"]\n\n\"PARAMETER\": [\"understanding transcription activity in vitro\"]\n\n\"PARAMETER\": [\"Gord\u00e2n et al., 2009\"]", {"Parameter": ["protein expression levels"]}]], [769, "In the transporter-mediated in vitro HDI, GA and PCA presented inhibitory effects on OAT1/3 and inductive effects on MDR1 and BCRP.", [" \"PARAMETER\": [\"OAT1/3\", \"MDR1\", \"BCRP\"]}\n\nThese parameters refer to specific transporters mentioned in the text.", {"Herb name": ["GA", "PCA"], "Target": ["OAT1/3", "MDR1", "BCRP"]}]], [770, "Communicable diseases are still leading causes of death and disability globally, according to WHO\u2019s Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020).", [" \"PARAMETER\": [\"communicable diseases\", \"Global Health Estimates 2000\u20132019\", \"GBD Diseases and Injuries\"]", {"Pathology": ["Communicable diseases"]}]], [771, "ex D. Don (P. capitatum), a Chinese herbal plant, is often used alone or in combination with antibacterial agents to treat urinary tract infections, pyelonephritis, and prostatitis in China (Chinese Pharmacopoeia Commission, 2010; Liao et al., 2011).", [" \"PARAMETER\": [\"D. Don\", \"P. capitatum\", \"Chinese herbal plant\"]", {"Herb name": ["ex D. Don (P. capitatum)"], "Ethnic group": ["Chinese", "Chinese"], "Drug": ["antibacterial agents"], "Pathology": ["urinary tract infections", "pyelonephritis", "prostatitis"]}]], [772, "Consequently, GA and PCA were chosen as PCE tracer components in the pharmacokinetic- and tissue distribution-based HDIs studies.", [" \"PARAMETER\": [\"GA\", \"PCA\"]", {"Herb name": ["GA", "PCA", "PCE"]}]], [773, "Approximately 60% of CIP is excreted in unchanged form into the urine (Vance-Bryan et al., 1990).", [" \"PARAMETER\": [\"approximately 60% of CIP\"]\n\n\"PARAMETER\": [\"unchanged form\"]\n\n\"PARAMETER\": [\"into the urine\"]\n\n\"PARAMETER\": [\"CIP\"]\n\n\"PARAMETER\": [\"Vance-Bryan et al., 1990\"]\n\nNote: The percentage value is included as a single parameter for simplicity, but it could be broken down into separate parameters for \"percentage\" and \"CIP\" if desired.", {"Drug": ["CIP"]}]], [774, "CIP is a known substrate of the ATP-binding cassette transporters, which have been implicated in its intestinal secretion, biliary excretion and secretion into breast milk (Vance-Bryan et al., 1990; Merino et al., 2006; Ando et al., 2007; Mulgaonkar et al., 2012).", [" \"PARAMETER\": [\"ATP-binding casstransporters\", \"intestinal secretion\", \"biliary excretion\", \"secretion into breast milk\"]", {"Drug": ["CIP"]}]], [775, "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A.", [" \"PARAMETER\": [\"\"]\n\nThis text does not contain any references to physiological or medical parameters. It is describing a gradient elution program for a chromatography method.", {}]], [776, "The supernate was utilized for the quantification of GA, PCA, and CIP.", [" \"PARAMETER\": [\"GA\", \"PCA\", \"CIP\"]\n\nThese parameters represent the specific compounds (GA, PCA, and CIP) that were quantified in the supernate.", {"Herb name": ["GA", "PCA"], "Drug": ["CIP"]}]], [777, "The precursor-product ion transitions of CIP and ofloxacin (internal standard) were 332.1\u2192288.1 and 362.2\u2192318.1, respectively.", [" \"PARAMETER\": [\"precursor-product ion transitions\", \"332.1\u2192288.1 (CIP)\", \"362.2\u2192318.1 (ofloxacin)\"]", {"Drug": ["CIP", "ofloxacin"]}]], [778, "After co-administration of CIP and PCE, the PK changes of GA and PCA are displayed in Figures 3, 4, respectively.", [" \"PARAMETER\": [\"PK changes\", \"GA\", \"PCA\"]", {"Drug": ["CIP"], "Herb name": ["PCE", "GA", "PCA"]}]], [779, "PCE significantly increased the tissue to plasma distribution coefficients (K  Tissue distribution profiles of ciprofloxacin (CIP) after intravenous administration of CIP in the absence (A) and presence (B) of PCE to rats, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of GA in normal rats after intragastric administration of PCE in the absence and presence of CIP are displayed in Figures 7A,B, respectively.", [" \"PARAMETER\": [\"tissue to plasma distribution coefficients (K)\"]}\n\nIn the context of the given text, it appears that \"PCE\" refers to probenecid and \"CIP\" refers to ciprofloxacin. Therefore, the parameters should be labeled as follows:\n\n\"PARAMETER\": {\n\"ciprofloxacin\": [\"tissue to plasma distribution coefficients (K)\"],\n\"probenecid\": [\"tissue to plasma distribution coefficients (K)\"]\n}", {"Herb name": ["PCE", "PCE", "GA", "PCE"], "Drug": ["ciprofloxacin (CIP)", "CIP", "CIP"]}]], [780, "CIP significantly increased the K  Tissue distribution profiles of gallic acid (GA) after oral administration of PCE in the absence (A) and presence (B) of ciprofloxacin, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of PCA in the absence and| presence of CIP are shown in Figures 8A,B, respectively.", [" \"PARAMETER\": [\"K tissue distribution profiles\", \"tissue distribution coefficients (K)\"]}", {"Drug": ["CIP", "ciprofloxacin", "CIP"], "Herb name": ["gallic acid (GA)", "PCE", "PCA"]}]], [781, "Since the liver metabolism (approximately 10%) and biliary excretion (approximately 1%) of the drug is relatively low (Vance-Bryan et al., 1990), the reduced circulating CIP in humans was mainly attributed to the change of CIP across the renal and intestinal epithelia.", [" \"PARAMETER\": [\"circulating CIP in humans\", \"renal and intestinal epithelia\"]", {"Drug": ["CIP", "CIP"]}]], [782, "The study was funded by the Scientific Research Project of Tianjin Municipal Education Commission (2021ZD017 and 2021ZD030), and the National Science and Technology Major Project of China under Grant number (2018ZX09734-002), Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine.", [" \"PARAMETER\": [\"2021ZD017\", \"2021ZD030\", \"2018ZX09734-002\"]}", {"Ethnic group": ["Chinese"]}]], [783, "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [" No parameters found in this statement.", {}]], [784, "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.", [" No parameters found in this statement.", {}]], [785, "Click here for additional data file.", [" I cannot follow the link or access external data files. Please provide the necessary information directly in the text for me to parse.", {}]], [786, "All tests were performed at similar laboratory environmental conditions controlling for air temperature, barometric pressure, and relative humidity.", [" \"PARAMETER\": [\"air temperature\", \"barometric pressure\", \"relative humidity\"]\n\n(Note: In this context, these parameters are mentioned for controlling conditions, so no specific values are given.)", {}]], [787, "The scale was anchored at each end with the labels \u201cnot at all\u201d (0 mm) and \u201cextremely\u201d (100 mm).", [" \"PARAMETER\": [\"0 mm\", \"100 mm\"]", {}]], [788, "However, the total AUC for CHO was lower in YM than PLC (13.3 vs. 15.00, p < 0.001).", [" \"PARAMETER\": [\"total AUC for CHO\"]\n\n\"PLC\": [\"15.00\"],\n\"YM\": [\"13.3\"]\n\nNote: I assumed \"PLC\" and \"YM\" are abbreviations for different groups or conditions. If they refer to something else, please let me know.", {"Parameter": ["AUC", "CHO"], "Herb name": ["YM"]}]], [789, "Total Energy Expenditure (TEE) was neither significantly affected by the treatment (YM vs. PLC) nor the exercise time (Figure 3).", [" \"PARAMETER\": [\"Total Energy Expenditure (TEE)\"]\n\nNote: No significant change was observed for the given parameter.", {"Parameter": ["Total Energy Expenditure (TEE)"], "Herb name": ["YM"], "Drug": ["PLC"]}]], [790, "This increase is comparable with 24% increase found during low to moderate exercise intensities determined using an incremental protocol in our previous study [22].", [" \"PARAMETER\": [\"24% increase\"]\n\nReferences:\n[22] [Your reference here]", {}]], [791, "Previous studies in human participants have shown promising effects of YM ingestion on metabolic rate and RER acutely [21], and after 12 weeks of ingestion, on blood lipid metabolites in healthy obese participants [11,21].", [" \"PARAMETER\": [\"metabolic rate\", \"RER\", \"blood lipid metabolites\"]", {"Herb name": ["YM"], "Duration": ["12 weeks"], "Pathology": ["healthy"]}]], [792, "The metabolic effects include adrengenic effects and stimulated central nervous system associated with caffeine, anti-lipolytic, and hypocholesterolemic properties in chlorogenic acids (mono- and di-caffeolquinic acids) hydroxycinnamic acids (caffeic acid, quinic acid) and triterpenic saponins, and other minerals and vitamins [5].", [" \"PARAMETER\": [\"adrenergic effects\", \"central nervous system\", \"caffeine\", \"chlorogenic acids\", \"mono- and di-caffeolquinic acids\", \"hydroxycinnamic acids\", \"caaffeic acid\", \"quinic acid\", \"terpeneic saponins\"]", {"Herb name": ["caffeine"]}]], [793, "However, further research is required to assess active ingredients of YM capsules and analyze their bioavailability following ingestion.", [" No specific parameters were mentioned in this sentence.", {"Herb name": ["YM"], "Parameter": ["bioavailability"]}]], [794, "Favorable psychomotor effects on mood state and satiety are often expected outcomes of fat and weight-loss supplementation protocols.", [" \"PARAMETER\": [\"mood state\", \"satiety\"]", {}]], [795, "The BF% data indicated all females who took part were at the lower BF% percentile, indicating that they were physically active, with higher  Although the positive effects of YM on fat-loss outcomes during exercise are found only in single trials, future research could test the longitudinal YM effectiveness, especially when combining regular exercise training with YM treatment.", [" \"PARAMETER\": [\"BF% percentile\"]\n\n\"PARAMETER\": [\"physically active\"]\n\n\"PARAMETER\": [\"fat-loss outcomes\"]\n\n\"PARAMETER\": [\"regular exercise training\"]\n\n\"PARAMETER\": [\"YM treatment\"]", {"Sex": ["females"], "Herb name": ["YM", "YM", "YM"]}]], [796, "R.A. collected the data and contributed to data analysis and manuscript writing.", [" \"PARAMETER\": [\"data\", \"data analysis\", \"manuscript writing\"]\n\nThis information is about the contributions of an author (R.A.) to the study.", {}]], [797, "Co., Seoul, Korea) and their identity was kindly confirmed by Prof. Yeong Bae Seo (a specialist in plant classification, Natural Products Research Institute, Seoul National University, Seoul, Korea).", [" \"PARAMETER\": [\"Seoul, Korea\", \"Prof. Yeong Bae Seo\", \"Natural Products Research Institute\", \"Seoul National University\"]", {}]], [798, "[ HEK293 cells transiently overexpressing OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters were purchased from Corning-Gentest (Tewksbury, MA, USA).", [" \"PARAMETER\": [\"HEK293 cells\", \"OAT1\", \"OAT3\", \"OCT1\", \"OCT2\", \"OATP1B1\", \"OATP1B3\"]", {"Parameter": ["OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters"]}]], [799, "Food and water were supplied ad libitum.", [" No specific parameters identified in this sentence.", {}]], [800, "Rats were cannulated with polyethylene tubing (PE-50, Natsume Co, Tokyo, Japan) in the jugular vein for sampling under anesthesia with isoflurane.", [" \"PARAMETER\": [\"rats\", \"jugular vein\", \"sampling under anesthesia with isoflurane\"]\n\nNote: In this context, \"rats\" is the organism under study, \"jugular vein\" is the specific location for cannulation, and \"sampling under anesthesia with isoflurane\" refers to the method used for the procedure.", {"Parameter": ["anesthesia"], "Drug": ["isoflurane"]}]], [801, "Mass Hunter software (Agilent Technologies) was used for LC-MS/MS system control and data processing.", [" \"PARAMETER\": [\"Mass Hunter software\"] (Agilent Technologies)", {}]], [802, "showed that the practice of herbal co-medication with prescription drugs cut across various patient demographics, with 38% of respondents reporting concomitant herbal use [6].", [" \"PARAMETER\": [\"percentage of respondents\", \"patient demographics\"]\n\nNote: No specific parameter was mentioned in the text related to herbal co-medication or prescription drugs, but the text does provide information about the percentage of respondents who reported concomitant herbal use and that this practice cuts across various patient demographics.", {}]], [803, "Since the accidental discovery of the ability of grapefruit juice to alter the pharmacokinetic profiles of felodipine through the inhibition of cytochrome P450 (CYP) and P-glycoprotein (P-gp), more studies have elucidated various mechanisms of HDI [11].", [" \"PARAMETER\": [\"the ability of grapefruit juice\", \"felodipine\", \"cytochrome P450 (CYP)\", \"P-glycoprotein (P-gp)\"]", {"Herb name": ["grapefruit juice"], "Drug": ["felodipine"], "Target": ["cytochrome P450 (CYP)", "P-glycoprotein (P-gp)"]}]], [804, "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian.", [" \"PARAMETER\": [\"celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture, valerian\"]", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "hydroxycut", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic", "valerian"]}]], [805, "Phytoestrogens and other bioactive components of celery can interact with the DMEs, including those in the CYP450 family.", [" \"PARAMETER\": [\"DMEs\", \"those in the CYP450 family\"]", {"Herb name": ["celery"], "Target": ["DMEs", "CYP450 family"]}]], [806, "Anecdotal pieces of evidence like this not only highlight the reality and severity of the consequences of HDIs, they underscore the importance of further studies to guide clinical decisions.", [" \"PARAMETER\": []", {}]], [807, "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61].", [" \"PARAMETER\": [\"symptoms of cognition decline and memory loss\", \"anxiety and mood disorders\", \"fatigue and general well-being\", \"cardiovascular disorders\"]", {"Study": ["Several controlled clinical studies"], "Herb name": ["ginkgo"], "Pathology": ["cognition decline", "memory loss", "anxiety", "mood disorders", "fatigue", "cardiovascular disorders"]}]], [808, "He was reported to have experienced a seizure before his death, and the toxicological autopsy results revealed subtherapeutic serum levels for both drugs.", [" \"PARAMETER\": [\"serum levels\"]}", {"Pathology": ["seizure"]}]], [809, "The inhibitory and inductive effect of the different phytochemicals in ginseng on CYP3A4 is demonstrated through the observed changes in the AUC and other pharmacokinetic parameters of midazolam in these human studies [27, 88].", [" \"PARAMETER\": [\"AUC\", \"pharmacokinetic parameters\"]", {"Herb name": ["ginseng"], "Target": ["CYP3A4"], "Parameter": ["AUC"], "Drug": ["midazolam"], "Study": ["human studies"]}]], [810, "Chronic use of ginseng on its own has been associated with manic psychosis [90].", [" \"PARAMETER\": [\"manic psychosis\"]\n\nReferences:\n[90].\n\nNote: The exact reference information is missing, so I couldn't include it in the output. However, I assumed that the reference [90] is related to the statement about ginseng and manic psychosis.", {"Herb name": ["ginseng"], "Pathology": ["manic psychosis"]}]], [811, "The pharmacological activities of kava have been attributed to kavalactones, which are concentrated in the rhizomes [96].", [" \"PARAMETER\": [\"kavalactones\"]\n\nReferences:\n[96] - {} (To be filled with the actual reference information)", {"Herb name": ["kava", "kavalactones"], "Herb part": ["rhizomes"]}]], [812, "Despite the general concern about its safety, kava is still popularly consumed for CNS benefits.", [" \"PARAMETER\": [\"CNS benefits\"]\n\n\"PARAMETER\": [\"kava\"]", {"Herb name": ["kava"]}]], [813, "A study in 18 health volunteers did not show any clinically relevant interaction between kava and bromazepam [104].", [" \"PARAMETER\": [\"\"]\n\n[104]: This citation does not provide any information about parameters.", {"Cohort": ["18 health volunteers"], "Herb name": ["kava"], "Drug": ["bromazepam"]}]], [814, "Kratom is also used as complementary medicine to manage diabetes, diarrhea, improve circulation, enhance alertness and concentration, and increase libido [111-114].", [" \"PARAMETER\": [\"diabetes\", \"diarrhea\", \"circulation\", \"alertness and concentration\", \"libido\"]", {"Herb name": ["Kratom"], "Pathology": ["diabetes", "diarrhea"]}]], [815, "Apart from CYP/P-gp induction, SJW mediates interactions through its serotonergic effects.", [" \"PARAMETER\": [\"serotonergic effects\"]", {"Herb name": ["SJW"]}]], [816, "investigated the ability of SJW to interact with CYP3A4 in a 2-way, open-label crossover study of 21 healthy subjects using midazolam as the probe substrate.", [" \"PARAMETER\": [\"21 healthy subjects\", \"CYP3A4\"]", {"Herb name": ["SJW"], "Target": ["CYP3A4"], "Study": ["open-label crossover study"], "Cohort": ["21 healthy subjects"], "Drug": ["midazolam"]}]], [817, "This is important because the vast majority of herbal products are orally administered.", [" \"PARAMETER\": [\"\"]", {}]], [818, "This is because many marketed herbal products are made of mixtures of different herbal species and/or dietary supplements whose biological disposition in humans is poorly understood.", [" No specific parameters were mentioned in this sentence.", {}]], [819, "CYP3A4 and P-gp are richly expressed in the human small intestinal enterocytes.", [" \"PARAMETER\": [\"CYP3A4\", \"P-gp\"]", {}]], [820, "This review identified 13 herbal products - celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian \u2013 all of which have shown interactions with specific neuropsychiatric drugs.", [" \"PARAMETER\": [\"celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture, valerian\"]", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic mixture", "valerian"], "Herb part": ["hydroxycut"], "Drug": ["neuropsychiatric drugs"]}]], [821, "Medicinal herbs are rich sources of natural bioactive compounds that could interact with drugs.", [" \"PARAMETER\": [\"medicinal herbs\", \"natural bioactive compounds\"]\n\nThese parameters refer to the entities mentioned in the text that are relevant to the pharmacological context.", {}]], [822, "Sirolimus displays a synergistic action with calcineurin inhibitors and a distinctive mechanism of action from calcineurin inhibitors, which are indispensable immunosuppressive agents in kidney transplantation.", [" \"PARAMETER\": [\"synergistic action\", \"immunosuppressive agents\", \"calcineurin inhibitors\"]", {"Drug": ["Sirolimus", "calcineurin inhibitors", "calcineurin inhibitors"]}]], [823, "This is especially important for drugs with a narrow therapeutic window.", [" \"PARAMETER\": [\"drugs with a narrow therapeutic window\"]", {}]], [824, "The patient received tacrolimus-based immunosuppression until April 2016, and then the treatment was switched from tacrolimus to sirolimus due to evident tremors.", [" \"PARAMETER\": [\"tacrolimus\", \"sirolimus\"]", {"Drug": ["tacrolimus", "tacrolimus", "sirolimus"], "Pathology": ["tremors"]}]], [825, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" \"PARAMETER\": [\"serum creatinine level\"]\n\n\"PARAMETER\": [\"74.27 \u00b5mol/L\"]\n\n\"PARAMETER\": [\"stable\"]\n\nNote: In this context, \"serum creatinine level\" refers to the concentration of creatinine in the blood serum. Creatinine is a waste product produced by muscle metabolism and its measurement is commonly used as an indicator of kidney function.", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [826, "Contrary to this safety perception, herb\u2013drug interactions could lead to serious adverse effects.", [" \"PARAMETER\": []", {"Pathology": ["adverse effects"]}]], [827, "Author contributions: MK drafted the initial and final versions of the manuscript.", [" \"PARAMETER\": [\"MK\"]\n\n\"ROLE\": [\"drafted the initial and final versions of the manuscript\"]", {}]], [828, "Sirolimus is an immunosuppressive drug used to prevent graft rejection.", [" \"PARAMETER\": [\"sirolimus\", \"immunosuppressive drug\"]", {"Drug": ["Sirolimus"], "Pathology": ["graft rejection"]}]], [829, "Therapeutic drug monitoring is required as with other immunosuppressive drugs.", [" \"PARAMETER\": [\"therapeutic drug monitoring\"]", {}]], [830, "Parsley, Petroselinum crispum, is a food, spice, and also a medicinal herb.", [" \"PARAMETER\": [\"Parsley\", \"Petroselinum crispum\"]", {"Herb name": ["Parsley", "Petroselinum crispum"]}]], [831, "Previous studies have shown the interactions between sirolimus and drugs that affect the activities of metabolizing enzymes and transporter proteins.", [" \"PARAMETER\": [\"sirolimus\", \"drugs that affect the activities of metabolizing enzymes and transporter proteins\"]", {"Drug": ["sirolimus"]}]], [832, "Parsley is a food, spice, and also a medicinal herb.", [" \"PARAMETER\": [\"parsley\"]\n\nThis is a common substance that is used as food, a spice, and also as a medicinal herb. No specific parameters related to parsley were mentioned in the text.", {"Herb name": ["Parsley"]}]], [833, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" \"PARAMETER\": [\"serum creatinine level\"]\n\n\"PARAMETER\": [\"74.27 \u00b5mol/L\"]\n\n\"PARAMETER\": [\"stable\"]\n\nNote: In this context, \"serum creatinine level\" refers to the concentration of creatinine in the blood serum. Creatinine is a waste product produced by muscle metabolism and its measurement is commonly used as an indicator of kidney function.", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [834, "In this patient, we reported the possible effect of parsley juice on the level of sirolimus.", [" \"PARAMETER\": [\"level of sirolimus\"]", {"Drug": ["sirolimus"]}]], [835, "Funding: The authors received no financial support for the research, authorship, and/or publication of this article.", [" No parameters found in this statement.", {}]], [836, "Data are expressed as mean \u00b1 S. D. (n = 6).", [" \"PARAMETER\": [\"mean\", \"standard deviation\", \"n\"]\n\nIn this context, \"n\" represents the number of experiments or observations.", {}]], [837, "The AUC data showed statistically significant differences between group 1 and 2 and between groups 2 and 3 possibly suggest the herb-drug interaction between Epimedium sagittatum extract and sildenafil.", [" \"PARAMETER\": [\"AUC\"]", {"Parameter": ["AUC"], "Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"], "Drug": ["sildenafil"]}]], [838, "et Zucc.)", [" I'm unable to determine what \"et Zucc.\" refers to without additional context.", {}]], [839, "Second, the pretreatment period of Epimedium sagittatum extract might have been too short to identify the possible herbal drug effect.", [" \"PARAMETER\": []", {"Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"]}]], [840, "The combined extraction solution was then evaporated to dryness.", [" No physiological or medical parameters were mentioned in this sentence.\n\n\"PARAMETER\": []", {}]], [841, "Maxim extract are available from the authors.", [" \"PARAMETER\": []", {"Herb name": ["Maxim"], "Extraction process": ["extract"]}]], [842, "A more detailed description of the regulatory environment in Europe, as well as its practical effects, can be found in the Bilia and C\u00e9u Costas review [13].", [" \"PARAMETER\": [\"the Bilia and C\u00e9u Costas review\"]", {}]], [843, "It most often means that we have less knowledge of benefits, as well as risks.", [" \"PARAMETER\": [\"less knowledge\"]\n\nIn this context, it refers to the unknown benefits and risks associated with the use of traditional hypoglycemic herbs.", {}]], [844, "Though non-pharmacological treatments are the main therapy for these patients, application of analgetic drugs is common, often over years.", [" \"PARAMETER\": []", {"Drug": ["analgetic drugs"]}]], [845, "From the combined literature, a list of the most frequently occurring species was established.", [" \"PARAMETER\": [\"species\"]\n\n(Note: Without specific information from the text, it is impossible to determine which species are mentioned most frequently.)", {}]], [846, "They found a prevalence of 56.6%.", [" \"PARAMETER\": [\"prevalence\"]", {}]], [847, "Most surveys on complementary and alternative therapy or supplement use by those patients did not ask for the species used [4,19,29] or were conducted outside of the geographical area of this review [30,31,32], or both [33,34].", [" \"PARAMETER\": [\"surveys\", \"complementary and alternative therapy or supplement use\"]", {}]], [848, "Thus, two studies from Canada and the USA were screened to find plants that patients might use.", [" \"PARAMETER\": []", {}]], [849, "A Spanish study reports Aloe vera [37].", [" \"PARAMETER\": [\"Aloe vera\"]", {"Ethnic group": ["Spanish"], "Herb name": ["Aloe vera"]}]], [850, "Many potentially hepatotoxic herbs are not studied extensively enough to determine a safe daily dose.", [" \"PARAMETER\": [\"daily dose\"]\n\n\"hepatically toxic herbs\"\n\n(Note: In this context, \"hepatically toxic herbs\" refers to the herbs that have the potential to cause liver damage.)", {"Pathology": ["hepatotoxic"], "Frequency": ["daily"]}]], [851, "Short-term use of opioids for patients who cannot reach pain relief otherwise may occur, e.g., to bridge the time until surgical intervention.", [" \"PARAMETER\": []", {"Drug": ["opioids"], "Pathology": ["pain"]}]], [852, "Another patient experienced liver injury after taking 500 mg leaf powder every 2\u20133 days as a laxative [117].", [" \"PARAMETER\": [\"500 mg leaf powder\"]\n\n\"PARAMETER\": [\"every 2\u20133 days\"]\n\n\"PARAMETER\": [\"as a laxative\"]\n\n\"PARAMETER\": [\"a patient\"]\n\n\"PARAMETER\": [\"experienced liver injury\"]", {"Pathology": ["liver injury"], "Amount": ["500 mg"], "Herb part": ["leaf"], "Extraction process": ["powder"], "Frequency": ["every 2\u20133 days"]}]], [853, "There are only food supplements available, with insufficiently defined product quality.", [" \"PARAMETER\": [\"product quality\"]", {}]], [854, "Cannabis preparations are emerging as a promising option for co-treatment of inflammatory diseases.", [" \"PARAMETER\": []", {"Herb name": ["Cannabis"], "Pathology": ["inflammatory diseases"]}]], [855, "This is debated, and there are hints to possible beneficial effects [135].", [" \"PARAMETER\": []", {}]], [856, "The European pharmacopoeia monographs pulverized dried bulbs of Allium sativum containing at least 0.45% allicin [154].", [" \"PARAMETER\": [\"Allium sativum\", \"at least 0.45% allicin\"]", {"Cohort": ["European"], "Herb part": ["bulbs"], "Herb name": ["Allium sativum", "allicin"], "Amount": ["0.45%"]}]], [857, "For the refined quantified dry extract, the ginkgolic acid content is limited to 5 ppm [154].", [" \"PARAMETER\": [\"ginkgolic acid content\", \"5 ppm\"]", {"Extraction process": ["refined quantified dry extract"], "Herb name": ["ginkgolic acid"], "Amount": ["5 ppm"]}]], [858, "Based on cases of severe bleeding events associated with ginkgo [169,170], the plant has been suspected to increase bleeding risk of patients with anticoagulant or platelet inhibiting co-medication.", [" \"PARAMETER\": [\"severe bleeding events\", \"patients with anticoagulant or platelet inhibiting co-medication\"]", {"Pathology": ["severe bleeding events", "bleeding risk"], "Herb name": ["ginkgo"], "Drug": ["anticoagulant or platelet inhibiting co-medication"]}]], [859, "There are in vitro experiments confirming thrombin inhibition [172].", [" \"PARAMETER\": [\"thrombin inhibition\"]", {"Study": ["in vitro experiments"], "Target": ["thrombin"]}]], [860, "The term \u201cginseng\u201d can be used for several drugs.", [" \"PARAMETER\": [\"ginseng\"]\n\nNote: In this context, it is important to clarify which specific form of ginseng is being referred to in the text to accurately identify the associated entities.", {"Herb name": ["ginseng"]}]], [861, "Seong et al.", [" \"PARAMETER\": [\"Seong et al.\"]\n\n(Assuming \"Seong et al.\" refers to the authors of a study)", {}]], [862, "A scientific opinion of EFSA [196] from 2018 states that the common food consumption is safe, as there are only few cases of HILI associated with tea consumption despite the widespread use.", [" \"PARAMETER\": [\"HILI (Hepatotoxicity Induced Liver Injury)\"]\n\n\"HILI associated with tea consumption\"\n\n\"few cases of HILI\"\n\n\"despite the widespread use\"", {"Pathology": ["HILI"], "Herb name": ["tea"]}]], [863, "HILI could occur more frequently in these groups because of the combination of risk factors.", [" \"PARAMETER\": [\"HILI\"]", {"Pathology": ["HILI"]}]], [864, "applied atorvastatin in rats after 3 weeks of drinking green tea or water.", [" \"PARAMETER\": [\"\"]\n\n(No specific parameters mentioned in the text)", {"Drug": ["atorvastatin"], "Duration": ["after 3 weeks"], "Herb name": ["green tea"]}]], [865, "They favor CYP, as the patient could be unusually susceptible due to the individual genotype [207].", [" \"PARAMETER\": [\"CYP\"]", {"Parameter": ["CYP"]}]], [866, "Curcuminoids have been shown to inhibit CY3A4 and 2C9 in vitro [230].", [" \"PARAMETER\": [\"CY3A4\", \"2C9\"]}\n\n[1]: {\"PARAMETER\": []}\n[2]: {\"PARAMETER\": [\"apparent clearance\"]},\n[3]: {\"PARAMETER\": [\"CL/Fs\"]},\n[4]: {\"PARAMETER\": [\"rs1142345\"]},\n[5]: {\"PARAMETER\": [\"in vitro\"]},\n[6]: {\"PARAMETER\": [\"CY3A4\", \"2C9\"]}\n]\n\nThis is a list of all the parameters found in the text. Each list contains the words that refer to the specific parameter.", {"Herb name": ["Curcuminoids"], "Target": ["CY3A4 and 2C9"]}]], [867, "Willow bark extract showed a smaller effect on platelet aggregation in humans than ASA [234].", [" \"PARAMETER\": [\"effect on platelet aggregation in humans\"]\n\nReferences:\n[234]: {} (for more information, please check the corresponding reference in the article)", {"Herb name": ["Willow bark extract"], "Parameter": ["platelet aggregation"], "Drug": ["ASA"]}]], [868, "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability.", [" \"PARAMETER\": [\"AUC\", \"inter-individual variability\"]", {"Drug": ["MTX", "ASA"], "Amount": ["between 7.5 and 15 mg", "+28%"], "Frequency": ["weekly"], "Parameter": ["AUC"]}]], [869, "The clinical significance of this phenomenon depends on individual susceptibility.", [" \"PARAMETER\": []", {"Parameter": ["individual susceptibility"]}]], [870, "It is important to make patients aware of the fact that plants can cause adverse effects and are not safe in every situation by being \u201cnatural\u201d.", [" \"PARAMETER\": [\"\"]\n\n(No specific parameters mentioned in the text)", {"Pathology": ["adverse effects"]}]], [871, "Valerian, for example, is marketed in Germany, mainly as HMP, and, thus, possibly a great proportion of consumption was not included in the survey by Garcia-Alvarez [7].", [" \"PARAMETER\": [\"HMP\"]", {"Herb name": ["HMP"]}]], [872, "This may result in translation errors or assigning mentions to the wrong species, in some cases.", [" \"PARAMETER\": []", {}]], [873, "Publisher\u2019s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" No parameters found in this statement.", {}]], [874, "Diabetes is a complex condition with a variety of causes and pathophysiologies.", [" \"PARAMETER\": []", {"Pathology": ["Diabetes"]}]], [875, "Herb\u2013drug interactions (HDI) may affect clinical safety and efficacy via additive/synergistic or antagonistic interactions among the herbal components and drug molecules.", [" \"PARAMETER\": [\"clinical safety and efficacy\", \"herb\u2013drug interactions (HDI)\"]", {}]], [876, "When these herbs and drugs are used together, pharmacodynamic HDI (either additive/synergistic) may occur.", [" \"PARAMETER\": [\"pharmacodynamic HDI\"]", {}]], [877, "It is composed of a large number of sulfur compounds, with suspected bioactive compounds called allyl thiosulfinates (mainly allicin) [65].", [" \"PARAMETER\": [\"allyl thiosulfinates\", \"mainly allicin\"]", {"Herb name": ["allyl thiosulfinates"]}]], [878, "This herb has been in use for diabetic treatment for almost two millennia [72].", [" \"PARAMETER\": [\"\"]", {"Pathology": ["diabetic"]}]], [879, "These findings suggest further research in individuals with diabetes is required to determine the effect of the combination of gymnema tea and metformin on blood sugar levels.", [" \"PARAMETER\": [\"blood sugar levels\"]", {"Pathology": ["diabetes"], "Herb name": ["gymnema"], "Drug": ["metformin"], "Parameter": ["blood sugar"]}]], [880, "Evidence supporting the interaction between Lycium and antidiabetics is experimental only.", [" \"PARAMETER\": [\"\"]\n\n(No specific parameters mentioned in the text)", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [881, "Findings such as these suggest that Lycium may have an additive effect when used in combination with conventional antidiabetics [86].", [" \"PARAMETER\": [\"Lycium\"]", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [882, "no interaction [98].", [" \"PARAMETER\": []", {}]], [883, "System-to-system or systems biology methodology is a more appropriate model for the evaluation of more complex interactions but its use is often limited by the availability of the relevant chemical and pharmacological data, especially in complex herbal interventions.", [" \"PARAMETER\": [\"the availability of the relevant chemical and pharmacological data\"]", {}]], [884, "Conversely, it is important to keep in mind that these interactions may also present therapeutic benefits as a result of synergism which may lead to enhanced drug effects or reduced adverse reactions.", [" \"\"PARAMETER\"\": [\"\"]\n\nThis sentence does not provide any specific parameter information. It is a general statement about drug interactions and their potential therapeutic benefits.", {"Pathology": ["adverse reactions"]}]], [885, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" This statement is not related to parameters in the context of pharmacology.", {}]], [886, "Asafetida has been used as a folk medication for various ailments including flatulence, cough, asthma, bronchitis, hysteria, and convulsions (Eigner and Scholz, 1999).", [" \"PARAMETER\": [\"flatulence\", \"cough\", \"asthma\", \"bronchitis\", \"hysteria\", \"convulsions\"]", {"Herb name": ["Asafetida"], "Pathology": ["flatulence", "cough", "asthma", "bronchitis", "hysteria", "convulsions"]}]], [887, "The O-demethylation of DEX to dextrorphan (DOR) is predominantly mediated by CYP2D6 (Barnhart, 1980; Schadel et al., 1995).", [" \"PARAMETER\": [\"O-demethylation\", \"DEX\", \"dextrorphan (DOR)\", \"CYP2D6\"]", {"Drug": ["DEX"], "Target": ["CYP2D6"]}]], [888, "So, DEX has been used as a common probe for both CYP3A and CYP2D6 activities (Spanakis et al., 2009; Yu and Haining, 2001), as well as in vivo in several studies (Ducharme et al., 1996; Funck-Brentano et al., 2005; Jones et al., 1996).", [" \"PARAMETER\": [\"DEX\"]\n\n\"PARAMETER\": [\"CYP3A\", \"CYP2D6 activities\"]", {"Drug": ["DEX"], "Parameter": ["CYP3A", "CYP2D6"], "Study": ["vivo in several studies"]}]], [889, "The internal standards codeine and betaxolol were of USP reference standard.", [" \"PARAMETER\": [\"codeine\", \"betaxolol\"] (both are USP reference standards)", {"Drug": ["codeine", "betaxolol"]}]], [890, "General-purpose reagents (GPR) were used for extraction processes, while HPLC grade solvents were used for HPLC determinations.", [" \"PARAMETER\": [\"general-purpose reagents (GPR)\", \"HPLC grade solvents\"]", {}]], [891, "Urine samples were eluted on a Zorbax SB-CN column (5\u00a0\u03bcm, 250\u00a0\u00d7\u00a04.6\u00a0mm).", [" \"PARAMETER\": [\"Zorbax SB-CN column\"]\n\n\"PARAMETER\": [\"5 \u03bcm\", \"250 \u00d7 4.6 mm\"]\n\n(Note: The specifications in the parentheses are part of the column description and should be included as a single entry in the PARAMETER dictionary.)", {}]], [892, "The in vitro formation of DEX metabolites in the presence of Asafetida was compared with the control by using a one-way analysis of variance (ANOVA), and a Post hoc Scheffe\u2019s multiple comparison test with a significant P value \u2a7d0.05.", [" \"PARAMETER\": [\"significant P value\"]}\n\nIn this context, the Post hoc Scheffe\u2019s multiple comparison test is used to determine which specific groups differ significantly from each other when the overall ANOVA result is significant. The \"significant P value\" refers to the probability level at which the null hypothesis (no significant difference between groups) can be rejected. In this case, it is less than or equal to 0.05.", {"Drug": ["DEX"], "Herb name": ["Asafetida"]}]], [893, "In the in vitro study, Asafetida resin alcoholic extract inhibited the formation of DOR from DEX in a concentration dependent manner (Fig.", [" 1],\"PARAMETER\": [\"DOR\", \"DEX\", \"formation\", \"concentration dependent manner\"]}\n\n1. Fig. [ is typically used to refer to a figure in a scientific document, so it is assumed to be a reference to a visual representation of data. However, without access to the actual figure, it is impossible to determine the exact parameters being referred to.", {"Study": ["in vitro study"], "Extraction process": ["Asafetida resin alcoholic extract"], "Drug": ["DEX"]}]], [894, "The activation was highest at 25\u00a0\u03bcg/ml concentration.", [" \"PARAMETER\": [\"25\u00a0\u03bcg/ml concentration\"]", {"Amount": ["25\u00a0\u03bcg/ml"]}]], [895, "The in vivo study was conducted on healthy human volunteers.", [" \"PARAMETER\": [\"healthy human volunteers\"]", {"Study": ["vivo study"], "Pathology": ["healthy"]}]], [896, "Therefore, the clinical study was conducted to confirm the in vitro results.", [" \"PARAMETER\": []", {"Study": ["clinical study"]}]], [897, "In conclusion, the significant Asafetida inhibitory effect on CYP3A4 metabolic activity was an important finding of this study.", [" \"PARAMETER\": [\"CYP3A4 metabolic activity\"]", {"Herb name": ["Asafetida"], "Target": ["CYP3A4"]}]], [898, "These may favor the occurrence of abemaciclib-related diarrhea, causing dose reductions and poor adherence and eventually negatively influencing patients' outcomes and quality of life.", [" \"PARAMETER\": [\"abemaciclib-related diarrhea\"]", {"Drug": ["abemaciclib"], "Pathology": ["diarrhea"]}]], [899, "Moreover, the reckless pieces of information about possible effects of diet, such as fatigue and loose stools, elicited confusion in the patient.", [" No specific parameters were mentioned in this sentence.", {"Pathology": ["fatigue", "loose stools"]}]]], "prompt": "<s> [INST] This is a scientific article about pharmacology.\nWe need to parse all the cited entities. Find every word refering to the described entities.\n\nThe following format must be followed:\n{\"PARAMETER\": [\"List of physiological or medical parameters found in text\"]}\n\nPlease do not add supplementary in information. If no information is found for a field, leave the field empty.\nThe cell homogenate was diluted with HEPES buffer to the appropriate protein concentrations. [/INST]{\"PARAMETER\": [\"protein concentrations\"]}</s> [INST] Some herbs such as celery could even affect the hepatic triglyceride concentrations. [/INST]{\"PARAMETER\": [\"the hepatic triglyceride concentrations\"]}</s> [INST] WHAT THIS STUDY ADDS      Concomitant treatments with echinacea increased the apparent clearance of S-warfarin but did not have a clinically significant effect on warfarin pharmacodynamics in healthy subjects. [/INST]{\"PARAMETER\": [\"apparent clearance\"]}</s> [INST] By contrast, for carriers of the CYP2C9*3 allele, the CL/Fs of glipizide (Kidd et al., 1999) and tolbutamide (Kirchheiner et al., 2002a) were significantly different from wild-type subjects, with ratios of 0.18 and 0.58, respectively. [/INST]{\"PARAMETER\": [\"CL/Fs\"]}</s> [INST] Therefore, rs1142345 was associated with the clinical effect of traditional hypoglycemic herbs. [/INST]{\"PARAMETER\": [\"rs1142345\"]}</s> [INST] TEXT HERE [/INST]"}